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Health care providers in the United States expend more than $400 million in unnecessary 
direct costs annually managing the effects of widespread drug shortages. Based on the 
theory of complexity and complex adaptive systems, the purpose of this exploratory 
multiple case study was to identify the strategies that health care pharmaceutical 
procurement leaders from the Eastern region of the United States use to address 
widespread drug shortages. Data were collected from 5 semistructured interviews with 
pharmaceutical procurement leaders, recorded field notes, and a review of public 
documents from company websites. Data analysis included deductive and open coding 
techniques. Emergent themes included: (a) proactive planning for supply chain and 
distribution channel disruptions, (b) creating strategic processes for alternative 
procurement methods, and (c) relying on proven sources of actionable information. 
Findings may influence business practices for health care procurement leaders by 
contributing new knowledge to develop strategies to address disruptions and drug 
shortages. Health care policy makers may use the findings to assess key strategies in 
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Section 1: Foundation of the Study 
Health systems rely on consistent supplies of pharmaceuticals to support acute 
and subacute patient care. Increasing disruptions within the supply chain and distribution 
channel place patients and health systems at risk for maintaining continuity of care 
(Sharma et al., 2013). Disruptions also cause lengthened patient treatment plans and 
increased health care spending (Hunnisett-Dritz, 2012; McLaughlin & Skoglund, 2015). 
Sharma et al. (2013) explained that globalization of modern treatment protocols places 
additional burdens on supply chains and distribution channels to maintain adequate 
supplies of critical medications.  
Ventola (2011) stated hospitals, clinics, and outpatient treatment centers in North 
America, as early as 2001, began experiencing widespread shortages of mainstay 
pharmaceuticals. Fox et al. (2009) commented that the frequencies of pharmaceutical 
shortage events continued to grow without reliable preventive strategies. In a 
pharmacology update, Mullins and Cook (2011) argued that doctors and clinicians 
continued to treat patients with substitute and alternate drugs that were less effective than 
branded medications and often had profound side effects. The extremely high cost 
associated with managing and mitigating supply chain disruptions remain through a 
period of health care reform (United States Department of Commerce, 2013). 
In 2013, complications found in some U.S. pharmaceutical supply chain 
disruptions were dependent on increases to the global market demand from emerging 
nations’ desires for westernized medicine (Sharma et al., 2013). Disruptions in the supply 
chain and drug distribution channel influence the demand curve for modernized 
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pharmaceutical products (Sharma et al., 2013). Basheer (2012) observed the process of 
product innovation and market exclusivity are vital components to a robust 
pharmaceutical economy; however, health care expenditures continue to become a 
greater portion of the U.S. gross domestic product (United States Department of Health 
and Human Services, Centers for Medicare and Medicaid Services, 2016). 
Fox et al. (2009) suggested scholars, legislators, and leaders of industry cannot 
provide comprehensive solutions to the issue of drug shortages and manufacturer 
interruptions. Fox et al. noted much of the focus of this problem was ex post facto 
strategies implemented to help health care providers mitigate the effects of drug supply 
disruptions. The adaptive nature of the complex and chaotic system known as 
pharmaceutical supply and distribution requires systematic approaches to understanding 
the dynamics of the issues (Abdulsalam, Gopalakrishnan, Maltz, & Schneller, 2015; 
Shah, 2004). 
Rosoff et al. (2012) and Born (2012) reported successful efforts to create a 
comprehensive universal protocol with strategic objectives to detect and minimize drug 
supply disruptions eluded hospital pharmaceutical procurement leaders. Rosoff et al. 
commented reductionist behaviors by many uninformed pharmaceutical stakeholders 
impede the likelihood of creating a viable solution because of the misunderstanding of 
the complex and chaotic behaviors in the system. I conducted an explorative multiple 
case study of how senior health care procurement leaders in the Eastern region of the 
United States describe impediments to the detection and mitigation of drug supply chain 
disruptions. This multiple case study was an opportunity to explore organizational and 
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independent strategies used in response to reported shortages as well as strategic planning 
used to minimize adverse effects in treatment protocols. Findings and conclusions from 
this the study may provide new knowledge and new information to support the 
development of additional leadership strategies, which may strengthen global responses 
to drug supply chain and distribution channel disruptions. The focus of this study was to 
explore the leadership strategies implemented to reduce the frequencies of disruptions to 
the pharmaceutical supply chain and distribution channel within the health system. 
Background of the Problem 
Since 2005, the compounded annual growth rate (CAGR) of drug shortages in the 
United States exceeded 23% (American Society of Health-Systems Pharmacists [ASHP], 
2014). The CAGR for national health care expenditures since 1960 was 8.86 % (Centers 
for Disease Control and Prevention, 2015). Quilty et al. (2011) indicated a 
pharmaceutical manufacturer experienced challenges maintaining product at adequate 
levels of inventory in the supply chain because of increased disruptions. Fox et al. (2009) 
indicated disruptive conditions led to substantial resource shifting of clinical staff 
attempting to obtain medications using other suboptimal strategies. Kaakeh et al. (2011) 
found similar responses from a survey of pharmacy directors. Heydari, Najar, and 
Bakhshi (2015) concluded intensive care nurses should receive specialized training to 
curtail supply chain disruptions and other training the practical management of the 
hospital's scarce resources. Drugs in short supply adversely affect disease states like 
cancer, infectious disease, and surgical procedures because of shortages of anesthesia 
medications (United States Government Accountability Office, 2014). 
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According to ASHP (2014), pharmaceutical drug shortages involve 220 individual 
pharmaceutical products. One of the greatest ongoing health risks from supply chain 
disruptions is the availability of generic sterile injectable drugs for cancer treatment 
(Woodcock & Wosinka, 2013). In 2014, chemotherapy drug types made up more than 
80% of the total reported shortages (ASHP, 2014; United States Food and Drug 
Administration [FDA], 2015). Chabner (2011) argued the unreliability of pharmaceutical 
supply access creates complex sets of issues such as rising drug costs, grey market 
utilization, and increasing related care for patients taking less effective alternative 
medication. 
Problem Statement 
The number of drug shortages reported to the Center for Drug Evaluation and 
Research (CDER) quadrupled from 61 shortages in 2005 to 282 shortages in 2012 (FDA, 
2014). Between 2005 and 2011, the CAGR of newly reported drug shortages exceeded 
23% (ASHP, 2016). U.S. health care providers expend more than $400 million in 
unnecessary direct costs annually managing the effects of widespread drug shortages 
(Fox, Sweet, & Jensen, 2014; Hoffman et al., 2012; Kaakeh et al., 2011). The general 
business problem was some health care pharmaceutical leaders address operational 
challenges resulting from pharmaceutical supply chain disruptions in a suboptimal 
manner. The specific business problem was some health care pharmaceutical 
procurement leaders have limited strategies to address disruptions in the drug supply 




The purpose of this qualitative multiple case study was to explore the strategies 
that health care pharmaceutical procurement leaders use to address disruptions in the drug 
supply chain and distribution channel. The participants in the semistructured interviews 
included five leaders from pharmaceutical procurement departments in health care 
systems who have successfully addressed the research problem. The companies included 
three health care organizations from the Eastern region of the United States. The 
participants shared their strategies of mitigating supply chain and distribution channel 
disruptions. The hospital pharmaceutical leaders also shared company documents and 
internal policies containing relevant data that supported the triangulation of data sources 
(see Denzin, 2012). The findings of the study may contribute to social change by 
improving health care leadership's understanding of the internal strategy limitations 
resulting from drug supply chain disruptions. Findings may also assist health care 
procurement leaders in understanding the perceived quality problems related to treatment 
delivery influenced by drug supply chain disruptions. In addition, the findings may 
increase health care leaders’ awareness of system challenges with pharmaceutical supply 
channel disruptions and drug shortages in the health care system. 
Nature of the Study 
A qualitative multiple case study (see Yin, 2014) was the most appropriate means 
of achieving a unique understanding of the meaning, motivation, and perceptions of 
health care procurement leaders facing drug supply chain disruptions. Pepe (2015) used a 
case study design to explore the decision-making by manufacturing personnel through 
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end users in a collaborative supply chain system. An investigator can use a qualitative 
case study to develop a deeper understanding of the rationale of health care procurement 
leaders to address disruptions in the drug supply chain. Case study inquiry is suitable for 
addressing research questions that require a meticulous understanding of processes in 
social or organizational constructs (Moll, 2012). Following the suggestions of Bernard 
(2013), I considered alternative research methods before choosing a qualitative approach. 
I concluded a quantitative or mixed methods approach was unsuitable for my study 
because the use of quantitative methodology impedes an investigator’s ability to probe 
the underlying study participants’ decision-making processes (see Alojairia & Safayenib, 
2012; Bernard, 2013; Knight & Cross, 2012 ). A mixed methods approach was a 
potentially promising research design; however, limited resources, participant 
availability, and time constraints render mixed methodology an impractical choice for 
this study (see Sadan, 2014). 
Using the suggestions of Bernard (2013), I considered the following major 
qualitative research designs: phenomenology, ethnography, case study, and grounded 
theory. I chose an exploratory multiple case study design. Yin (2014) argued that a case 
study design enables the researcher to answer how and why questions. Patton (2015) 
observed case study research questions also answer what questions. A case study 
approach is an effective way to explore a real-life phenomenon in a natural setting (see 
Cronin, 2014). Based on the guidance of Moustakas (1994), I decided a 
phenomenological study was not applicable because the focus of the study was not on the 
lived experiences regarding a particular event or to find out the unique or common 
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experiences that individuals may have experienced. A grounded theory design would not 
be appropriate because the research purpose was not to develop a new theory (see 
Bernard, 2013, Denzin & Lincoln, 2011). Denzin and Lincoln (2011) suggested an 
ethnographic study is not suitable when the investigator does not intend to focus on any 
group culture through direct observations. The case study design was appropriate to 
explore the phenomenon of supply chain and distribution channel disruptions.  
Research Questions 
The overarching question for this study was the following: What strategies do 
health systems pharmaceutical procurement leaders use to address drug supply chain and 
distribution channel disruptions? 
Interview Questions 
1. What types of strategies do you use to manage supply disruptions in the 
pharmaceutical supply chain and distribution channel? 
2. What are the most important factors you consider when implementing strategies 
to reduce or eliminate supply chain disruptions?  
3. What strategies have been the least effective in reducing or eliminating supply 
chain and/or distribution channel disruptions?  
4. What specific supply chain management strategies do you use to address 
disruptions in the supply chain or distribution channel? 
5. How have your organization’s supply chain management strategies changed or 
evolved since you assumed the leadership role? 




7. What other information would you like to discuss, which we have not already 
addressed? 
Conceptual Framework 
The objective of this study was to explore strategies that senior procurement 
leaders practice to reduce or eliminate disruptions in the pharmaceutical supply chain and 
distribution channel. An investigator can use a single conceptual framework as a guide 
(see Ravitch & Riggan, 2016) to assist in the exploration of the strategies practiced by 
senior procurement leaders to mitigate disruptions in the supply chain and distribution 
channel. Modern complexity theory and complex adaptive systems evolved through the 
research by Kauffman (1995) in complexity sciences at the Santa Fe Institute (1986-
1997). Kauffman conceptualized the idea that complexity theory has an enormous scope 
of business application because all real-world systems are complex. Complexity theory, a 
multidisciplinary science (Di Toni & Comello, 2013), served as a viable lens to develop a 
deep understanding of the strategies used by senior procurement leaders to alleviate 
supply chain and distribution channel disruptions. Complex adaptive systems (CAS) 
theory was a scientifically appropriate conceptual framework to use in this study (see Di 
Toni & Comello, 2013).  
Complex Adaptive Systems 
Investigators use complexity theory to analyze complex systems by developing an 
understanding of the structure and behaviors of a system. The premise of complexity 
theory was the understanding of a hidden order or a mathematical structure in the 
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behavior of systems. Geer-Frazier (2014) found complexity leadership generates 
innovation, learning, and adaptation of an organization and a system. A central concept in 
complexity theory was the notion of emergence (Drack, 2009). Emergence supports the 
rejection of reductionism in science because the natural world has been organized in a 
hierarchical fashion from the simplest (subatomic) to the most complex systems 
(ecosystem) (Iosim, 2016). Mazzocchi (2012) identified hierarchical levels that contain 
emergent principles not found in lower levels of the system; therefore, an investigator 
would have difficulty explaining the functional behaviors of the system by utilizing only 
the basic information obtained at the lowest levels of the system. Another central concept 
of emergence is the notion of feedback. The discovery of positive and negative feedback 
loops in financial investments, which drive the system forward and away from 
equilibrium challenges the conventional notion of systems theory identified in previous 
research (Arsenault, Clayton, & Peng, 2013). Conversely, Kuziemsky (2016) stated 
complex adaptive systems (CAS) were diversely open-ended systems that interact 
nonlinearly with each other and their environments demonstrating capabilities of learning 
and evolving through experiential exposure. This perception was especially true of 
negative feedback systems, which are found in health, human services, and educational 
programs (Gossett, 1989). 
Definition of Terms 
The following terms were defined below: 
Drug shortage: Drug shortage is a situation in which the total supply of all 
clinically interchangeable versions of a regulated drug by the FDA is inadequate to meet 
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the current or projected demand at the patient level (CDER, 2014). 
Electronic health record: An electronic health record (EHR) is a longitudinal 
electronic record of a patient’s historical health information generated by one or more 
encounters in any care delivery setting. EHRs commonly contain a patient’s, diagnoses, 
medications, medication reactions, treatment plans, immunization history, allergies, 
radiology images, and laboratory and test results (Health Information Technology, 2015). 
ePrescribing: ePrescribing is the transmission via electronic media of prescription 
or prescription-related information between a prescriber, dispenser, pharmacy benefits 
manager, or health plan, either directly or through an intermediary, including an e-
prescribing network between the point of care and the dispenser (United States 
Department of Health and Human Services: Office of the National Coordinator for Health 
Information Technology, 2012). 
Feedback loop: A feedback loop is a closed sequential circular path exhibiting 
cause and effect through information and causal stimulation and produces a specific 
behavior because of its structure and activity (Strauss & Borenstein, 2015).  
Grey markets or gray markets: Grey or gray markets refer to an unintended 
parallel marketplace in which products are bought and sold without authorization or 
knowledge of the original manufacturer (McBride et al., 2013). 
Meaningful use: Meaningful use is a three-stage process referred to in the Patient 
Protection and Affordable Care Act (PPACA) that promotes the ideals of efficient and 
comprehensive exchanges of electronic health information related to patient encounters. 
Enhancing electronic health records allows health care provider to qualify for incentives 
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from the government, which continues the value stream in future exchanges (Centers for 
Medicare and Medicaid Services, 2014). 
Reverse payment or pay for delay: Reverse payment or pay for delay is a highly 
criticized common practice of a pharmaceutical patent holder that pay potential 
competitors of generic drugs to delay introduction of less costly product; thereby, 
securing an extended period of market exclusivity (Jones, Carrier, Silver, & Kantarjian, 
2016). 
Secondary use: Secondary use is an enhancement to health care data and 
individual patient encounters for expanding knowledge about diseases and appropriate 
treatments and strengthening the understanding of the effectiveness and efficiency of 
health care systems (National Institute of Health, 2012).  
Assumptions, Limitations, and Delimitations 
Some types of scholarly inquiry address public views of reality through the 
analysis of values, practices, rituals, assumptions, and perceptions found in paradigms 
(Denzin & Lincoln, 2011). The scholarly researcher accepts that some methods of the 
analysis are critically limiting in nature such as the reasoning process, human 
incompetence, or lack of crucial resources, which present a potential for research 
deficiency. Scientific exploration must address shortcomings in an optimal way and 
research studies must exist within the designated boundaries of the researcher’s 
assumptions, limitations, and delimitations (Denzin & Lincoln, 2011). 
Assumptions 
An assumption is an intangible perceived truth that cannot be proven but assumed 
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(Merriam, 2014). The first assumption was participants, who held senior level positions 
with their employers, would provide complete and truthful answers to interview 
questions. The purpose of the data collection process is to solicit meaningful, clear, and 
truthful responses while maintaining professional integrity (Lichtman, 2014). To achieve 
the desired responses, qualitative researchers rely on the research principle of participant 
confidentiality, which eliminates the possibility of identity exposure when answering 
sensitive questions (Yin, 2014). 
I assumed participants had the health care organization’s best interest in mind 
when answering the interview questions. Qualitative researchers should employ active 
listening skills and not deviate from questions except to clarify participants’ perceptions 
through open-ended questioning (Rubin & Rubin, 2012). A final assumption was the 
participants had experience in pharmacy leadership and were capable of articulating their 
experiences regarding the research problem. Qualitative researchers should identify 
emerging themes and patterns from the data in an unbiased manner (Lichtman, 2014; 
Yin, 2014).  
Limitations 
A limitation is a condition or restriction preventing the state of completeness 
(Kirkwood & Price, 2013). The primary limitation was a general lack of academic 
research material available in qualified peer-reviewed journals. Personnel from 
government departments and industry organizations report the bulk of direct empirical 
data with a similar but differing method of peer-reviewed scholarly publishing. 
Inferences drawn in the study may not apply to other industries or other geographical 
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areas. Qualitative researchers attempt to reconcile the differing degrees of knowledge 
transferability based on possible research design deficiencies (Marshall & Rossman, 
2016). The current study contained no longitudinal component; therefore, the findings 
reflected a brief point in time regarding the participants’ perceptions (see Rubin & Rubin, 
2012). 
Delimitations 
Delimitation are self-imposed limitations or restrictions (Bernard, 2013). The 
delimitations of the study included senior leaders perceptions of pharmaceutical 
procurement and administration strategies for medium to large health systems. Ensuring 
sample sufficiency and data saturation is necessary in choosing a purposeful interview 
sample size (Rubin & Rubin, 2012). I intended to interview two to three individuals at 
each of the three sites to achieve data saturation (see Rubin & Rubin, 2012).The sample 
objective was six to nine participants. According to Rubin and Rubin (2012), saturation 
of the data is evident, comprehensive, and focused when further exploration of 
perceptions of the participants support commonly held understandings between the 
participants. 
Significance of the Study 
Contribution to Business Practice  
The findings from the study may contribute to the body of knowledge related to 
pharmaceutical supply chain and distribution channel disruptions. Leaders may use the 
information to fill gaps in their business practice to mitigate specific areas of disruptions. 
Understanding strategies used by health care leaders may provide valuable insight into 
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both effective and ineffective methods to reduce or eliminate pharmaceutical supply 
chain and distribution channel disruptions. Health care executives may also use the 
findings from this study to evaluate the need for future strategies and to make informed 
decisions. 
Findings from this study may contribute to the development and implementation 
of organizational or industry protocols needed to strengthen the responses to notifications 
or conditions of drug supply chain and distribution channel disruptions. Senior 
procurement leaders may develop integrated best practices through a deepened 
understanding of the influences of pharmaceutical delivery. Refinement of best practice 
models may help health care providers address excess costs and leverage new strategies 
to eliminate non-value added costs.  
Implications for Social Change 
This study was a deductive exploration of the strategies used to mitigate drug 
supply chain and distribution channel disruptions in the U.S. health care environment. 
Drug supply chain and distribution channel disruptions represent one of the most 
challenging problems confronting health care providers. Health care procurement leaders 
must attempt to reduce costs related to treatment while delivering better value for the 
health care dollar (Schweitzer, 2013). Drug supply chain and distribution channel 
disruptions affect the cost control process because the medical practitioner reassigns 
clinical staff to search for other means of procuring drugs in short supply or to research 
substitute medications when faced with delays (Schweitzer, 2013).  
Study findings may lead to social change by educating senior health care leaders 
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about growing challenges encountered in health care, related to the resolution of drug 
shortages through repurposing administrative and clinical resources. The pending 
challenges brought about by the PPACA may push patients, providers, and payers to 
demand more efficient productive and distributive organizational practices within the 
drug distribution channel. The study findings may contribute new knowledge to health 
care organizations attempting to adopt new methods and strategies of addressing drug 
supply chain and distribution channel disruptions. Health care policy makers may 
reconsider key processes in distributing pharmaceutical products from manufacturers to 
end users based on the finding of the study. 
A Review of the Professional and Academic Literature 
The multiple case study design enabled me to explore qualitative perceptions of 
senior leaders to the discover best practices and new knowledge related to management 
of drug shortages in the United States. I completed a review of the professional and the 
academic literature to assess the need for this study, which included professional, 
academic, governmental, and industrial journals, books, dissertations, and authoritative 
reports. The content of the review includes the most recent trends facing the industry and 
stakeholders.  
Academic Sources Utilized to Conduct the Review 
The online Walden University library was the primary source for the literature 
review. Business and management databases, as well as health sciences databases, 
provided integrated information because of the dual focus of the study. Query of 
business's and management databases included Business Source Complete/Premier, 
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ABI/Inform Complete, Emerald Management Journals, Sage Premier, LexisNexis 
Academic, and the National Bureau of Economic Research identify the business aspects 
of the research study. Interrogation of Health Sciences databases included MEDLINE, 
PubMed, and Science Direct identify health care aspects of the research study. I excluded 
articles from newspapers, magazines, and trade publications because of the potential 
perception of bias. 
The total number of references was 278. Of these, 250 (90%) have publishing 
dates between 2012 and 2017. In the review of professional literature, the total references 
equal 159. In this section, 136 references (86%) have publishing dates between 2012 and 
2016. Of the 278 total references, 272 (98%) were either (a) a peer-reviewed journal, (b) 
an academic resource book, (c) a doctoral dissertation, or (d) an authoritative source.  
Key Words, Phrases, and Terminologies 
I used the following keywords, phrases, and terminologies when searching the 
reference databases for the literature review: drug shortage, manufacturer delay, 
pharmaceutical scarcity, pharmaceutical supply chain, drug distribution channel, grey 
market, drug substitution, therapy interruption, alternate therapy, stock out, pay-for-
delay, clinical trial delay, patent expiration, compounding pharmacy, vendor-managed 
inventory,and reverse payments. 
Diversity of Literature Sources 
The regulated nature of pharmaceutical manufacturing and product distribution 
created a need to review literature from various clinical professions, governmental 
agencies, industrial organizations, and private firms assessing the pharmaceutical supply 
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chain and distribution channel. The FDA regulates the quality of pharmaceutical products 
by protecting the rights of patients who are subject to clinical trials of new medications. 
The FDA’s responsibilities include monitoring pharmaceutical promotional material. 
Some of the selections in literature review included information released by government 
agencies deemed authoritative. 
The research topic incorporates regulations from numerous government bodies; 
therefore, the separation from the academic discourse and the discourse of the regulatory 
body was difficult to characterize. Industry and private organizations offer 
comprehensive reporting to identify high-level market conditions and assessment of 
future revenue opportunities necessary for stakeholder competition. Literature about drug 
shortages from these groups appears to be subjective in nature because of the potential 
economic benefits gained by the users. Some for-profit companies like IMS Health and 
the health care Distribution Management Association provided widely accepted 
meaningful market analysis (Generic Pharmaceutical Association, 2012), which was 
considered authoritative but lacked certain rigors of academic interrogation. I used these 
types of informational reports to validate the content in the peer-reviewed literature, 
which may help to assess and validity of the literature review. 
Significant Legislation Affecting Pharmaceuticals 
Five pieces of intertwined legislation affecting the pharmaceutical industry 
created complex sets of regulatory boundaries and legal compliance challenges. First, the 
Bayh-Dole Act of 1980 remediated previous government regulations related to patent, 
trademark, and intellectual property statutes for universities and institutions receiving 
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federal funding for research and development. Second, the Hatch-Waxman Act of 1984 
simplified the process of generic introduction as a means to make affordable medications 
accessible to more Americans (Hemphill & Sampat, 2012). The Act allowed generic 
manufacturers to take advantage of faster and more cost efficient methods of introducing 
low-cost drugs into the marketplace than in previous years. Some scholars considered this 
Act as placing a bounty worth millions of dollars on a drug innovator’s product patent 
(Hemphill & Sampat, 2012). 
Third, the Medicare Prescription Drug Improvement and Modernization Act of 
2003 (MMA) created Part D benefits for Medicare recipients. Part D benefits helped 
Medicare beneficiaries acquire prescription medication at a discount. The MMA also 
pinned price increases for drugs used in intravenous (IV) therapy to 6% of average sale 
price. Fourth, the 2011 Executive Order 13588-Reducing Prescription Drug Shortages 
required pharmaceutical manufacturers to provide the FDA with a 6-month notification 
for any potential drug shortages or delays (Executive Order No. 13588 3 C.F.R. 281, 
2011). Additionally, Executive Order 13588 prohibited the stockpiling and price gouging 
in the supply chain and distribution channel (Executive Order No. 13588 3 C.F.R. 281, 
2011; USGAO, 2014). Finally, in 2012, the FDA passed the United States Food and Drug 
Administration Safety and Innovation Act (Pub. L. 112-114) (FDASIA, 2012), which 
allowed the FDA to collect user fees for drugs and medical devices from the medical 
industry (USGAO, 2014). These funds streamlined the FDA’s processes for drug and 
medical device approvals to create an efficient and expeditious process for generic 
application approvals (United States Food and Drug Administration, 2014).  
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Constraints on Traditional Economic Theories 
Recent federal legislation designed to increase consumer access to affordable 
health care outcomes and to reduce the costs associated with health care delivery 
constrain fundamental economic theories. Health care economics do not operate in 
perfectly competitive markets (Phelps, 2012). Health care economics do not consist of 
low entrance and exit barriers, homogeneity of product, a full understanding of product 
quality; a single entity does not influence market pricing. In contrast, the health care 
economies consist of imperfect market conditions and complexities of feedback loops 
reflecting the value of resource consumption impair the ability to examine allocative 
efficiencies throughout the supply chain and distribution channels (IMS Health, 2012). 
Excess capacity and excess demand characteristics in pharmaceutical supply chains and 
distribution channels are economically inconsistent with those in traditional theories of 
price elasticity because of filters placed within feedback loop structures of drug supply 
and demand (Crawford, 2010). Pharmaceutical health care markets exhibit conditions of 
supply inelasticity, partly because the lifesaving, products are available to consumers 
who might pay any price to obtain them (Crawford, 2010). 
Themes in Literature Review 
Six themes were prevalent in the current body of academic literature, (a) supply 
and demand, (b) regulatory and public health policy, (c) capacity and sustainability of the 
pharmaceutical supply chain, (d) business decisions, (e) complexity of pharmaceutical 
delivery systems, and (f) adverse effects on patient outcomes. I provide a comprehensive 
discussion focused on complexity sciences and their applicable disciplines. The majority 
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of the current literature include information relate to ex post facto behaviors, which 
follow drug shortage events. A smaller portion of the current literature focuses on ex ante 
organizational processes to address the leadership responses to the research problem. 
Gaps in the academic literature exist in the ex ante contribution. The exploration of 
complexity theory, as applied to this research problem, may yield definitive results 
because other management researchers have yet to completely grasp the capabilities of 
complexity sciences (see Pollack, Adler, & Sankaran, 2014). 
Complexities Sciences 
Complex adaptive systems (CAS). Complex adaptive systems are intricate, self-
organized, complex, chaotic systems, composed of independent agents (Higgins, 2013; 
Iosim, 2016; Neely, 2015; Sturmberg, O'Halloran, & Martin, 2012a; Tsasis, Evans, & 
Owen, 2012). A range of variables interacting with each other and emerging from agent 
adaptations (norms) to form a system may influence system behaviors (Higgins, 2013; 
Sturmberg et al., 2012a; Tsasis et al., 2012). Strumberg, O'Halloran, and Martin, (2012b) 
argued health care delivery systems follow the CAS construct. Strumberg et al. (2012b) 
observed (a) no existence of a central control point or referring authority driving system 
design, (b) varieties of stakeholder influences creating complexity, and (c) system agents 
developing structural mechanisms that deviate from system norms to serve the interests 
of individual agents. Competitive systems must operate between order and disorder to 
optimize performance and adapt to the critical queues in the competitive industries in 
which they operate. 
Tsasis et al. (2012) used a qualitative research design to explore participants’ 
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experience in health systems integration to assess the utility of a CAS framework in 
integrated care. Tsasis et al. concluded that barriers to system change toward integrated 
care resulted from a lack of understanding of (a) interplay among diverse organizational 
components, (b) contextual factors that moderate a system’s capacity to integrate, and (c) 
organizational resistance to adapt or learn from emerging experiences. Kuziemsky (2016) 
argued for using the CAS approach to support management decision-making in health 
care because traditionally prescribed methods were used for stable and predictable 
systems. Gilson, Elloker, Olckers, and Lehmann (2014) suggested sense making, the 
process individuals use to understand their environment, which shapes their 
understanding of how organizational environments work and the interplay among system 
components to reform health care. Gilson et al suggested that during organizational 
change, individuals attempt to understand their local experiences by engaging colleagues 
to generate shared interpretations of change initiatives, which may or may not be aligned 
with organizational intentions. 
Complexity theory (CoT). Complexity theory is a toolset of theoretical and 
conceptual methods used by researchers in the development of nonlinear abstract 
structures (Cudworth & Hobden, 2013; Psychogios & Garev, 2012). Complexity is a 
decentralized configuration of multiple objects lacking a nucleus and a defined command 
structure, but having characteristics of an evolving or learning entity (Jianbo, Feiyan, 
Jianfang, Jing, & Yinhe, 2013). In contrast, Cudworth and Hobden (2013) suggested 
complexity theory lacked common threads and tools to solve complex social problems. 
During the 20th-century complexity theory had roots in three interdisciplinary fields: (a) 
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cybernetics, (b) systems dynamics, and (c) general systems theory (theoretical biology). 
Early cyberneticians included mathematicians Pitts, Weiner, and von Neumann, 
engineers Bigelow and Shannon, and neurobiologists McCulloch, Rosenbluth, and 
Lorente de No (Byrne & Callaghan, 2014). 
From 2000 to 2010, researchers focused on complexity theory for new 
applications and new areas of research (Zuchowski, 2012). Serdarasan (2013) stated the 
degree of interdependencies of system relationships, and the volume of system 
components characterized the sense of increased complexity and randomness. 
Baykasoglu (2016) concluded system complexity for retail supply chain increased with 
the use of a central forecasting tool. Serdarasan used findings in the context of 
complexity to develop leadership best practices for supply chain management. The U.S. 
pharmaceutical supply chain consists of multiple autonomous entities, governmental 
regulations, objectives, stakeholders, and processes. When considered as a whole, 
pharmaceutical supply and distribution entities comprise a complex system of 
interdependent relationships (Janvier-James, 2012; Kaakeh et al., 2011; Mullins & Cook, 
2011; Shah, 2004). 
A central concept in complexity theory is the notion of emergence (Baykasoglu, 
2016; Drack, 2009). When researchers reject reductionism, they may identify emergent 
behaviors in the system they are exploring. Reductionism theorists have sought to explain 
behaviors and relationships at the smaller unit level, which contrasted with the arguments 
of Baykasoglu (2016) and Drack (2009). Shah (2004) suggested pharmaceutical supply 
chains and distribution channels contain many complex processes, formulas, coordination 
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issues, and development challenges. Morçöl (2012) stated complexity theorists use 
conceptual tools and methodological tools to simplify because of the human simplifying 
mind. 
Feedback and feedback loops. Another central concept in complexity theory is 
the notion of feedback. Information in a complex system is a tool to understand the 
degree of integration in relationships. Self-organizing components in a complex system 
are (a) dynamic, (b) nonlinear, (c) co-evolving, and (d) interconnected with other system 
components. Intricate biological systems comprise varying levels of feedback within 
hierarchical levels (Jørgensen, Nielsen, & Fath, 2016; Nielsen, 2016). Systems have 
dynamic information driven feedback loops that transforms the system to achieve its goal 
and to achieve equilibrium to allow the system to maintain its functions (Adomavicius, 
Curley, & Gupta, 2013).  
Several scientific tenets comprise feedback loops. Feedback loops contain 
adaptive characteristics of complex systems. Without feedback loops that are both direct 
(+) and inverse (-), complex adaptive systems cannot change or evolve and become 
obsolete. Co-evolution governs that self-preservation relies on the constant 
communicative interaction between all interdependent entities (Akgun, Keskin, & Byrne, 
2014). The discovery of positive feedback loops in financial investments that drive the 
system forward, and away from equilibrium (Arsenault et al., 2013) challenges the forms 
of systems thinking identified in previous research. Additionally, Li, Yang, Sun, Ji, and 
Feng (2010) discussed a precise notion of complex adaptive systems network (CASN), 
which was similar to the explanation from Kuziemsky (2016) but also included the notion 
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of adaptation as a choice of survivability. Understanding the makeup of feedback loops 
within the supply chain and distribution channel was paramount to the exploration of the 
strategies associated with the research question. 
The nature of feedback loops evokes the notion of circular or increased 
complexity in the chains of causation (Mella, 2015). Feedback loops exhibit distinct 
patterns of organizational closure forming and creating harmony. These patterns also 
show autonomy and the means to activate a change to extend self-preserving 
characteristics (Beer, 2014). Feedback loops are patterned organizational behaviors with 
an abstract pattern of self-adaptive, self-organizational, and self-emergent behavior. New 
patterns of organizational behavior emerge when the system presents conditions 
acceptable for modification (Beer, 2014). Feedback loops are information conduits 
operating on dynamic change and acting on system difference or system dissimilarity. 
Feedback loops contain an originator adapting through responses to its behavior 
(Akgun et al., 2014). Meanings of the feedback message come to the researcher in the 
answers to the message. Self-adaptation changes reflect in the replies made to the 
originator’s message. Message noise or conflicting intentions may render the response 
invalid or impaired. Feedback loops achieve a purpose or satisfy values. Values and 
purposes may appear implicit or tacit. In satisfying a value or achieving a purpose, the 
feedback loop may increase (+) or decrease (-) the previous action, change to a different, 
but corresponding behavior, change to a different type of behavior or change the 
reference point of the outcome. Mella (2015) suggested systematic maximization without 
consideration in other areas of the system results in extreme behaviors affecting system 
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dynamics. Mella suggested looking for both consistency and variance in causal chain 
exploration.  
Several distinct characteristics exist in feedback loops. Feedback loops may 
encroach on physical boundaries because information conduits are free from either 
internal or external physical limitations. Feedback loops have cycle times and delays that 
may not appear efficiently measurable. Cycle time, queue time, or delay was the length of 
time for all parts of the feedback loop to interact and process the message by completing 
its journey around the loop. Cycle, queue, or delay may occur in milliseconds or longer 
depending on the complexity and the distance from the originator. Longer cycle times 
may skew the message and may decrease the visibility of systematic relationships. 
Decentralization in pharmaceutical supply chains may appear subject to lengthy feedback 
delays because of the sheer expanse of the loop’s path. 
Feedback loops have two basic types. The first basic type was a positive or direct 
feedback loop. The positive feedback loop (+) has three main physiognomies: self-
amplification, self-reinforcement, and acceleration in system design. Positive feedback 
loops have direct relationships to other process variables. Financial process models, 
personal nutrition models, and social economics use feedback models to understand 
system characteristics (Higgins, 2013) 
The second type of feedback loop (-) is the negative or inverse feedback loop. 
Characteristics of negative feedback loops are stabilization, balance, equalization, and 
convergence. Negative feedback loops are self-sustaining and self-regulating. Negative 
feedback loops have inverse relationships with other process variables. As they go up, the 
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other variables will go down; as they go down, the other variables will go up. In 
comparison, positive feedback loops thrust the system to operational limits and 
boundaries through exponential growth or inconsistent behavior while negative feedback 
loops push the system to dynamic equilibrium and convergence through comparisons of 
the current state to the desired state. 
Feedback loops have thresholds and boundaries. Reinforcing and balancing 
feedback loops demonstrate aspects of limitations and thresholds (Morecroft, 2015). 
Reinforcing feedback loops may move the system toward and eventually over a 
threshold. Balancing feedback loops maintain the system within bounds and close to 
midpoints. Escalating feedback loops depend on the rate of system change. Steep inclines 
or declines in the rate of change obstruct proper balancing feedback response times 
(Morecroft, 2015). 
Feedback loops may include controls or varying degrees of tolerance to support 
self-adaptability (Macías-Escrivá, Haber, del Toro, & Hernandez, 2013). In the past, 
control engineering focused on feedback modeling in dynamic systems to increase the 
knowledge of the science (Macías-Escrivá et al., 2013). Proximity to system thresholds 
inhibits balancing feedback response times. Increasing tolerances may reduce the tuning 
ability of the controls. 
Feedback loops operate on multiple levels. The human body operates many 
feedback loops, which maintains homeostasis (a desired metabolic state) (Gianaros & 
Wager, 2015). In mechanical sciences, this state is known as equilibrium. Multiple 




False positive and false negative feedback loops regularly exist in natural sciences 
(Yamaguchi et al., 2012) and overwhelmingly in health care. Impaired data collection 
techniques caused false indicators in complex systems (Yamaguchi et al., 2012). The 
potential for false positive and false negative indicator readings in supply chains may 
cause material disaggregation of systems knowledge leading to a gap in system 
understandings further impairing decision-making (Guertler & Spinler, 2015). Identifying 
the correct methodology and the scheduling of feedback loop systems measurement may 
contribute to the elimination or reduction of false indicators. 
Feedback loops support the ongoing operational cycle of complex adaptive 
systems such as pharmaceutical supply chains. The complex and chaotic behaviors in 
feedback loops are natural occurrences that may contribute to the difficulties of 
increasing system knowledge or other metrics tied to effectiveness or efficiency. Systems 
may fragment into infinite numbers of levels determining causal compatibility or 
relevance to the governing objective of a particular process (Jerbrant, 2013). Critical 
system knowledge was essential for proper alignment of operational strategies related to 
disruptions in drug supply chains and distribution channels. 
General systems theory (GST). Scientists such as von Bertalanffy (1934), who 
introduced GST in 1934, and Emerson, Luhmann, Rapoport, and Churchman defined, 
shaped, and supported the notion of GST in the research process. General systems theory 
was the brainchild of Ludwig von Bertalanffy, who collaborated with Gerard, Rapoport, 
and Boulding while visiting Stanford University creating the Society for General Systems 
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Research (SGSR) in 1956. Poincare founded modern forms of systems dynamics in 1880 
originally discovered by Sir Isaac Newton. System dynamics has new aspects, such as 
chaos theory, catastrophe theory, and fractal geometry with the strong influences of the 
computer revolution. In a supporting fashion with CAS theory, general systems theory, 
complexity theory, and chaos theory (ChT) may support the understanding of paradigms 
of the disruptions in the pharmaceutical supply chain and the drug distribution channel. 
Mishra, Kumara, and Garg (2013) studied the manufacturing, procurement, and 
distributions processes of supply chain management using general systems theory. As the 
supply channel system grows, so would the need for growth in the supporting systems 
(Mishra et al., 2013). The basis for advancing operational process efficiency is operating 
with enterprise governance best practices using a general systems theory approach or 
systems thinking (Medvedeva, 2012; Stephens, 2013; White & Fortune, 2012). Sweeney, 
Grant, and Mangan (2015) limited their research analysis to supply chain management in 
Ireland because of the emerging complexities of the current market along with increased 
globalization of product sourcing. 
A system is a group of elements arranged in a particular design Mangal (2013). 
Boulding (1956), a contemporary of von Bertalanffy, described GST as theoretical 
modeling of levels existing between abstract principles of mathematics and distinctly 
specialized disciplines. Systems theories use a methodological approach to understanding 
the functions and behaviors of system objects. Bode and Wagner (2015) discussed the 
existence of positive direct relationships between supply chain disruptions and the 
complexity found in vertical, horizontal, and spatial systems. Baykasoglu (2016) and 
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Drack (2009) argued the impossibility to know every part and every relationship in a 
system. Conversely, Baykasoglu and Drack suggested the possibility of researching 
system laws above individual system parts. Pharmaceutical supply chains exhibit most of 
the same challenges as indicated by Drack. U.S. pharmaceutical supply chains and 
distribution channels may demonstrate characteristics of highly structured and or highly 
functional systems. 
General systems thinking. The focus of general systems thinking is on the 
behaviors of whole systems. The concept of system thinking originated from a complex 
computer simulation model for handling management problems (Marshall & 
Farahbakhsh, 2013). Researchers using systems thinking constructs examined 
relationships between different parts of a system, thereby reducing the effect of 
complexity on the interpretation of the findings (Marshall & Farahbakhsh, 2013). Wallis 
(2013) suggested the use of systems thinking and complexity theory supported the 
creation of enriched public policies. General systems thinking help researchers 
understand the whole system was greater than the sum of all parts (Logan, 2015). 
Chaos theory (ChT). Early modern physicists were unable to solve the nonlinear 
solutions to differential equations (De Brasi & Laracy, 2013). Dynamical time delayed 
systems may exhibit multiple opulent or nonperiodic behaviors including the possibility 
of high-dimensional chaotic behavior (Soriano, Flunkert, & Fisher, 2013). Deterministic 
chaotic systems, evolved into radically different states when exposed to minute variances 
from the original state (Franzke, Osprey, Davini, & Watkins, 2015). In the 1960s, 
Edward Lorenz studied intricate mathematical equations related to varying weather 
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conditions and resurrected the importance of chaos theory for a newer generation of 
meteorological researchers (Krishnamurthy, 2015). In a contrasting approach, researchers 
would not use ChT theory for a qualitative study because any system that continually 
operates on the fringes of chaos cannot appear productive and a system continually 
operates on the fringes of order lacks the capacity to adapt to environmental changes and 
ceases to exist (Spencer & Carlan, 2008). Croson, Donohue, Katok, and Sterman (2014) 
concluded managers and leaders have difficulty controlling systems that include 
complex, volatile behaviors with feedback and information delays; therefore, the 
researchers suggested developing enhanced training tools. 
Complex systems have conceptual structures similar to a spider’s web (Di Toni & 
Comello, 2013); the slightest disturbance to a remote area of the web resonates 
throughout the complex system and potentially manifests itself in areas unrelated to the 
original point of origin. Gubin and Santos (2012) identified chaotic systems by the 
divergences of trajectories where the original state of each system was comparable. The 
pharmaceutical supply chain and the distribution channel exhibits many of the same 
structural characteristics of a spider’s web. The similarities are because of the multiple 
groundings found in the regulatory, legal, ethical aspects and the interrelated associations 
of the entities in the system. Burns, Bradley, Weiner, and Shortell (2012) identified 
micro-systems (individual patient care), mesosystems (population delivery care models) 
and macrosystems (industry and governmental regulation) existing in the health care 
delivery system. The various systems identified by Burns et al. demonstrate a defined 
model of system integration and interconnectedness between the health care provider and 
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clinical operational processes. 
General systems theory methodology supports the interrogation of models with 
complex entities created from the interactions of constituents by conceptualizing the 
variables of constructs. Use of general systems theory permits the researcher to focus on 
the dynamics of defining specific functionality and supports the discovery of internal and 
external relationships and abstract properties. General systems theory advances the 
investigator’s potential to explore normative and critical perceptions concurrently. 
Systems sciences contain a vast collection of tools to study real lived perceptions and 
develop cognitive maps, which help investigators understand the perceptions, 
articulations, conceptions, and explanations of complex entities. 
Complexity is a framework of emerging scientific approaches containing 
theoretical and conceptual tools (Byrne & Callaghan, 2014). Complexity theory 
methodology assesses how incremental changes precipitate behavioral changes to a 
complex system Complexity theory emphasized the relational thinking of organizational 
and network processes. Complexity theory may introduce new perspectives on how to 
approach open systems using the notion of emergence and non-linearity, which may find 
use in the assessment of international system concepts (Rouse & Seban, 2014). 
Chaos theory clarifies the complexity of perceived randomness or chaotic 
behaviors (Soriano, Flunkert, & Fisher, 2013). Understanding the foundations of chaos 
theory promotes the development of mathematical tools to help in the development of 
solutions to complex business problems such as complex supply chains (Mason, 2013). 
Chaotic operating environments in business normalize as supply chains and distribution 
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networks become multinational and multicultural. Chaos theory may contain the 
understanding of the fluctuations and unpredictable nature of supply and demand for 
critical use commodities.  
For the purpose of addressing my research question, I used CAS theory to 
describe health systems. Health systems interventions are complex in nature, comprised 
of many interacting components, and require organizational agility in decision-making 
(flexible leadership) to meet changing and sometimes chaotic market dynamics (Paina & 
Peters, 2012). Additionally, CAS theory helps researchers identify and describe the 
behaviors and outcomes of interactions between the agents and environments of defined 
systems (Nan, Zmud, & Yetgin, 2014). 
Supply and Demand 
Blome, Schoenherr, and Rexhausen (2013) identified supply chain agility as a key 
tenet of operational excellence. Blome et al. suggested multiple supply chains in multiple 
countries may cause extensive logistical disruptions because of the lack of integration of 
the health care supply chain. In the health care continuum, supply and demand involve 
the orchestration of different entities gathering products and therapies for medically 
needy consumers with predisposed requirements. The abundance or lack of feedback 
information was a determinant of the degree of integration and interdependence of the 
system (Faucher, 2013). 
Becker et al. (2013) indicated minute disturbances in the supply chain for the few 
companies (sole source) manufacture sterile injectables for oncology may cause extensive 
periods of drug shortages. Fragmentation of feedback information, because of the diverse 
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locations of manufacturing facilities, may impair the ability to collect and analyze data on 
a consistent basis. Kaakeh et al. (2011) point to multiple Internet sites containing 
fragmented data where study participants only rate 2% of the sites as having very good 
content. Information gaps and data fragmentation within the management reporting 
applications in the distribution channel result from different uncertainties in supply and 
demand and diverse system complexities (Chaudhuri, 2015; Cherici et al., 2011; Fox et 
al., 2009). Drug shortage administration from the aspect of information gathering may 
cause diligent efforts to maintain customary standards of care for all patients (Becker et 
al., 2013).  
The economic theory of supply and demand contains the concept of elasticity or 
inelasticity of price; however, Becker et al. (2013) argued profits for generic sterile 
injectables, used in the majority of oncology treatment regimens, are subject to increase 
price limits by reimbursement regulations in the MMA. This legislation influenced the 
profit margin for mainstay drugs used successfully in clinical practice for decades thus 
oncology drugs may demonstrate limited pricing responses to elasticity or inelasticity 
conditions (Chabner, 2011; Havrilesky, Garfield, Barnett, & Cohn, 2012; Woodcock & 
Wosinka, 2012). 
The manufacturing of pharmaceutical drugs by the manufacturer first requires the 
appropriation of raw materials, then the process of turning raw materials into the active 
pharmaceutical ingredient (API). Steinbrook (2009) argued certain types of drug supplies 
are unreliable especially when patient demand steadily increased. Even though high 




Information from analyzing retail distribution channels may contain insights of 
how vendor managed inventory (VMI) contract agreements may reduce costs and 
improve performance (Guimaraes, Crespo de Carvalho, & Maia, 2013). Guimaraes et al. 
(2013) identified particular partnership relations among participants within the supply 
chain may create information sharing, which was more efficient than traditional inventory 
models. A multi-site general hospital was the focus of this single case study.  
A central finding to Guimaraes et al. (2013) quantitative single case study was the 
notion of VMI, recommending the manufacturer instead of the supplier control the 
volumes of product within the distribution channel. Guimaraes et al. concluded VMI 
scenarios reduce total channel costs to a greater degree than when health care workers 
manage the volume of product within their supply warehouses. This condition reduces 
direct effects of uncertainty among channel partners and seeks to eliminate excessive 
costs. 
Loss of equity in capital markets. According to Kumar, Liu, and Scutella (2015) 
increases in the direct and the indirect cost was not the only economic disruptions faced 
by pharmaceutical manufacturers and distributors in India. Kumar et al. (2015) concluded 
equity loss related to the performance of the manufacturer’s stock demonstrated no 
relation to the location of the disruption or responsible party. This study reflected the loss 
of equity in long-run stock performance may manifest itself in future cash flows as well 
as capital structure (Kumar et al., 2015). Perceptions of changes in economic risk affect 
future demands for increased investment returns. 
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Kumar et al. (2015) calculated underperformance of stocks for Indian 
organizations experiencing disruptions with the larger portion of the performance 
challenge occurring before the announcement of the disruption in manufacturing. In the 
10-day period, before disclosure and following the disclosure, Indian companies lose 2.88 
percent of shareholder wealth (Kumar et al., 2015). The findings from the study 
conducted by Kumar et al. may demonstrate financial disincentives, which may dissuade 
early supply deficiency disclosure as suggested in other academic discussions (Fox et al., 
2009; Johnson, 2011; Kaakeh et al., 2011; Krisl, Fortier, & Taber, 2013). 
Difficulties managing risks associated with potential supply disruptions magnify 
with the effects of global sourcing, increased supply chain stakeholders, and increasing 
product lead times (Chopra & Sodhi, 2014; Quilty et al., 2011; Schweitzer, 2013). Global 
sourcing increased stakeholders and increased lead times may increase complexities in 
feedback loops (Shah, 2004) and diminish the reasonableness of disruption management 
(Kumar et al., 2015). Kumar et al. concluded supply chain disruptions in developing 
countries may have a greater negative influence on stock and equity than in the U.S. 
Information fragmentation. Information sharing fragmentation was a primary 
concern of one study conducted in 2011 (Kaakeh et al., 2011). Kaakeh et al. discussed the 
existence of multiple drug shortage websites, which only 2% of their surveyed population 
deemed as having actionable content. The lack of websites with cohesive content may 
contribute to additional resource planning necessary to compile and interpret data from 
multiple locations to manage disruptions. Kaakeh et al. reported survey respondents in 
their study reported they were unaware of varying disruptions in the supply chain until 
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they attempted to purchase the product from a wholesaler because of limited information 
found on websites. One of the complications studied by Becker et al. (2013) was multiple 
definitions of the term drug shortage. Differing definitions with various scopes 
unnecessarily look to add to the complexity and confusion of the problem (Becker et al., 
2013; Le et al., 2011; Ventola, 2011). Ventola also concluded the broadly used term 
medically necessary also differed among groups and agencies. 
Although external information dissemination was critical to health systems, 
Kaakeh et al. (2011) argued pharmacists must also provide support to internal 
information systems resulting from drug shortages. Kehl et al. (2015) concluded 
physicians in integrated health systems were less likely to experience drug shortages. 
Extra resource applications from the pharmacists focused on educating internal clinicians 
on alternate or substitute drugs, updating formularies with new drug information, 
modifying treatment policies, and communicating with supply chain and distribution 
channel partners about shortages. Efforts to mitigate drug shortages caused pharmacists 
to forego other responsibilities. The lack of consistent information sharing including the 
definition of the term drug shortage caused Kaakeh et al. to conclude senior clinical staff 
may not effectively manage drug shortages. The findings in the study indicate FDA 
regulators should require drug manufacturers to provide advanced notification of at least 
six months before product shortages or manufacturing interruptions. 
Fragmentation of the pharmaceutical supply chain and distribution channel exists 
because of complexities in the historical design. Revisions are extremely difficult to 
implement for total system changes or improvements (Rees, 2011). Mikihisa (2015) 
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suggested the existence of stability and product quality in supply chains because of 
production leveling. Production leveling was an operational smoothing process of 
production demand planning (Bandyopadhyay, 2016). This manufacturing concept 
creates economies of repetition. Economies of repetition build on the premise 
manufacturers face uncertain demand yet must assemble multiple products to meet 
production expectations. Bandyopadhyay (2016) suggested a leveled production process 
reduces the detrimental effects of fragmentation through operational enhancements in the 
balancing of supply and demand. 
Sandhil and Gupta (2013) reported hypothetical improvements in supply chain 
management through the implementation of an Enterprise Resource Planning (ERP) tool. 
Sandhil and Gupta indicated the intended goal of using an ERP system was to identify a 
single real-time truth from multiple data sources and complex interfaces between 
suppliers and customers. Design deficiencies in fragmented supply chain management 
systems do not track product flows properly from manufacturer to distributor and then 
from the distributor to the end user. Implementing an ERP system was a valid approach 
to reconciling and analyzing data from the supply chain because of the focuses on 
delivering actionable information in different forms. Melnyk, Narasimhan, and 
DeCampos (2014) called for future comparative studies to understand the context and 
characteristics of distinct supply chains.  
Sandhil and Gupta (2013) posited the primary goal of supply chain management 
was to reduce inventory. Sandhil and Gupta’s conclusion does not support the data in 
their report. Schaltegger and Burritt (2014) suggested two competing strategies for supply 
38 
 
chain management: risk and opportunity. The risk strategy relates to the methodology of 
supply chain leaders to eliminate adverse effects while opportunity relates to the 
methodology to increase the positive effects of supply chain management (Schaltegger & 
Burritt, 2014). Supply chain management effectually optimizes inventory levels and 
product turnover through constant analysis of the monitoring points within the supply 
chain. 
In special circumstances such as natural disasters or terrorist attacks, health care 
providers require utilization of some unique but not commonly used pharmaceutical 
products. Limiting the specialized inventories used by disaster responders during 
humanitarian relief efforts may put public health at greater risk than maintaining lean 
inventory supply levels. Tukamuhabwa, Stevenson, Busby, and Zorzini (2015) concluded 
supply chain management research in cross-functional knowledge sharing strategies, 
cross-organizational collaboration, and improved combined technological approaches 
strengthen the foundation of future supply chain management strategies for disaster relief 
responses. 
System complexities in a growing globalized supply chain. Cherici et al. (2011) 
postulated instabilities reside in the supply chain because of systems complexities. In this 
commercial analysis, Cherici et al. suggested globalization of the pharmaceutical supply 
chain lead to increased product recall, a reduction of API quality because of the lack of 
foreign regulatory inspections, and a decrease of product profit margins. Each case of 
instability may cause delays, increase costs, or amplify life-threatening medical errors. 
Part of the manufacturing process for medication requires an abundance of 
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foreign-sourced raw material (Cherici et al., 2011; DeOlivera, Theilken, & McCarthy, 
2011; Johnson, 2011; Quilty et al. 2011; Ventola, 2011). Cherici et al. (2011) suggested 
80% of raw materials are foreign sourced. Johnson (2011) also submitted raw materials 
for the production of existing low margin API’s be at risk of diversion for the 
manufacturing of more profitable next generation products. Cherici et al. (2011) indicated 
42% of pharmaceutical product recalls for sterile injectable drugs related directly to the 
quality of the manufacturing process. Cherici et al. (2011) theorized additional costs from 
the product recall will burden the manufacturer and may divert profits from addressing 
the manufacturing deficiency or investing in modern equipment and personnel training. 
Cherici et al. (2011) suggested adopting a formal purchasing policy and maintaining clear 
channels of communication may help to manage drug shortages. Pharmaceutical product 
recalls present additional processing challenges because of less than optimal reverse 
distribution channels (DeOlivera et al., 2011). 
DeOlivera, Theilken, and McCathy (2011) and Woodcock and Wosinka (2013) 
reasoned a growing question of sustainability existed in the pharmaceutical supply chain. 
DeOlivera et al. (2011) concluded the increase in the duration of drug shortages supports 
the notion of decreased sustainability within the supply chain. The introduction of lean 
manufacturing and lean supply processes had detrimental effects on the viability of many 
mainstay drugs (DeOlivera et al., 2011; Fox et al., 2009, Le et al., 2011). In 2011, 
multiple drugs existed within the same therapeutic class on extended shortage, increasing 
manufacturing complexity for newer therapies, and increasing shortages in areas such as 
pediatric oncology or anesthesiology (DeOlivera et al., 2011; Le et al., 2011). Even the 
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slightest disturbance may exacerbate fragile lean supplies (Fox et al., 2009; Ventola, 
2011). 
One of the most affected drug classes was oncology, which includes sterile 
injectable medication (Balkhi et al., 2013; Sharma et al., 2013). DeOlivera et al. (2011) 
concluded the proliferation of drug shortages related to this class continues to present a 
clinical challenge to oncologists and patients. Proportionately, with other medications 
experiencing shortages, sterile injectables increased 37% in 5 years (DeOlivera et al., 
2011). Complexities in the manufacturing process of these types of drugs may have a 
causal relationship to shortage conditions within the drug class (Balkhi et al., 2013). 
Industry consolidations and solely sourced pharmaceuticals. Industry 
consolidations influence the economic health of the industry (Dorsey et al., 2009; Fox et 
al., 2009; Schweitzer, 2013). In this quantitative study, Dorsey et al. (2009) analyzed the 
economic costs related to the drug substitution for a drug used to treat Parkinson’s 
disease. When the production of Apotex consolidated to one manufacturer, the supply of 
the medication experienced shortages and delays (Dorsey et al., 2009). The societal costs 
associated with this shortage, lasting four months, totaled $75,000.00 (Dorsey et al., 
2009). 
Consolidation through mergers and acquisitions are a method used in industry to 
diversify the organization’s drug portfolio and to spread economic risk among greater 
portions of the organization (Dorsey et al., 2009; Fox et al., 2009; Schweitzer, 2013). 
Dorsey et al. (2009) viewed these types of consolidations as potentially anti-competitive 
because of the internal economic conflicts between branded and generic drugs, which 
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may hinder the production of lower cost products. Iacocca, Sawhill, and Zhao (2015) 
concluded pharmaceutical manufacturers are reluctant to lower prices during brand to 
generic conversions because of conditions of brand loyalty and price insensitivity. 
Consumers have a growing preference for newer drugs in the market (Iacocca et al., 
2015). Dorsey et al. concluded single sourced drugs may be at risk for increased 
inspection levels for all facets of the production process. This condition could require the 
manufacturer to expend additional costs towards the inspection process. 
Early warning sentinel systems for supply chain disruptions. Born (2012) 
stated the accumulation of allocative and productive inefficiencies in the U.S. drug 
supply chain and distribution channel required congressional leaders to devise a 
collective response plan among all stakeholders. The collective response would reduce 
the negative qualitative and quantitative effects of drug supply disruptions (Born, 2012). 
In the pharmaceutical industry report, Fox et al. (2009) offered several observations. Staff 
members of effective health care organizations are primarily required to participate in 
strategic planning including management of drug supply chain disruptions as part of 
business contingency planning. Drug shortages may occur without adequate advanced 
warning even with the introduction of new technology in the supply and distribution 
network (Jagsi et al., 2014). Another observation from Fox et al. was rural hospitals may 
appear at greater risk because of the lack of borrowing power from neighboring hospitals 
or pharmacies. Fox et al. argued drug shortages may cause unnecessary situations of 
large-scale stockpiling or hoarding as a reaction to new shortage notifications, while 
Gupta and Huang (2013) stated that wholesalers should stockpile hard to acquire 
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products. Fox et al. associated this type of behavior to the lack of information because of 
system complexities, fragmentation, and uncertainty created by inadequacies within 
feedback loops. 
Fox et al. (2009) recommended the development of an early-warning sentinel 
system designed to notify health care providers when a potential supply interruption 
exists. Hunnisett-Dritz (2012) found clinical use documentation in treatment protocols of 
most drug classes, which identify acceptable forms of drug rationing or substitution. 
Advanced warning programs may reduce the possibility of patient prioritization, drug 
rationing, and changes in therapy regimens, each having an ethical consideration as part 
of the decision process (Chabner, 2011; Fox et al., 2009; Johnson, 2011; Krisl et al., 
2013; Quilty et al., 2011; Ventola, 2011). Fox et al. warned of legal implications resulting 
from improper care, which may harm the provider’s reputation and cause additional 
expenses to defend possible legal proceedings. In an opinion article, Born (2012) 
identified a 2011 bill introduced in the United States Senate, the Preserving Access to 
Life-Saving Medications Act (S. 296), which added civil penalties to manufacturers who 
failed to notify the FDA adequately of instances, which may lead to supply interruption 
or shutdown.  
In a quantitative study reviewing future pharmaceutical expenditures, Hoffman et 
al. (2012) revealed 78% of all retail prescriptions in 2010 were generic equivalents to 
branded medications. The direction of consumer markets leans towards less expensive 
generic drugs, with lower profit margins than the original formulation, and away from 
brand name drugs. Hoffman et al. and Schweitzer (2013) declared utilization of generic 
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drugs continues to grow in outpatient settings, but the growth of generic utilization was 
flat in hospital settings. 
Hoffman et al. (2012) surmised health care systems in the United States would 
expend an additional $216 million in annual labor costs related managing drug shortages. 
Kaakeh et al. (2011) and Ventolla (2011) arrived at a similar amount of expense in their 
studies as Hoffman et al. When the less expensive drug was in short supply, additional 
health system profits are lost to the procurement of more expensive alternate medications 
(Hoffman et al., 2012; Kaakeh et al., 2011, Le et al., 2011; McBride et al., 2013; Ventola, 
2011). Hoffman et al. illustrated this problem by discussing the difference in the market 
price for levoleucovorin, the alternate drug, which was 60 times higher than the generic 
sterile injectable drug leucovorin. Leucovorin was a mainstay oncology drug used to treat 
colon and rectal cancer for several decades (Van Cutsem et al., 2012). 
To moderate overall growth, Hoffman et al. (2012) concluded reductions in drug 
expenditures attributed to the conversion of brand name drugs to generic equivalents help 
to subdue costs. Likewise, biosimilars, the generic approved version of a biologic agent, 
have the potential of contributing to cost savings. Hoffman et al. discovered 39% of 
clinical practitioners were unfamiliar with the concept of biosimilar use, and 21% would 
require additional information before making any decision to prescribe the product. 
In a 2011 quantitative study, Le et al. (2011) argued children, elderly, and 
individuals with rare diseases face the greatest challenges resulting from drug shortages 
or supply interruptions. This issue exists partially because as of June 1, 2011, Le et al. 
calculated the average duration of a drug shortage reported to ASHP was 511.1 days. Le 
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et al. (2012) and Krisl et al. (2013) postulated shortages affect almost every therapeutic 
class of drugs. Severely challenged individuals may prove physically or mentally unable 
to endure the length of the average shortage without the introduction of other costly 
medical interventions (Krisl et al., 2013). 
Additional risks to productive efficiencies lay in the absence of multiple active 
ingredient manufacturers for drugs in short supply (Le et al., 2011). Manufacturing 
capacity has an effect on supply chain efficiencies (McBride et al., 2013). Le et al. (2011) 
observed almost 50% of all drug shortages reported to ASHP, relate to products made by 
fewer than four manufacturers. Le et al. also calculated 76.5% of all drug shortages are 
sterile injectables creating a substantial negative impact on oncology treatment protocols. 
Resulting from the procurement of alternate or substitute drugs, Krisl et al. 
(2013), Le et al. (2011), and McBride et al. (2013) theorized the providers incur 
additional costs because of additional (a) tracking methodologies, (b) training of clinical 
personnel, and (d) monitoring of the affected patients. Frequently, this changeover must 
take place rapidly because of the lack of notification from the manufacturer. The 
unplanned therapy disruption has adverse effects on treatment outcomes (Le et al., 2011). 
Krisl, Fortier, and Taber (2013) studied drug shortages from the perspective of 
organ transplants. Krisl et al. discussed complexities of the changes made to prove 
treatment regimens when cornerstone transplant drugs are in short supply or completely 
discontinued. Clinicians may face difficult decisions to ration particular drugs when 
supply was limited or delayed. Challenges to transplant patients may continue because of 
adverse effects of alternate or substituted drug treatment (Krisl et al., 2013). Krisl et al. 
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(2013) theorized other drugs may fall into supply deficiencies because of the switch away 
from the original product placing an undue burden on the supply of the alternate product. 
Hawley, Mazer-Amirshahi, Zocchi, Fox, and Pines (2016) concluded medications for use 
in hospital emergency departments (ED) face severe challenges because of the steep 
increase in the occurrence of ED shortages since 2008. 
Situational awareness in supply chain conditions. Awareness of supply chain 
conditions was the first step in the contingency planning process for transplant clinicians 
(Krisl et al., 2013). The next steps involved comprehensive assessments of the 
therapeutic and operational process in understanding durations, severity, and the affected 
population. The findings in the analysis helped the researcher understand what types of 
products would be in demand during a shortage (Krisl et al., 2013). Krisl et al. (2013) 
supported increased communications from every entity as a tool to manage drug 
shortages efficiently. 
Schweitzer (2013) had a different perspective on how to resolve drug shortages. 
Instead of resolutions from industry, Schweitzer proposed to have the FDA implement 
two possible solutions. Schweitzer contended profit margin pressures from industry 
manufacturers have led to the globalization of production environments where 
manufacturing of multiple products or components were at a single site. Nagurney, Yu, 
Masoumi, and Nagurney (2012) indicated financial pressures and reduced profit margin 
pushed some manufacturers to cease production entirely. Schweitzer maintained lean 
inventory levels were insufficient to sustain long durations of shortages or disruptions. A 
tradeoff of economic risk exists between the financial advantages of lean inventories and 
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the potential financial costs of remediating drug supply disruptions. Each manufacturer 
evaluates and chooses their level of risk knowing the costs and their flexibility during 
changes of direction.  
Regulators at the FDA should first develop ways to improve their inspection 
process before conditions warrant taking the deficient production facility offline 
(Schweitzer, 2013). The outcome of the inspection should not reflect passing or failing 
but rather one of four grading levels designed to identify the quality aspects of the 
production process and the upkeep of the facility (Gupta & Huang, 2013; Schweitzer, 
2013). Schweitzer (2013) also explained consumers are sensitive to quality issues and 
may be more apt to pay for products with greater effectiveness and reduced risk. Gupta 
and Huang (2013) recognized that industry lacks quality indicators for consumer 
evaluation, which may support the notion of improving the profit margin for better 
quality products. 
Sharma et al. (2013) discussed the global perspective of drug supply chains and 
distribution channels. New emerging markets, such as Brazil, India, China, Mexico, and 
Russia, experienced the benefits of greater health care access including access to 
mainstay drugs. Sharma et al. estimated the CAGR for global pharmaceuticals was 5% 
between 2011 and 2017. Emerging markets will increase spending another 16% of health 
expenditures by 2015 (Sharma et al., 2013). 
From a pharmaceutical consumption perspective, Sharma et al. (2013) calculated 
spending on brand name products would decrease 23% in the global market because of 
patent expiration. The markets would experience the same percent of the increase in 
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generic formula spending respectively (Sharma et al., 2013). This global shifting 
circumstance may exert additional capacity pressure on generic manufacturers. Sharma et 
al. suggested India’s pharmaceutical manufacturing industry be a consideration for large 
manufacturers as a means to produce low-cost products. Given the shrinking U.S. wage 
gap with countries such as China, Mexico, and India, the pharmaceutical industry should 
require other stable economic incentives to place large volumes of production 
requirements in locations with a growing labor force. 
Fragile complexities exist in the supply of raw materials used for the treatment of 
enzyme-deficiency disorders and radioactive isotopes used in cardiac and bone scans. 
Steinbrook (2009) as an example suggested a virus hindered the growth of ovarian cells 
in Chinese hamsters used to develop biological medications. Clinical managers at the 
production plant were able to use part of their safety stock and help with information on 
dose conservation during the cleaning and sterilization process of the facility. In the 
second example, two nuclear reactors unexpectedly shut down causing a shortage of 
Technetium-99M, a radioactive isotope used in radiopharmaceuticals (Steinbrook, 2009). 
Each of the reactors showed signs of aging because of neglected long-term maintenance 
requiring immediate attention. 
Steinbrook (2009) identified fragility in the supply chain for 
radiopharmaceuticals, calling into question the effects of global political pressures to 
reduce excess amounts of highly enriched uranium, which may fall into the hands of 
terrorists. Steinbrook (2009) proposed shifting production to low-grade uranium to make 
some of the radiopharmaceutical products because low-grade uranium was not suited to 
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use in the production of a weapon of mass destruction. Steinbrook realized 
comprehensive contingency plans have a higher possibility of success rather than 
improvising when faced with a clinical crisis. 
Quilty et al. (2011) offered examples of supply opacity by explaining that new 
supply shortages and disruptions occurred because of natural disasters across the globe. 
Hospitals in Australia had two weeks of advanced notice to prepare for a penicillin 
shortage. Quilty et al. suggested nations reliant on pharmaceutical imports are more 
vulnerable to the system fragility, which may threaten the state of public health. 
Quilty et al. (2011) observed how a large Australian hospital prepared to assess 
the effects of a local disaster on drug stocks. Quilty et al. postulated no specific 
guidelines existed to help plan for disaster contingencies in the hospital. Furthermore, 
Quilty et al. called into question the importance of constructing pharmacies to withstand 
basic types of disasters. This position on business contingency resonated throughout 
Ventola’s (2011) study. Quilty et al. also hypothesized the importance of requiring local 
manufacturers to build excess capacity; thus, creating safety stocks of critical 
medications, which supports sustainability in light of potential disasters. Quilty et al. 
suggested planning for natural disasters should include intelligent supply thresholds of 
essential disaster medications to assist in extensive recovery efforts. 
Ventola (2011) argued supply and demand could exceed expectations as feedback 
response interpretation fails to modify the conditions of the system. Ventola identified the 
presence of this situation by discussing the problems in the supply chain caused by a 
change in a therapeutic guideline for pediatric influenza vaccines. Ventola pointed to the 
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Centers for Disease Control’s failure to provide advance warning to the manufacturers 
before expanding the age requirements for this therapy. 
FDA regulators may expand agency capabilities to assist manufacturers and 
health systems with issues related to drug shortages (Ventola, 2011). Drug wholesalers 
with constrictive supply chain models such as product exclusivity agreements with 
manufacturers may create shortages without implied intent (Ventola, 2011). Wholesalers 
provide higher quality communications about drug shortage notifications and or updates 
on the status when placed in strategic positions. Based on survey data Ventola (2011) 
wholesalers ranked last as an information resource for drug shortages. Ventola also 
observed an increased supply risk in geographic areas serviced by only one wholesaler. 
Spencer and Carlan (2008) discussed the effects of complexity theory found 
within the automobile industry. Spencer and Carlan hypothesized positive feedback loops 
disrupt employee safety in manufacturing environments. In this study, parallel situations 
exist similar to those in pharmaceutical manufacturing. Positive feedback loops in the 
automobile manufacturing industry disturb the control environment as they do in the 
pharmaceutical environment. The coincidental similarities discussed by Spencer and 
Carlan are concerning because comparable levels of manufacturing complexities exist 
between automobiles and pharmaceuticals. In both industries, comparable regulatory 
oversight exists. 
Positive feedback loops, described in Spencer and Carlan’s (2008) study, have 
irremediable and indeterminable outcomes, which magnify risks for system and process 
functions leading to manufacturing interruption or complete collapse. Negative feedback 
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loops such as those found in ISO 9000 or ISO TS 14000 series can mitigate the effects of 
positive feedback loops and restore system equilibrium. The interactions between 
positive and negative feedback loops help to develop new organizational processes thus 
moving strategic objectives, such as quality or zero defect manufacturing closer to 
realization. 
Stevenson and Busby (2015) focused on the prominence of counterfeit and 
adulterated drugs, which may enter the global supply chain or distribution channel and 
cause further disruptions. Bollampally and Dzever (2015) argued for the further research 
and potential global use of radio frequency identifiers (RFID) to reduce counterfeit and 
adulterated drugs in the supply chain. In developed countries, minimal counterfeiting 
exists because of the overlapping regulatory and security measures in place within the 
supply chain, distribution channel and at the end user (Blackstone, Fuhr, & Pociask, 
2014). 
Greater percentages of tainted products exist in emerging markets than established 
markets, which seem to indicate the absence of a structured quality assessment process in 
newer economies (Bollampally & Dzever, 2015; Woo, Wolfgang, & Batista, 2008). Woo 
et al., (2008) reported since the introduction of Internet-based pharmacies, the FDA 
investigators published online a list of foreign-based pharmacies, which have instances of 
selling counterfeit medications. 
Woodcock and Wosinka (2013) theorized the root cause of drug shortages was 
because of the absence of incentives and rewards for production quality. Lack of quality 
perceptions from the buyer and end user was because of limited visibility in the market, 
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which includes stability of the supply chain and distribution channel (Gupta & Huang, 
2013; Woodcock & Wosinka, 2013). The focus of Woodcock and Wosinka’s (2013) 
discussion was the notion of supply interruptions becoming channel shortages. Lean 
inventories, single sourced manufacturing, aging equipment, and facilities contribute to 
supply interruption risk (Woodcock & Wosinka, 2013). Shah (2004) suggested the supply 
chain was a value channel where innovations in organizational development reverberate 
through the flow of products. The supply chain and distribution channel are also a source 
of usable information and a source of valuation.  
Regulatory and Public Health Policy 
The FDA was responsible for a large portion of the regulations associated with 
pharmaceutical manufacturing and product development. Pharmaceutical policy was a 
sub-category of health policy with responsibility for framing the drug development 
process. Pharmaceutical policy manages the factors of use and delivery and qualifies the 
components of drug formularies. These elements help shape the pharmaceutical industry 
landscape. Chabner (2011) opined as pharmaceutical spending outpaced medical 
spending, the United States began passing laws to curb the growth of drug expenditures. 
The United States Food and Drug Administration. Before 1980, regulators at 
the FDA acted paternally in a protectionist approach to drug approvals and manufacturing 
inspections (Richert, 2016). The FDA regulators would frequently exert their influence 
on manufacturers because of perceptions of patients requiring protection from unsafe 
products devoid of clinical benefits (Richert, 2016). Several executive administrations 
leading up to the AIDS movement in the early 1980s supported this behavior. 
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The AIDS movement of the 1980s pushed FDA’s senior leadership to reconsider 
changing its direction because of patient activism. Richert (2016) suggested the FDA 
transitioned away from protecting patients from quality issues to helping patients gain 
access experimental drugs by allowing them to weigh the treatment risks independent of 
clinical trial participation. Butterfield, Cash, Pham, and Advocacy Committee for the 
Pediatric Pharmacy Advocacy Group (2015) suggested the FDA include special 
management processes for pediatric drugs in their mitigation strategies.  
Dorsey et al. (2009) concluded single source generic products may have potential 
risks with the lack of available substitutes. Considering drug shortages in generics, 
patients who switched back to the more expensive branded drug were less likely to return 
to the original generic version (Dorsey et al., 2009). McLaughlin and Skoglund (2015) 
suggested drug shortages are especially apparent in the outpatient home infusion areas of 
health care delivery often lacking viable alternates or substitutes. This circumstance 
prolongs higher than expected drug spending and contrasts with the economic goals of 
branded to generic pharmaceutical conversions. 
Ventola (2011) discussed the need to increase the methods and cadence of FDA 
communications. The FDA may receive as much as a 6-month notification from a 
manufacturer alerting the agency of potential manufacturing problems (Ventola, 2011). 
Increasing the lead-time of notifications may help other manufacturers to increase the 
capacity of their production lines and potentially avert a severe shortage situation. 
Ventola also concluded wholesale manufacturers and other specialty distributors must act 
in the best interest of the market by alerting their customers in the early stages of 
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shortages or delays. 
Crediting the diligence of the FDA, Woo et al. (2008) declared the U.S. 
pharmaceutical supply chain as one of the safest and most secure pipelines in existence. 
Globalization now brings additional complexities and challenges to maintain security 
from counterfeit or adulterated products entering the supply chain and distribution 
channel (Link et al., 2012; Woo et al., 2008). Woo et al. posited globalization also 
increased the complexity with not only the number of new products but also the 
organizations working in the industry. Officials at the FDA have also posted on-line lists 
of Internet pharmacies, which distribute counterfeit drugs from a foreign-based pharmacy 
(Woo et al., 2008) 
Roberts (2014) concluded information security was an important component of 
the security of the drug supply channel. Woo et al. (2008) recommended the FDA use a 
combination of safety and security concerns when marshaling resources to apply to drug 
shortages. Combating problems of data inconsistencies, fragmentation of systems and 
regulatory bodies, and the problem with import circumvention, Woo et al. concluded 
electronic pedigrees affixed to pharmaceutical containers represent the most effective 
means of reducing or eliminating counterfeits or adulteration. Woo et al. did not discuss 
the costs of global implementation, which may prohibit practical application of a vital 
element of supply chain safety. 
Y2K: The infancy of the FDA’s response to drug shortages. Kweder and Dill 
(2012) discussed in their empirical study the genesis of drug shortage monitoring. 
Established by officials at the FDA in 1999, the Drug Shortage Program’s (DSP) mission 
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was monitoring the drug supply chain and distribution channel for interruptions caused 
by the passing of the century into a new millennium. Although nothing extraordinary 
came about from the Y2K phenomena, smaller pharmacies inquired with the FDA about 
obtaining assistance. Officials at the FDA responded by revising the feedback process 
between the distributors and the providers (Kweder & Dill, 2012). 
Reported shortages and delays of medications increased, and the durations 
became longer and more frequent, which caused regulators at the FDA to focus more on 
the quality issues of the production process (Kweder & Dill, 2012). The DSP began 
tracking drug shortages in 2005. Initially, the DSP report contained 61 known shortages, 
which 51 were sterile injectables for use with oncology patients (Kweder & Dill, 2012). 
In this study, Kweder and Dill (2012) argued a significant amount of authority evade the 
FDA. The FDA regulators cannot make a manufacturer produce a product or increase 
production levels of the product, decide how and where to distribute, and until recently 
could not require advanced notification of a pending shortage, delay or discontinuance of 
any product (Kweder & Dill, 2012). 
New improvements for FDA’s business process. Officials at the FDA are 
recommending their regulators take on the role of a first responder when notified of 
pending shortages. Chabner (2011) discussed new efforts by the FDA to step up the 
frequency of inspections of new and refurbished facilities. Regulators at the FDA will try 
to expedite approvals for non-domestic sources of products. Pfizer and Sanofi are among 
growing number of drug companies offering generics overseas, which are comparable to 
those found in the United States (Chabner, 2011). Chabner postulated the drug 
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manufacturers should encourage FDA officials to examine these sources of 
pharmaceutical supply and open new market sources to stem the rising incidents of 
shortages and delays. 
Woodcock (2012) commented on the leadership position of the FDA related to 
developing the manufacturing quality of domestic manufacturing facilities. Woodcock 
offered commentary to suggest other manufacturing sectors utilized various quality and 
defect management systems like ISO series and Lean Six-Sigma to attain higher 
standards Woodcock commented these types of programs would strengthen domestic 
manufacturer’s ability to resolve the intractable problems of shortages and delays. 
All types of U.S. pharmaceutical manufacturers, large and small, producing 
branded and generic products, prescribed, or over-the-counter have been the subject of 
supply disruptions (Woodcock, 2012). Improving the mission of the FDA by (a) 
implementing more educational programs for manufacturers, (b) conducting more 
investigations before manufacturing quality becomes a disqualifying characteristic, and 
(c) promoting the elevation of manufacturing sciences among global manufacturing 
aligns industry goals with the compliance goals of the FDA (Woodcock, 2012). 
Pharmaceutical patent regulations in drug development process. A central 
feature of drug development was the reward of a patent and market exclusivity. Granting 
of patents from the United States Patent and Trademark Office happen after FDA 
regulators issue approval. Patents have a 20-year lifespan. During the patent period the 
recipient of the patent can recoup costs associated with the research and development of 
future medications; however, in countries like Japan and Europe, government regulations 
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may place constraints on the price of the newly patented drug (Daemmrich, 2013). 
Patents enable drug manufacturer to recoup costs associated with the development of the 
drug along with the costs of other drugs, which failed the clinical trial process (Basheer, 
2012). 
Market exclusivity rights granted by regulators at the FDA may run concurrently 
with the patent. Exclusivity was a method of creating market economic parity between 
generic and new product innovation competition for 180 days and 7 years depending on 
the type. Basheer (2012) argued pharmaceutical manufacturers require longer patent 
exclusivity because of the large capital expenditures; however, research findings 
suggested manufacturers may take advantage of weak areas in FDA legislation to protect 
investments in research and development. 
In his findings, Kesselheim (2011) concluded pharmaceutical development 
increased through government research projects following the Bayh-Dole Act of 1980. 
Concerns about intellectual property protection may raise the investment costs of 
biomedical research and slow the investigative process (Kesselheim, 2011). Additionally, 
the passing of the Hatch-Waxman Act in 1984 ignited the tremendous expansion of the 
generic market (Hemphill & Sampat, 2012), which drove down the costs associated with 
drug treatment regimens. 
Kesselheim (2011) evaluated the effects of the Orphan Drug Act and concluded 
the act had limited success while finding support for his conclusion in the results from 
similar European legislation. Orphan drugs are more likely to hold a substantial profit 
margin and less likely influenced by generic competition than brand name drugs 
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(Kesselheim, 2011). In an earlier study, Kesselheim observed a potential for the 
manufacturer to manipulate the deployment of orphan drugs to earn incentives citing the 
original 1989 release of epoetin alpha (Epogen, Amgen). Initially, the drug released as an 
orphan drug for anemia, but in later clinical indications doctors used the medication in 
cancer and cardiovascular treatment. Kesselheim summarized market exclusivity alone 
did not influence product innovation because of other confounding issues. The best 
scenario for the industry and public health was linking incentives to tangible treatment 
outcomes (Kesselheim, 2011). 
Kesselheim (2011) conducted an empirical review of major pieces of legislation. 
From a legislative perspective, drug development was a uniquely complex process, which 
requires substantial capital investments and was highly resource intensive. The patent and 
market exclusivity rewards help to offset the losses from the failed clinical trials of other 
pharmaceutical projects. Fleischhacker, Ninh, and Zhao (2015) claimed the clinical trials 
supply chain requires more research exploration to support consistent outcomes. 
Kesselheim proposed stretching the product patent to 25 to 30 years for highly 
therapeutic drugs may have limited economic effect because of the highly discounted net 
present value (NPV) of the calculation in later years. Instead, Kesselheim promoted the 
notion incentives aligned with development outcomes would produce a better response 
from manufacturers. 
In an earlier empirical study, Kesselheim (2011) speculated patent extension 
should spur drug development and innovation in research. Spreading out financial returns 
may reduce the initial price of the drug, thereby increasing levels of therapy compliance 
58 
 
(Kesselheim, 2011). Kesselheim postulated some of the approved drugs related to the 
Prescription Drug User Fee Act (PDUFA) of 1992 wind up on recall possibly because of 
rushed approvals. Kesselheim argued misuse of incentives often influence cost savings to 
patients and the government. 
Kesselheim, Polinski, Fulchino, Isaman, and Gagne (2015) discussed potential 
effects on approval pathways, which the Generic Drug User Fee Act (GDUFA) had on 
the FDA’s ability to increase processing of new generic applications. The expected total 
fees, $299 million per year for 5 years, would help agency officials at the FDA acquire 
resources and technologies needed for long-term administration of the program (Sisodia, 
2013). Sisodia (2013) calculated the program would cost an average of 10 cents per 
prescription. The fees will assist smaller first-time entrants with the ability to receive 
expedited reviews and reductions in the time to commercialize their product (Krisl et al., 
2013). 
 The FDA will undergo momentous but warranted changes between 2013 and 
2017, which will (a) enhance organizational efficiency, (b) build backlog and application 
metrics, (c) promote good manufacturing processes from site inspections, and (d) explore 
new industry guidelines. The proposed enhancements provide layers of safety (Krisl et 
al., 2013; Sisodia, 2013). Officials at the GDUFA may attempt to create parity between 
foreign and domestic good manufacturing processes (GMP) inspections and to identify 
those manufacturers who do and do not receive regular GMP inspections. Sisodia (2013) 
concluded the GDUFA helps new entrants and increases the quality and access to lower-
cost generic medications, which may support the mitigation of drug shortages. 
59 
 
Schweitzer (2013) discussed another possible change to FDA regulations 
suggesting regulators at the FDA implement a grading system rather than a pass-fail 
system for manufacturer inspections, which may influence consumers and producers to 
strive for higher quality rankings. Higher quality rankings indicate a competitive 
advantage for producers. Consumers have shown sensitivity to ranking or grading 
schemes in other areas (Schweitzer, 2013). Schweitzer further concluded consumers may 
pay for quality and may have stronger brand loyalty to manufacturers, who consistently 
rank higher on the quality scale. 
The FDA regulations contain a pass-fail system, similar to the previous system of 
the food service industry. Regulators in cities around the United States moved away from 
this grading system in favor of letter grade quality indicators (Schweitzer, 2013). 
Restaurant owners may appear concerned with slipping grades than whether they were 
going to pass or fail a health department inspection. This mindset may translate to 
pharmaceutical manufacturers and provide an extra incentive to maintain higher levels of 
quality in their manufacturing process.  
Reverse payments or pay for delay: Unintended consequences. The growing 
process of reverse payments concerned Kesselheim (2011). Reverse payments mean 
generic manufacturers accept payments from brand-name manufacturers to delay the 
release of the generic equivalent (Hemphill & Sampat, 2012; Kesselheim, 2011). Reverse 
payments or the pejorative pay for delay tactics effectively increase the market life of 
branded drugs (Hemphill & Sampat, 2012). When the patent for terazosin (Hytrin, Abbott 
Laboratories) expired, and the generic manufacturer was about to enter the 180-day 
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exclusivity period, Abbott Labs paid the generic challenger to delay the launch of the 
generic drug (Frank & Hartman, 2015). The results of pay for delay settlements caused 
economic damage by artificially extending inflated drug costs to patients and both private 
and government insurers (Hemphill & Sampat, 2012). This transaction was a perceived 
consequence of the Hatch-Waxman Act, which should expeditiously facilitate the 
abundance of affordable drugs into the supply chain (Frank & Hartman, 2015; Hemphill 
& Sampat, 2012). Chabner (2011) proposed to improve the Hatch-Waxman Act by 
requiring the generic applicant to include a declaration of the production levels and 
methods of production redundancies to meet the market demands, prior to filing, for 
patent invalidation. 
Frank and Hartman (2015) observed both branded, and generic manufacturers 
support the legal standing of pay for delay settlements by promoting therapeutic and 
generic competition. In contrast, consumers perceive pay for delay settlements are anti-
competitive in nature because they eliminate a low-cost provider from entering the 
market. Hemphill and Sampat (2012) posited some of the court decisions favor settlement 
over protracted litigation. Furthermore, Frank and Hartman observed generic competition 
was the only method of fighting the influences of branded market economies. In patent 
law, the litigation settlements favor the innovator over the consumer. This conflict seems 
to increase delays in cost savings, which creates treatment compliance issues not found in 
treatments with low-cost medications (Kesselheim, 2011). 
Persuaded by the settlement offer of a pharmaceutical company, generic 
companies holding an Abbreviated New Drug Application forego manufacturing the 
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bioequivalent drug because the proposed settlement outweighs the profit potential of the 
generic launch (Kesselheim, 2011). Kesselheim further argued a 30-month generic launch 
delay awarded to the manufacturer for protesting the invalidation of its patent adds 
continuing challenges to the accesses of lower cost drugs. Kesselheim suggested looking 
at the cause of weak or invalid patents as the best solution to the issue. Currently, 
Congress was now considering making changes to patent laws relieving pressures on 
judges to choose between strengthening public health policy and eliminating unnecessary 
legal actions (Kesselheim, 2011). 
Drug importation and compounding pharmacies for critical national shortages. 
Hunnisett-Dritz (2012) conducted a case study to describe the process of importing the 
drug from outside the United States using the Personal Importation Policy (PIP) of the 
FDA. Cytarabine, an antineoplastic agent, used to treat several types of leukemia, was in 
short supply, in the United States, in 2011, but not in short supply globally (Hunnisett-
Dritz, 2012). A large acute care hospital, which treated approximately 2,000 new cancer 
patients per year, decided to locate and to procure Cytarabine from a reputable European 
supplier because of lingering shortages of oncology drugs (Hunnisett-Dritz, 2012). 
The hospital’s pharmacy team utilized the PIP guidelines to import a one-time 
small supply of the drug from the European supplier at an elevated per unit cost 
(Hunnisett-Dritz, 2012). Hunnisett-Dritz highlighted the decision process and the 
components of the risk-benefit assessment; however, no information was available to 
assess the costs associated with the procurement process including the repurposing of 
staff, both hospital and supplier, to complete the transaction. Hunnisett-Dritz (2012) 
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attempted to demonstrate the thought process of senior procurement leaders faced with 
difficult challenges and limited resources. 
Barlas (2011) opined Hospira, the manufacturer of propofol 1%, an important 
drug used in operating room sedation, was subject to recall of the product because of 
particles found in the vials. Officials at the FDA could not identify sufficient stock in the 
domestic supply chain; therefore, APP’s Fresenius Propoven 1% was temporarily 
imported. This importation was outside of the PIP constraints. Barlas (2011) suggested 
the imported drug had special dispensing preparations, which created a new set of 
procedures and risks. All health care providers may consider the positive aspects of a 
global governing agency because of the globalization of the supply chain (Johnson, 2011; 
Kweder & Dill, 2012). Regulators at the FDA, as a last resort, will relax importation rules 
to supplement the distribution channel artificially until the United States approved 
manufacturer was capable of resuming production (Kweder & Dill, 2012; McBride et al., 
2012). 
Outterson (2012) discussed the health benefits of having compounding 
pharmacies available to support critical drug shortages; however, Outterson argued for 
greater regulatory involvement by the FDA in light of the outbreak of fungal meningitis 
at the New England Compounding Center in 2012. These businesses operated an 
undefined grey area of health care supply (Outterson, 2012). FDA officials attempted to 
regulate the larger industrial-scale compounding sites with limited success. Outterson 
argued several factors of concern exist when evaluating products from a compounding 




Outterson (2012) explained the solution may require full disclosure to physicians 
and patients regarding the origin of the product, increased incentives for whistle-blowers 
and modifications of reimbursement standards for these types of operations. Outterson’s 
explanation focused on ex-post facto conditions. More workable solutions may focus on 
ex-ante standard compounding processes across the various state and local laws and 
establish uniform criteria for industrial-sized compounding operations, which service 
high patient volumes. These conditions ease support to local markets when supply 
disruptions exist for pharmaceutical prescribers. 
Medicare Prescription Drug, Improvement, and Modernization Act. 
Hornbrook et al. (2014) discussed substantial reimbursement changes by the federal 
government under the MMA affecting how government sponsored health insurance 
reimburses drug treatment administration on non-acute settings. Link, Hagerty, and 
Kantargian (2012) argued the reduction of reimbursement would redefine treatment 
methodologies of oncologists and the clinical settings for patients. Woodcock and 
Wosinka (2013) claimed prior to the enactment of MMA, price competition for sterile 
injectable drugs were already present in industry. Medicare and Medicaid beneficiaries 
purchase the most oncology drugs of any other payer class (Hornbrook et al., 2014). 
Hornbrook et al. (2014) reported one of the steepest reductions in reimbursement was a 
long-term cornerstone drug, Taxol (paclitaxel). Reimbursement for Taxol declined 81% 
from $138.28 to $25.84 beginning January 2005 (Havrilesky et al., 2012; Hornbrook et 
al., 2014). Link et al. (2012) suggested setting reimbursement floor limits for price 
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reduction would bolster the production of already lower cost generic oncology products. 
Creating a floor limit would provide a greater profit margin for pharmaceutical 
manufacturers without greatly increasing pharmaceutical spending (Link, Hagerty, & 
Kantarjian, 2012). Kinney (2013) reported physician reimbursement was the focus of 
several pieces of legislation; however, the emphasis was on controlling fraud and abuse 
and not creating fair compensation.  
One of the health care cost benefits of having oncologists administer these types 
of drugs was treatment infusion occurred in the physician’s office, helping to reduce the 
higher cost treatment in acute care centers (Malin, Weeks, Potosky, Hornbrook, & 
Keating, 2013). Further research may determine the long-term financial influence of 
MMA (Hornbrook et al., 2014; Malin et al., 2013). Havrilesky, Garfield, Barnett, and 
Cohn (2012) confirmed this position. The regulations in the MMA do not address the root 
causality of this situation by placing the economic burden on oncologists rather than 
requiring pharmaceutical companies to disclose the cost structures of their products. 
Chabner (2011) offered an argument suggesting multiple interrelated problems 
are the source of drug shortages and delays. Companies record a very small profit margin 
on the ledgers when they sell manufactured generic products on older equipment in less 
efficient settings (Link et al., 2012; Woodcock & Wosinka, 2013). This condition 
emphasized the need for legislators to understand the ramifications of reducing 
reimbursement (Link et al., 2012; Woodcock & Wosinka, 2013). The risk of shortage or 
interruption increases when exposed to leaner inventories and demands on raw materials 
shared with medications, which are more profitable (Chabner, 2011; Link et al., 2012). 
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Historical inspection records show a portion of the quality issues causing supply 
disruptions related to product contamination caused by older equipment in the 
manufacturer’s facility. Although a pharmaceutical product was still in high demand, 
some manufacturers, because of reduced reimbursement, hazarded their manufacturing 
process to maintain even small profit margins (Woodcock & Wosinka, 2013). 
Colla, Morden, Skinner, Hoverman, and Meara (2012) conducted a study to 
investigate changes in chemotherapy treatment at the end of life, leading up to and after 
the implementation of the MMA. Colla et al., (2012) concluded decreased utilization of 
chemotherapy existed for patients after the full implementation of the MMA legislation. 
Colla et al. (2012) concluded while chemotherapy treatment declined 20% in physicians’ 
offices, no such decline existed in hospital outpatient treatment centers. Antithetical 
outcomes existed for end of life cancer patients receiving treatment regimens in a 
physician’s office or outpatient clinic. Colla et al. (2012) suggested the reason may 
appear because of the lack of financial benefit to the oncologist prescribing chemotherapy 
in a hospital setting. Although more individuals have access to treatment, the intent of the 
act failed to control costs and harmed manufacturer’s ability to maintain production of 
the less profitable products.  
Capacity and Sustainability of the Supply Chain and Distribution Channel 
Woo et al. (2008) in a public policy article suggested the American 
pharmaceutical supply chain boasts one of the most impressive high standards of quality 
and security among other global pharmaceutical delivery systems. Spending in the U.S. 
pharmaceutical market by the year, 2016 will reach over $363.3 billion (IMS Health, Inc., 
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2012). The large aging population in the United States requires the drug supply chain and 
distribution channel to demonstrate characteristics of capacity and sustainability. The 
characteristics of capacity and sustainability may help the shift in process by health care 
providers to utilize pharmaceutical treatment regimens to meet evolving needs. Emerging 
nations not yet assimilated to westernized medical practices have unknown medical 
demands; thus, unknown supply demands exist on differing production timetables. 
This segment of the literature review includes: (a) the structural aspects of the 
pharmaceutical supply chain, (b) compounding pharmacies, and (c) the risks of grey 
markets. The complex and chaotic cadence of the pharmaceutical lifecycle challenges the 
notion of sustainability. As more disease states receive treatment with new drug 
regimens, the supply chain expands, just as distribution channel expansion occurs with 
new consumers.  
Globalization of the pharmaceutical supply chain. In 2015, officials in 17 
emerging market countries will spend more than $308 billion on medications (Sharma et 
al., 2013). According to Woo et al. (2008), China and India made up approximately 40% 
of all foreign FDA registered manufacturing sites in 2008.The entire pharmaceutical 
economy expects to grow at a rate of 5% CAGR (IMS Health, Inc., 2012). Maintaining 
high standards of quality and security are prominent objectives of all parties of the supply 
chain. Jaberidoost et al. (2015) concluded political unrest and war in countries like Iran 
have nearly eliminated the pharmaceutical supply chain. Sharma et al. (2013) suggested 
because of a large amount of brand to generic conversions; pharmaceutical organizations 
would build manufacturing facilities as a cost savings measure in emerging economies. 
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Sharma et al. (2013) posited some of the drug classes like oncology and 
antibiotics have a higher growth rate in countries such as India, China, Russia, Brazil, and 
Japan. This economic incentive may become a new marketing roadmap for 
manufacturers. One of the most serious concerns for pharmaceutical supply chain 
analysts was the information limitations to predict forward demand because of the lack of 
data collection to support feedback models Sharma et al. (2013). Newly developed 
products to treat new disease states require the economic benefits of adding 
manufacturing capacity to the supply chain equation. 
Gray and Manasse (2012) discussed the paradox of product expansion without 
capacity expansion. New pharmaceutical products for new disease states exist in the 
supply chain without the benefit of adding new manufacturing capacity. Without surplus 
capacity, minor disruptions can have catastrophic effects on the supply chain (Gray & 
Manasse, 2012). Without adequate data collection, a way of predicting demand or 
capacity may not exist; therefore, procurement leaders may consider what if strategies to 
assist with managing supply chain and distribution channel disruptions.  
Reports of worldwide shortages of mainstay drugs in fragile markets became 
normative (Goozner, 2012; Gray & Manasse, 2012). Again, the fragmentation of the 
information feedback loops was evident in this discussion. Neither discussion identified a 
common fundamental protocol in alerting markets of possible shortages or delays. The 
amount of employee time or resources health care procurement leaders may save if they 




Goozner (2012) opined even though pharmaceutical regulators in the United 
States reached out to other markets for assistance in importing drugs in short supply, 
those nations also had similar supply disruption issues. The economic slowdown of 2008 
and 2009 coupled with the instability of the European financial markets caused investors 
to withdraw investments from pharmaceutical stocks. In turn, a decrease in investor 
capital may have created novel economic challenges for the manufacturers to upgrade or 
maintain equipment and facilities during the downturn of the economy. 
Quilty et al. (2012) described the evolving global supply chain as a Pandora’s Box 
of vulnerabilities because of simple demographic differences. Disruptions from natural 
disasters such as fire, floods, and earthquakes may harm system equilibrium causing 
supply disruptions. Quilty et al. suggested the senior leadership staff members of The 
World Health Organization should include regulatory language associated with disaster 
recovery in its version of good manufacturing quality guidelines. Quilty et al. explained 
as the supply chain reaches the remote area, the risk of disruption increases 
exponentially. 
Schweitzer (2013) discussed the industry’s transition of complex supply chains 
for raw materials and finished pharmaceutical products from industrialized nations to 
emerging nations with lagging technology because of reduced profit margins. Schweitzer 
concluded the FDA found difficulty inspecting the offshore facilities rendering FDA 
supervision of foreign facilities ineffective. In one particular example, a manufacturing 
facility in China went without inspection because the FDA did not have a Mandarin-
speaking inspector. Noteworthy to this incident was the large heparin recall from this 
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facility in 2008 (Schweitzer, 2013). 
Both Cherici et al. (2011) and Johnson (2011) discussed the risks of raw material 
shortages occurring in distant locations outside of the U.S. manufacturer’s purview. Raw 
materials are the source of all drugs and hold the key to the production. Ventola (2011) 
posited a single raw material distributor could supply multiple manufacturers. Ventola 
further theorized an interruption of raw materials would affect all manufacturers. These 
interruptions could come from issues other than natural causes such as political unrest, 
wars, terrorism, and trade disagreements (Ventola, 2011). 
Woo et al. (2008) concluded the growing global base of pharmaceutical 
manufacturing created a risk for counterfeit or adulterated drugs. The global markets add 
complexity to a fragmented and siloed system, lacking complete visibility (Woo et al., 
2008). In this study, Woo et al. suggested the use of product DNA or the placement of 
RFID systems on the packaging to curb product tampering. 
Advantages of a growing global pharmaceutical production environment in 
emerging countries are the potential to solicit higher numbers of populations to provide 
human tissue, blood, stem cells, and other raw materials to make drugs and new biotech 
therapies (Farrugia & Cassar, 2013; Salter, Zao, & Datta, 2014). Emerging nations may 
also have new raw materials to use in pharmaceutical development from previously 
unknown plants, animals, or natural features. The literature review did not include 
discussion related to new raw materials, but this point of view was important to include in 




Lean manufacturing and lean inventory practices. Jahanbakhsh and Akafpour 
(2013) examined trade-offs between financial reward and risk in a lean production 
environment. Much of the pharmaceutical supply chain and distribution channel design 
engineers embraced lean thinking because of the financial rewards attributed to cost 
reduction. Lean production contains foundations of agility and flexibility gained by 
reducing or eliminating non-value added activities and concentrating on value added 
activities. Jahanbakhsh and Akafpour discussed the transition from a traditional push 
system to a more efficient pull system provides better workforce utilization and cost 
control than traditional methods. Pull systems enable the customer to pull the product 
through the supply chains with better quality and lower cost than traditional methods. 
Feedback models in the pull system alert upstream process areas of the need to satisfy a 
pending demand. Mehralian, Zarenezhad, and Ghatari (2015) suggested business 
environments rich with uncertainty and unpredictability deal with the changes by 
developing organizational agility or process fitness. 
From a financial perspective, lean production reduces overall costs because the 
production schedules align with demand drivers thus eliminating waste in idle processes. 
This process was also a vital component of Just-in-Time (JIT) delivery. One of the 
challenges with this methodology was for the manufacturer to be thoroughly entrenched 
in the culture, both internally and externally because unpredictable demand challenges 
can disrupt a production system out of alignment with customers and suppliers. Alizadeh 
(2012) interjected the idea of exponential smoothing in lean production where the 




Just as lean production reduced costs for manufacturers, lean inventories reduced 
the costs of inventory holding and the cost of obsolescence (Fox et al., 2009). Lean 
inventories in health systems, distributors, and large mail order pharmacies help health 
care professionals maximize the organization's cash flow. Investors and other 
stakeholders recognize this practice as sound business management. Manufacturers are 
commonly managing the inventory levels of the distributors to ensure the supply level 
was appropriate for the demand. Fox et al. debated if inventory levels in rural hospitals 
should reflect the risks of delivery problems because of the distance from the distributor 
and the lack of other health care providers to borrow critical products. The remote 
location of some health systems was a risk because the health system personnel may not 
be capable of maximizing inventory cost savings as hospitals in urban settings. 
Grey market distributors. Hospitals and wholesale distributors average one 
month of supply while health systems average about 2 weeks (DeOlivera et al., 2011). 
Woodward (2012) reported opportunistic distributors appear attractive to remote 
locations and hoard or stockpile drugs in short supply and then sell them to needy 
providers at significantly higher prices than before the shortage. Grey market distributors 
operate strictly for profiteering purposes (Chaudhry, 2014; Qureshi et al., 2012). Some 
products acquired on the grey market sold for as much as 600% of the regular wholesale 
distribution cost. Ahmadi, Iravani, and Mamani (2015) determined the extent of grey 
market distribution has increased with the growth of efficient global logistics networks.  
Woodward (2012) suggested grey market distributors, although legal, represent a 
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medical risk because of lacking process standardization. Industry questions their ability to 
obtain problematic drugs and sell them to hospitals with a limited and often contradicting 
chain of custody documentation. Hospitals have little alternative, but to trust the 
distributor and dispense the medication especially in time-sensitive acute care situations. 
Woodward (2012) argued the government has not done enough to control medical price 
gouging. The current political response was ineffective against this growing area of 
pharmaceutical distribution. 
Business Decisions 
Multiple drivers contributed to business strategy development. The swift global 
economic downturn in 2008 and 2009 caused executives of companies in the 
pharmaceutical market to pay closer attention to sales and profits rather than research and 
development. Pharmaceutical manufacturers were less likely to upgrade manufacturing 
equipment and facilities because investors withdrew massive amounts of money from the 
stock market. Barlas (2013) discussed the decision by the manufacturer not to upgrade 
equipment or facilities may be one of the reasons for drug supply disruptions  
One of the objectives of operating a large publically traded pharmaceutical 
company was to take a portion of the profit and reinvest the profit into the organization's 
infrastructure to maintain its capital assets, like buildings and equipment. Another 
objective was to take a portion of the profit and return the profit to investors in the form 
of stock dividends. Both objectives may make the stock appear as an attractive 
investment. When companies face threats to their profit margin, the executives from the 
company may abandon one or both of the objectives above. Since the investor was an 
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essential source of funding, the choice was likely to reduce capital maintenance until 
financial conditions change and permit the resumption of manufacturing the product. 
Barlas (2013) opined severe price competition influenced the capabilities of 
generic manufacturers to maintain equipment and facilities. The notion of paying for 
quality resonates through the health care industry. Barlas indicated pharmacy leaders see 
government-mandated pricing control as a contributing factor to drug shortages. Barlas 
opined the industry may need subsidies from the government to help generic producers 
deliver products similar to government crop subsidies paid to farmers. Barlas suggested a 
national reserve stockpile administered by the Centers for Disease Control; however, no 
cost-benefit analysis was available for drawing these conclusions. 
The value and reimbursement imbalances in the system confound the perception 
of sustainable cash flows. Kumar, Liu, and Scutella (2015) reasoned when 
pharmaceutical manufacturers in India discover specific potential supply disruptions for a 
drug, investors, and stakeholders of the firm may conclude a possible risk of equity loss 
exists. Market uncertainty may lead to unstable financial performance. From a system's 
perspective, the disruptions within the supply chain may influence the financial health of 
other stakeholders related to this industry.  
Crawford (2010) expressed pharmaceutical manufacturers employ highly paid 
lobbyists to argue for maintaining industry status quo when lawmakers attempt to 
introduce pricing regulations to lower the overall cost of care. One of the pricing 
regulations needing regulatory intervention was the issue of price discrimination, which 
suggests the individual price of the product in various markets be subject to inconsistent 
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pricing (Crawford, 2010). Circumstances of this type would mean the manufacturer could 
manipulate profits as needed. Health care regulations with minimal government 
intervention seemed to insulate manufacturers from most of the financial pressures during 
the last economic downturn. Crawford reported the drug makers maintained profit 
increases and confirmed positive earnings guidance throughout the economic slowdown 
between 2006 and 2009. 
Government intervention was not entirely bad for business (Crawford, 2010). In 
his analysis, Crawford explored pricing controls on monopoly producers of goods and or 
services. Crawford decided regulating prices may increase the quantity in the supply 
chain by reducing the risk of disruptions. The objective of Crawford’s study was to assess 
manufacturers of branded drugs having a healthy profit margin and not necessarily 
analyzing the effects on generic product profits. 
The business perspective of reverse payments. Academic literature related to 
reverse payments or the pejorative pay-for-delay scenarios identified opposing 
viewpoints. Hemphill Kraus (2012) posited senior leadership in the pharmaceutical 
industry rely heavily on patent protection for products and for steady profits. Others 
claim the patent protection supports product exclusivity and the capability to attract 
investors strengthening the equity flow to companies interested in the research and 
development (Drake, Starr, & McGuire, 2015). At stake are substantial long-term 
revenue rewards and the balance between innovation and competition. Drake et al. (2015) 
concluded stock prices for the patent holder fell 6% when the settlement notification 
included a reverse payment.  
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Hemphill Kraus (2012) posited the pay-for-delay scenario was disruptive to the 
spirit of the Hatch-Waxman Act by providing an imbalance between the innovator and 
the competition. In two instances, the FTC pursued litigation to invalidate pay-for-delay 
settlements because they seemingly violated anti-trust legislation (Hemphill Kraus, 
2012). Manufacturer’s profits for branded pharmaceuticals decrease once the generic 
producer has gained access to the marketplace. The loser in this profitability fight was the 
consumer (Hemphill Kraus, 2012; Kesselheim, 2011). 
Hemphill Kraus (2012) described different methods, which branded, and generic 
manufacturers sidestepped the United States Circuit Court’s antitrust intervention. 
Generic manufacturers will often include an unrelated product license, which functionally 
overstates the settlement price to the branded firm. In other instances, Hemphill Kraus 
identified branded drug firms would just supply the product to the generic firm at a 
discounted price, which then placed their generic label on the product and sold the new. 
Hemphill Kraus concluded because of the evolving settlement product at favorable prices 
structures in pay-for-delay settlements; the courts will have difficulty identifying and 
condemning these actions. 
Complexity of the Pharmaceutical Delivery System 
Narayana, Pati, and Prem (2014) suggested the existence of academic reservations 
within supply, capacity, and demand functions related to systems complexities in the 
pharmaceutical delivery system. Narayana et al. indicated limited academic research in 
pharmaceutical supply chain management contributes to the complexity within the supply 
chain and distribution channel. Research conducted by investigators in academia into new 
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product development, upstream processes, and increased business integration show small 
frequencies of interest (Narayana et al., 2014).  
Woo et al. (2008) discussed how the globalization of supply chains increased the 
degree of complexity because of additional lines of transportation, new distributors and 
repackagers, warehouses, expediters, brokers, and import or export agents. Woo et al. 
observed complexities in the system and fragmentation of regulators support the 
possibility to introduce counterfeit products because information gathering takes place 
only at the point of entry and not sequentially throughout the distribution process. Woo et 
al. argued in a public policy article the FDA cannot and should not police the entire 
supply chain; the industry must rely on systematic capabilities of advanced technological 
solutions to reduce or eliminate threats of drug supply disruptions. Janvier-James (2012) 
concluded the development and growth of supply chains involve intensive management 
planning of functions and roles by personnel to become efficient. 
Janvier-James (2012) used the findings of the study to identify potential solutions 
to the resource fragmentation in the supply chain. Woo et al. (2008) recommended using 
an executive order, which formed the Interagency Working Group on Import Safety to 
manage the safety concerns of imported products in the United States. Utilizing the 
process of working cooperatively, employees of government agencies and private sector 
manufacturers will solve problems at the source rather than mitigating them after product 
importation (Woo et al., 2008). Members of the Interagency Working Group on Import 
Safety’s focus was on ex-ante solutions but disbanded without public explanation. 
Spencer and Carlan (2008) discussed the complexities of the automobile industry 
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in the same context of the pharmaceutical supply chain. Spencer and Carlan postulated 
the automobile production environment operates far from equilibrium because of 
deficient equipment maintenance, and facility cleanliness, which leads to the issue of 
worker safety and health. Likewise, with pharmaceutical production, positive feedback 
loops push the system into imbalance possibly for the same reasons with similar 
consequences. 
From a complexity theory perspective, Spencer and Carlan (2008) theorized the 
automobile production process as operating between order and chaos highlighting the 
natural progression of emergent behaviors. Similarly, the pharmaceutical supply chain 
faces areas of order and areas of chaotic behavior as the realization of globalized medical 
care integrates into domestic practices. Gimenez, van der Vaart, and van Donk (2012) 
found adverse effects on supply chain costs with the increase of structured 
communications to obtain system integration. The global health care landscape will yield 
additional similarities over time.  
The emergence of pharmacoeconomics and biogenetic drugs add further 
complexity to the manufacturing process (Shah, 2004).Users of the pharmacoeconomics 
discipline assess the total costs and outcomes of treatment and biogenetic drugs target 
individual patient treatment regimens based on DNA mapping (Shah, 2004). Terror 
attacks with biologic agents and pandemic instances such as H1N1 influenza, Ebola, 
Zika, or Avian Flu (H1N5) necessitating new capacity needs requiring the addition of 
supportive products to the supply chain and distribution channel (Shah, 2004). New types 
of demands related to pandemics and bioterrorism may mandate manufacturers revise the 
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production process to become agile and flexible when delivering new drug therapies, 
which may eventually drive the system into further imbalance. 
In a process simulation and case study, Li, Yang, Sun, Yi, and Feng (2010) 
discussed CASN evolve because of influences from demand, market conditions, and 
regulatory measures. Li et al. cautioned industry firms to become more diligent about 
refusing inappropriate regulation because new regulations could quell adaptive and 
emergent behaviors necessary for the health of the supply network. Maintaining vibrant 
long-term relationships are vital to the performance of the stakeholders in the supply 
network. 
Li et al. (2010) identified costs and quality as the most important elements of the 
evolutionary process. From a managerial control standpoint, Li et al., observed CASN 
has an ability to adapt and emerge through self-organization. Li et al. suggested 
standardizing the manufacturing process into central locations to produce finished 
products where cost controls and quality maintenance procedures can have a maximum 
effect on operational controls. Contrasting theories appear to exist between Li et al., and 
others regarding globalization. Li et al. prefer the comfort of boundaries and rules, which 
are more concrete than other studies. 
Fox and Tyler (2013) observed the difficulty encountered by buyers making 
value-based decisions when the information was unavailable in an understandable and 
consumable format. Fox and Tyler supported the study by Woodcock and Wosinka 
(2013) and stated the conclusions of the study were rational. When discussing 
fragmentation, Fox and Tyler reported the FDA Orange book, FDA Medwatch Reports, 
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and FDA Form 483 (inspection reports) in conjunction with manufacturer appraisals 
provide a more comprehensive assessment of the degree of quality manufacturing 
processes. Fox and Tyler also reported the buyers were unable to make reasonable 
procurement choices without a proper manufacturer disclosure. 
Adverse Effects on Patient Outcomes 
Aside from the social aspect of drug shortages having a physical effect on 
patients, economic burdens increase on health care providers whom must pursue sudden 
alternative processes to care for the serious conditions (Institute of Safe Medication 
Practices [ISMP], 2010). ISMP was the nation’s leading authority on medication safety 
and acts as a centralized reporting location for medication errors in the United States. In 
2010, members of ISMP surveyed health care practitioners (N=1800) to understand the 
perceptions related to drug shortage treatment options. Members of ISMP reported 630 
(35%) of the 1800 surveys reported a near miss incident, which could have injured a 
patient further, directly tied to a drug shortage. 
In the survey, members of ISMP (2010) reported approximately 68% of the 
respondents were pharmacists. In the responses, nearly 80% reported severe financial 
impact related to the management of drug supply disruptions. The survey conducted by 
the members of ISMP also identified nearly 70% of respondents used significant 
resources administering or preparing alternative medications for patients. More than half 
of the respondents surveyed identified internal hoarding of drugs in short supply at their 
medical facility. These situations may be responsible for the 55% of the reported anger 
from physicians toward pharmacists and nurses identified in the survey.  
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The members of the ISMP (2012) survey team conducted a follow-up survey of 
100 practitioners to understand if the harmful effects of drug shortages continued. The 
introduction of substitute or alternate medications into the treatment regimen forced 
patients and caregivers into unfamiliar situations. Drug supply disruptions do not allow 
patients or their caregivers ample time to familiarize themselves with the dosing, 
administration, and new side effects of the new drug. Respondents to the ISMP 2012 
survey reported alternative medications accounted for derisory care in 35% of the cases. 
Practitioners in the follow-up survey reported medication errors related to strength and 
form of administration in greater than 25% of the responses. The survey contained many 
horrific adverse patient outcomes including multiple deaths because of errors in 
administering alternative or substitute medications. 
Mullins and Cook (2011) suggested in a pharmacy update article the causes of 
drug supply disruptions are numerous, and the effects on patient care are immeasurable. 
In their update article, Mullins and Cook suggested some drugs have alternates; some 
have substitutes, and some drugs have neither causing patients to endure long durations 
without the proper drug therapy. Mullins and Cook observed acute patient admissions to 
the hospital increased because disease states progress when the patient does not receive 
adequate drug therapy. For instance, Mullins and Cook observed patients receiving 
medication therapy for spinal cord injuries were unable to receive treatment with a high 
dose of methylprednisolone immediately following the injury because of shortages. 




Physicians and clinical practitioners select new alternative drugs with subtle 
differences in side effects, efficacy, duration of treatment, and interaction with other 
drugs, which potentially could also be alternate or substituted (Mullins & Cook, 2011). 
Each gradation of a new treatment procedure increases the risk of errors in judgment or 
practice. Iterations of new processes require the introduction of new cost structures into 
the budget allocation, further pressuring the cost curve. 
Mullins and Cook (2011) reported in a pharmacy update article increased costs 
affect three areas of health care treatment. Patients face higher deductibles when taking 
branded drugs instead of generics. Insurance companies pay for the costs of branded 
drugs or alternate therapies resulting from changes in patient treatment. Hospital leaders 
lose profit when using more costly drugs in procedures and when locked into a fixed 
price reimbursement from the insurer. Hospital leaders and physicians lose revenue when 
they have to cancel or delay procedures because of the inability to secure one or more of 
the drugs used in the procedure. 
The different faces of drug supply disruptions. For children with Hodgkin’s 
Lymphoma, the best curative treatment regimen involves a drug, mechlorethamine or 
nitrogen mustard, which has over 50 years of clinical use. Metzger, Billett, and Link 
(2012) opined pediatric Hodgkin’s Lymphoma was an extremely treatable form of 
cancer. The alternative drug in the treatment regimen was cyclophosphamide. Metzger et 
al. (2013) suggested treating children with the alternate product would significantly 
reduce the effectiveness of the therapy. The alternate drug had a greater occurrence of 
debilitating side effects. 
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The health issues created by drug supply disruptions retrograde the treatment of 
this condition by several decades (Metzger et al., 2013). Once thought to be highly 
treatable, Hodgkins Lymphoma was just a manageable waiting game. Until the supply of 
this product returns to acceptable levels, hospitals and doctors must rely on alternate or 
substitute chemotherapeutics resulting in serious inferior patient outcomes (Metzger et 
al., 2013). Metzger et al. recommended increasing clinical evaluation of alternate or 
substitute products before including them in new treatment regimens. 
Griffith, Pentoney, and Scheetz (2012) reported that antimicrobial agents are 
second to oncological drugs in total drug shortages. Griffith et al. posit the growth of 
antimicrobial shortages changed treatment paradigms from a more measured informative 
approach to one of a calamitous process. In their longitudinal empirical study, Griffith et 
al. discussed 87% of the reported shortages were generic. Of the reported cases, greater 
than 60% related to quality manufacturing issues. Griffith et al., also observed the 
shortages did not resolve expeditiously nor was any advanced warning given by the 
manufacturer. 
Griffith et al. (2012) stated the key to drug shortage management was proper 
stewardship by institutional pharmacists. These individuals would act as a centralized 
communications link between the external reporting sites, FDA, and ASHP, alerting the 
institution of emerging supply information. The pharmacists may marshal additional 
resources and stakeholders for formulating business contingency strategies (Griffith et al., 
2012). Paina and Peters (2012) suggested using the theoretical tools of complex adaptive 
systems to optimize outcomes during the scaling up of new health care processes as a 
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means to achieve efficiency.  
Goldsack et al. (2014) utilized an online survey of pharmacy directors (N=1334) 
to identify the challenges of delivering treatment therapy to oncology patients and to 
identify the effects of these conditions on organizational cost drivers. Respondents to this 
survey communicated 64% had run out of at least one oncology drug from their 
formulary. One-quarter of the responses identified one or more safety events related to 
substitute or alternate oncology medications, where the reaction was moderate to very 
high. A fair percentage of the responses felt a reasonable risk of patient mortality exists 
because of drug supply chain and distribution channel disruptions. 
Management of drug shortages has multiple implications in addition to 
complexity (Nagurney, Yu, Masoumi, & Nagurney, 2012). Institutional clinical managers 
prioritized patients to receive treatment based on clinical standing (Goldsack et al., 2014). 
Greater than one-fifth of the survey participants reported receiving referred patient or 
referring patients to other institutions to continue treatment because the medication was 
unavailable and no alternate or substitute drug exists. Saedia, Kundakcioglu, and Henry, 
(2016) recommended using a complex algorithm to manage inventory supply; however, 
the algorithm assumes at least two substitute medications exist in the supply chain. Based 
on the findings in the previous research of Goldsack et al. (2014), Saedia et al.’s (2016) 
assumption was invalid because of the limitations to the population of the algorithm. 
Continuity of care was another challenging dimension of drug shortages because the 
provider commits resources to either accept new patients or transfer patients to other 
providers to complete treatment. One of the challenges to maintaining treatment regimens 
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was to locate a provider who participates in the patient’s insurance program. 
The Goldsack et al. (2014) survey included inquiries related to facility costs 
associated with drug supply disruptions. More than two-thirds of the respondents 
acknowledged a moderate to severe increase in facility costs in the areas of extra resource 
allocations, paying higher prices for alternate, or substitute drugs and procuring drugs in 
a secondary or grey market. Goldsack et al. concluded none of the legislation recently 
adopted such as PDUFA, GDUFA, and FDASIA has had a measurable effect on 
influencing drug supply disruptions for sterile injectables for oncology drugs. 
Rosoff et al. (2012) offered a structured decision matrix based on four ethical 
benchmarks. Adhering to the guiding principles of accountability for reasonableness, 
Rosoff et al. identified the benchmarks as (a) transparency, (b) relevance, (c) appeals, and 
(d) enforcement. A committee of various hospital staff oversaw the development of the 
policy. A unique feature of this policy was the presence of a compounding pharmacy, 
which may help the hospital staff to mitigate critical needs. 
Propofol, a sterile injectable used in anesthesia introduction and management, was 
in short supply at an academic hospital (Roberts et al., 2012). Propofal’s primary use was 
in surgical sessions preparing the patient for sedation. Without a consistent supply of this 
drug, clinical staff must re-evaluate new surgical sessions to determine if alternate or 
substitute drugs are available and if a patient can tolerate the treatment (King & Ogg, 
2012). Shortage of this drug means delayed recovery and rehabilitation from the patient’s 
underlying illness or injury further complicating the continuity and cost of care. 
Propofol was one of the growing drugs in the neuromuscular blocking agents list 
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added to the increasing list of drug shortages. Anesthesiologists rely on propofol because 
propofol was a proven product with little or no side effects (Roberts et al., 2012). This 
product had a stable demand, where historically the manufacturer had little or no excess 
capacity. 
Medical practitioners may ignore the label instructions of single-use propofol 
vials by multiple entries as a means of extending the administration of the leftover 
product, which should alarm the FDA. This unethical practice led to the outbreak of 
Hepatitis C causing the testing of another 40,000 individuals for other serious conditions. 
King and Ogg (2012) stressed the need for medical clinicians to act responsibly by 
adhering to safe medication practices even in the event of drug supply disruptions.  
Drug supply disruptions effect on affordable care. Implementation of the 
PPACA supported the formation of integrated health care delivery structures, which share 
the costs and profits of patient care (O’Donnell & Vogenburg, 2013). Affordable Care 
Organizations (ACO’s) and other groups of providers assume the total responsibility of 
care for covered individuals in return for a lump sum payment from an insurer. The ACO 
was accountable for improving patient outcomes while accepting the financial and legal 
risk of the patient population. O’Donnell and Vogenburg (2013) reported on the legal 
aspects of drug shortages, medical errors, and related cost overruns. 
Hospitals and health systems under this type of operating framework were at risk 
because Medicare can sanction penalties for inadequate care that result in additional 
treatment or readmission, which providers are unable to bill (Bharel et al., 2013; 
O’Donnell & Vogenburg, 2013). O’Donnell and Vogenburg debated which conditions of 
86 
 
drug supply disruptions put providers at the greatest legal risk. This situation calls for the 
evaluation of failure to supply language in procurement contracts as a novel means to 
reduce potential legal liability in risk-bearing clinical providers. Data does not exist to 
support the considerations of how these new types of organizations will administer care 
in situations of drug supply disruptions (O’Donnell & Vogenburg, 2013). 
Teagarden and Epstein (2013) identified a new form of integrated provider 
structure, the Pharmacy Benefit Manager (PBM). This type of organization operates on 
the premise of supplying mail order prescriptions across all 50 states and earns its 
revenue through management of cost-saving formularies. These companies represent a 
significant portion of the consumable pharmaceutical product and requiring daily high 
volume shipments to keep pace with outbound orders. 
Teagarden and Epstein (2013) recommend PBM’s consider a conservative 
approach to reacting to drug supply disruptions by resisting hoarding or have methods of 
validating patient demands through a pre-authorization program. Teagarden and Epstein 
reported when PBMs become more capacious the data generated by filling prescriptions 
may have an extended use by predicting forward demand or predicting changes in 
demand. This type of secondary use may support new methodologies to alert or monitor 
the drug supply chain and distribution channel for inconsistent behaviors.  
Transition and Summary 
A comprehensive review of the literature associated with drug supply disruptions 
affirmed the confounding problem interconnects with multiple areas of causality. Clinical 
professionals, academia, and government leadership have drawn inferences individually 
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and jointly as to the potential solutions to this problem. The legislators in the federal 
government through many different agencies enacted regulations and statues to create 
equal and cost-efficient access to pharmaceutical health care treatment (Fox et al., 2009). 
Mature and emerging industrial economies influenced the evolution of pharmaceutical 
development and delivery. The laws of supply and demand do not translate well in this 
business sector because of the high degrees of price inelasticity coupled with the high 
levels of government regulation and intervention. health care expenditures related to 
pharmaceutical spending increase despite efforts to slow its growth in part because of the 
ineffective protocols to address drug supply disruptions (Schweitzer, 2013). The 
statement of the problem and study purpose was consistent with how health care 
procurement leaders perceive the obstacles and challenges with detecting and mitigating 
drug supply disruptions. An investigator can use general systems theory and complex 
adaptive systems network analysis to identify interactions in dynamic systems, which 
create impairments in the feedback loops within drug supply chain and distribution 
channels.  
In Section 2, I describe the structure and manner of the execution of the study. 
Section 3 includes an overview of this study and presentation of findings from the 
analysis of collected interview data. Section 3 also includes discussion of professional 
applications of the research to health systems organizational practice and the presentation 




Section 2: The Project 
Section 2 contains the following subsections: (a) the purpose of the study, (b) a 
discussion of the researcher’s role, (c) a description of participant strategies for the 
conduct of the study, (d) descriptive information on the research method and design, (e) 
amplification of the participant population, and (f) explanation of the ethical research 
process. Additionally, this section contains specific information on the data collection 
technique, instrumentation, and data analysis. Furthermore, this section contains a 
description of reliability and validity. 
Purpose Statement 
The purpose of this qualitative multiple case study was to explore the strategies 
that health systems pharmaceutical procurement leaders use to address disruptions in the 
drug supply chain and distribution channel. The participants in the semistructured 
interviews include five leaders from pharmaceutical procurement departments in health 
systems who had successfully addressed the research problem. The companies included 
three health care organizations from the Eastern region of the United States. The 
participants shared their strategies of mitigating supply chain and distribution channel 
disruptions. The hospital pharmaceutical leaders also shared additional company 
documents and internal policies containing relevant data that supported the notion of 
triangulation (see Denzin, 2012). The findings of the research may contribute to social 
change by addressing important issues. The first concern was improving health care 
leadership's understanding of the internal strategy limitations resulting from drug supply 
chain disruptions. The second matter was assisting health care procurement leaders to 
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understand the perceived quality problems related to treatment delivery influenced by 
drug supply chain disruptions. The final benefit was increased health care leaders 
awareness of systemic challenges with the pharmaceutical supply channel disruptions and 
shortages in the health care system. 
Role of the Researcher 
In qualitative research, Denzin and Lincoln (2011) stated the researchers are 
responsible for the design, collection, and interpretation of data. Palmer, Fam, Smith, and 
Kilham (2014) added the researcher must also ensure the mitigation of ethical concerns 
and the privacy of the study’s participants. Although research design, data collection, and  
data analysis are important considerations for the qualitative researcher, the role of the 
researcher as an interpreter of meaning is also a foundational consideration in guiding 
their actions (Denzin & Lincoln, 2011). As the translator of meaning, the researcher is 
inseparable from the phenomenon and context they are exploring in identifying the 
strategies to address the problem of drug supply disruptions. 
In this qualitative case study, my role as the researcher was to explore the 
strategies of health systems pharmaceutical procurement leaders practice to eliminate or 
reduce supply chain and distribution channel disruptions. Based on the suggestions from 
Jacob and Fergerson (2012), I followed an interview protocol, which was useful when a 
researcher seeks to understand the experiences and perspectives of individuals 
participating in a study. Qualitative researchers utilize open-ended interview questions to 
further explore responses as an adjunct to obtaining deeper understandings of participant 
responses and substantive direction of new understandings. I collected and interpreted 
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data in a reliable method to mitigate bias (see Kemparaj & Chavan, 2013; & Smit, 2012). 
I bracketed my prior knowledge and experiences concerning leadership procurement 
strategies, participants’ potential reactions, personal emotions, or opinions of individuals 
participating in research interviews. No previous relationships existed with the 
participants. Areas of potential bias for the study included the following concerns: (a) 
uncertainty of resource allocations, (b) fluidity of the pharmaceutical supply chain and 
distribution channel, (c) historical practices to contemporary events, and (d) strategies 
utilized but not widely recognized in the industry. 
Bailey (2014) defined qualitative research as an inductive approach used to gain a 
deeper understanding of a person or group’s experience about a shared experience or 
phenomena. Maxwell (2013) suggested identifying and managing personal biases prior to 
beginning an interview to ensure the integrity of the data collection and analysis process. 
Following Maxwell’s (2013) recommendations, I was mindful of personal biases and 
focused on my responsibilities and duties throughout the data analysis process, prior to 
beginning the review of documents and participant interviews. I reviewed the Belmont 
Report’s Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research (United States Department of Health and Human Services: Office for Human 
Research Protections, 1979) and completed the National Institutes of Health (NIH) Office 
of Extramural Research Protecting Human Research Participants certification 
(Certification No.:883410) as documented in Appendix E. Three basic ethical principles 
guided the research, in accordance with the findings of the Belmont Report. These 
principles were respect for individuals, beneficence, and justice. 
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I have 20 years of managerial experience with multiple supply chains, global 
distribution channels, and clinical drug therapies. Unbiased interviewing techniques were 
used to support the conduct of all interviews. The case study protocol (Appendix D) 
guided the conduct of all interviews. Denzin and Lincoln (2011) concluded effective 
qualitative researchers strive to present interview questions in a neutral manner, record 
the interview, and take notes throughout every interview. Participants had the opportunity 
to respond to each interview question and to offer additional insights and perspectives on 
the problem of inconsistent drug supplies. 
Participants 
The eligibility criteria for the five health care procurement leaders to participate in 
the study were the following: (a) employed in a leadership position with a pharmaceutical 
health system, (b) administration and development of pharmaceutical supply chain and 
distribution channel strategies, (c) responsible for the administration, provision, delivery, 
and regulation of pharmaceutical supplies, and (d) demonstrated implementation of 
successful strategies to address supply chain and distribution channel disruptions (see 
Appendix B). I sent emails to the current executive leadership teams of three health care 
organizations in the Eastern region of the United States, which operate pharmaceutical 
procurement departments to explain an overview of my study and to find out if they 
would be willing to allow their pharmaceutical procurement leaders to participate in the 
study. I encouraged the members of the executive leadership teams to contact me so I 
could discuss the purpose of my study in detail. If any member of the executive 
leadership team contacted me, I would discuss the overview with them and provide basic 
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information about my problem, purpose, research question, and interview protocol, which 
I intended to follow. I would explain to the members of the executive leadership team the 
prospective study participants may include chief procurement officers (CPO), chief 
operations officers (COO), senior vice presidents, vice presidents, directors, and associate 
directors who could represent a knowledgeable and experienced group, which may assist 
me in addressing my research question. Additionally, I would explain to the members of 
the executive leadership team’s need to sign a formal letter of cooperation (Appendix G) 
with myself as the researcher giving me permission to conduct research as a graduate 
student at Walden University. 
If members of the executive leadership team had an interest in supporting the 
study, I would ask for the contact information of the person who was in various 
leadership positions of their pharmaceutical health system’s supply chain. Prospective 
interview participants would then be sent an invitation letter (Appendix A) and a consent 
form Study participants would acquire a full understanding of their rights through the 
informed consent notification prior to signing the consent form. Participants were able to 
contact me by phone or by email if they had any questions. All participants would have 
the opportunity to decide whether to participate in the study on a voluntary basis based on 
the contents of the letter and information provided in the consent form. The participants 
were initially advised they had the ability to withdraw at any time while the interview 
process was taking place. If a participant changed their mind or chose not to participate in 
the study, they were free to withdraw. Although voluntary participation may decrease the 
response rate for a study, the likelihood of honest responses may increase because 
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individuals who willfully submit responses feel decreased pressure to fabricate responses 
(Marshall et al., 2013). The names of the health systems and individual participants 
remained confidential. 
After signing the consent form, I arranged to meet the participants at an agreed 
time and location. The individual participants agreed to participate in open-ended 
semistructured interviews conducted in face-to-face interviews to share their strategies. If 
the study participants desired, after the interviews, the procurement leaders had an 
opportunity to share additional company documents such as news releases, standard 
operating procedures, policies, and best practices for the purposes of triangulation (see 
Lichtman, 2014).  
I gained access to participants by petitioning members of the current executive 
leadership team of three health care organizations having pharmaceutical procurement 
departments in the Eastern region of the United States requesting support of the study and 
access to their most knowledgeable employees. After several formal discussions and a 
thorough review of the proposal for conducting research, I obtained a letter of 
cooperation (Appendix G) authorizing the data collection and interview process and 
member checking. Working with the company’s human resources department, I also 
gained access to the names of potential participants who fit the eligibility criteria for this 
study. By following these procedures, I used purposive sampling to obtain a sample of 
knowledgeable and experienced leaders currently employed by health systems. The 
sample obtained using a reliable process was appropriate for understanding the strategies 
that pharmacy procurement leaders successfully use to administer the pharmaceutical 
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supply chain and distribution channel strategies in addressing drug shortages. 
Establishing a working relationship with business leaders also required a formal request, 
in advance, describing the nature of the study and the possible benefits and discomforts 
associated with participating. 
Study participants in the sample pool were expert pharmaceutical supply leaders 
in pharmaceutical procurement procedures for health systems. Each study participant 
received an informed consent form to review and sign. I developed effective working 
relationships with the participants by encouraging participants to share information from 
their perspectives. Marshall and Rossman (2016) encouraged qualitative researchers to 
frame initial and follow-up questions in an open-ended manner and listen attentively in a 
relaxed manner to the participants’ responses. 
Measures taken to ensure ethical protection of participants included, but were not 
limited to, (a) use of informed consent forms, (b) confidentiality agreements, (c) approval 
of the proposed study from the Walden University institutional review board (IRB), and 
(d) an increased sensitivity to physical and emotional stress exhibited by the participant. 
Potentially qualified participants received e-mail letters that included descriptions of the 
intent and study objectives. The e-mail notifications included sufficient information for 
participants to determine their willingness to participate in the study. Appendix A 
includes the template for the cover letter to recruit study participants. 
If the study participants desired, after the interviews, the procurement leaders 
shared additional company documents and policies for the purposes of triangulation. 
Based on the concepts of Denzin (2012), the hospital pharmaceutical leaders also shared 
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additional company documents and internal policies containing relevant data, which 
supported the conception of triangulation. To support the recruitment of additional 
individuals to the study, the initial study participants were able to recommend the 
inclusion of additional persons in the study (Gyarmathy, Johnston, Caplinskiene, 
Caplinskas, & Latkin, 2014) based on their specialized knowledge and expertise of 
pharmacy supply chains and distribution channels. I also developed effective working 
relationships with participants by encouraging participants to share information from 
their perspectives. Using the guidance of Patton (2015), I was mindful to remain neutral 
and convey to study participants their attitude, experiences, insights and knowledge had 
importance in the study, thus building rapport. Marshall and Rossman (2016) encouraged 
qualitative researchers to frame initial and follow-up questions in an open-ended manner 
and listen attentively to the participants responses. 
Research Method and Research Design 
Research Method 
The guiding framework for the exploration of the study research question was a 
qualitative research method (see Denzin & Lincoln, 2011; Vanio, 2013). Researchers 
using the qualitative research method's design allowed the conduct of a qualitative 
assessment and helped develop a deeper understanding of the rationale of health care 
providers faced with reapportioning members of their workforce to address the problem 
of drug supply disruptions. Bernard (2013) argued for careful consideration of other 
alternative research methods before deciding on a study design. Bernard (2013) and 
Knight and Cross (2012) determined quantitative or mixed method studies were not 
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appropriate applications for some studies based on the inability to probe underlying study 
participant relationships and decision-making processes. Sadan (2014) suggested mixed 
methods approach was a potentially promising research design; however, my limited 
resources, participant availability, and critical time constraints rendered mixed 
methodology an impractical choice. 
Research Design 
Case study research was the optimal design for this study because well-defined 
research questions compliment the statement of the problem, the purpose of the research, 
and the nature of the research study. A purpose of case study research was to contribute 
to enhance and strengthen theory rather than oversimplification of a population (Sharma 
& Kamalanabhan, 2012; Webb, Bunch, & Wallace, 2015). Yin (2014) argued case study 
research designs allow the researcher to preserve the universal and evocative 
characteristics of real-lived events. Stake (1995) emphasized researchers conducting case 
studies need to represent the multiple realities described by study participants and 
interpret data collected from document reviews, observations, and interviews to construct 
descriptions of phenomena.  
Other qualitative research designs do not support the rich case exploration and 
thick descriptions desired for the study. The use of a phenomenological design by an 
investigator would have permitted data collection from the conduct of interviews 
(Moustakas, 1994) but would not allow for the gathering of information from publicly 
available documents and artifacts. Ethnographic study designs would have been 
appropriate for the examination of the beliefs and behaviors of culture-sharing groups 
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(Marshall & Rossman, 2016), which was an inappropriate focus for the study of 
strategies used by health systems pharmaceutical procurement leaders to address drug 
supplies disruptions. Grounded theory study design, as described by Omar, Davis-
Sramek, Fugate, and Mentzer (2012), did not support the study objectives of in-depth 
case exploration and analysis because grounded theory researchers are reliant on the 
creation or identification of one or more underlying theories, which does not support the 
study objective of in-depth multiple case study and analysis. 
In the research study, I concentrated on concerns associated with drug supply 
disruptions. Zyngier and Burstein (2012) suggested case study research contributes 
explicit descriptions of the governing issues related to the research topic. Sillanpää, 
(2015) recommended using qualitative case studies for exploring and understanding 
modern phenomena within the field of supply chain management. Goffin, Raja, Marek-
Szwejczewski, and Martinez (2012) used a repertory grid technique (RGT) during 
interviews in their case study to help the participants articulate complexities of supply 
chain management.  
Using the concepts of Yin (2014), I selected a qualitative case study as the most 
appropriate means of achieving a unique understanding of the meaning and motivations 
of the experiences and perceptions of health care providers faced with the problem of 
supply chain disruptions. Investigators may use a case study research design to explore 
those situations, where the evaluation of the intervention or strategies identifies no clear 
or single set of outcomes (Yin, 2014). 
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Population and Sampling 
The sample population for the study consisted of individuals in hospital 
pharmaceutical procurement leadership positions in three health systems settings along 
the Eastern region of the United States with responsibility for the administration, 
provision, and procurement of drugs and drug supplies. The objective of the study was 
the collection of data from documents and participants possessing knowledge of drug 
procurement channels and knowledge of drug shortage remediation. Accordingly, I 
utilized purposeful sampling to recruit participants with appropriate knowledge and 
experience to participate in this study. Purposeful sampling was a nonprobability 
sampling technique useful for a particular group because of their characteristics (Cassidy, 
2013). In a qualitative study, Jondle, Ardichvili, and Mitchell (2014) utilized purposeful 
sampling to explore how business executives characterize ethical business cultures. 
I also utilized snowball sampling as an apparatus for recognizing and recruiting 
further study participants. A researcher can use snowball sampling to support the 
identification of new participants within difficult to recruit or elite populations (Bernard, 
2013; Holloway et al., 2015). Use of the snowball sampling method allows a researcher 
to ask current participants to identify and recommend additional participants (Bernard, 
2013; Holloway et al., 2015). Kim (2015) employed snowball sampling during business 
research to recruit participants for a qualitative case study of the significance of 
biotechnology clusters in San Diego. Kim expressed value in snowball sampling for 
influencing rich and meaningful stories from the participants. 
No correlation existed between sample size and data saturation (see Marshall, 
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Cardon, Poddar, & Fontenot, 2013). I defined an appropriate sample size for the study of 
the problem of inconsistent drug supplies by considering the number of potential 
qualified participant sites. Potential participant selection included analysis of the number 
of hospitals, and the number of knowledgeable persons involved with pharmaceutical 
supply chains and or distribution channels in the Eastern region of the U.S., and the 
targeted number of participants from each site. Rubin and Rubin (2012) suggested the 
number of sites selected for a qualitative study remains dependent on the nature of the 
study, research questions, and the number of factors, which may influence the studied 
phenomenon. Hospital pharmaceutical procurement leaders with responsibility for the 
administration, provision, and procurement of drugs and drug supplies contributed 
perspectives on the organizational strategies addressing the problem of inconsistent drug 
supplies. Based on the three site types included in the study and an assumption of two to 
three interviews per site type, I determined a minimum pool size of 3 to 6 participants 
was an appropriate beginning for my study. 
O’Reilly and Parker (2013) observed sample population adequacy for a 
qualitative study was a function of the topic of study, participant availability, and 
sufficiency of sample size for permitting the examination of the research study questions. 
Rubin and Rubin (2012) asserted the inclusion of a large number of interviewed 
participants was not necessary to achieve balance and thoroughness during the conduct of 
a qualitative study. Nilsson et al. (2016) and Patton (2015) recommended qualitative 
researchers should define sample size from considerations of the purpose of the study and 
the assessment of the diverse opinions and perspectives offered by the study participants. 
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Rubin and Rubin (2012) suggested a minimum of two to three interviews per subsample 
area was sufficient to ensure the achievement of a suitable depth and diversity of 
perspectives to achieve saturation on a topic. Lichtman (2014) suggested saturation was 
an iterative process of case sample selection and simultaneous data collection until no 
new information was generated from the data collection. Saturation was a determinant of 
sample size (Walker, 2012). I expected to achieve saturation and a rich diversity of 
perspectives at the completion of 3 to 6 interviews because of the narrowed scope of the 
research study to people in hospital pharmaceutical procurement leadership positions 
through a multiple case study approach. Lichtman suggested smaller sample sizes in 
qualitative research help the researcher to obtain depth in the material. Bernard (2013) 
suggested researchers utilize small sample sizes by using purposeful sampling to identify 
and recruit study participants.  
Ethical Research 
Several principles guide the ethical conduct of a researcher when working with 
human subjects. The principle of informed consent requires the researcher to disclose 
both the risks and benefits of participation to potential study participants. The principle of 
voluntariness requires participants in a research project must be completely voluntary 
because a person’s choices should be based on free will and not related to coercion or 
duress in any way (Edlund, Hartnett, Heider, Perez, & Lusk, 2014; Hardicre, 2014). The 
final principle required that study participants should not encounter any risks to their 
safety or well-being and to be protected from harm (Walden University, 2015). In 
concordance with these principles, I sought and received approval from the Walden 
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University IRB for permission to conduct the study.  
Based on Walden University IRB requirements for ethical research, study 
participants should not encounter any risks to their safety or well-being and should not 
require protection (Walden University, 2015). During the exploration of sensitive topics 
in the interview, participants may experience the minor risk of discomfort such as fatigue, 
stress, or become upset (Seidman, 2013). If difficulties related to participant stress exist 
during the collection of the data, the participant or research may stop or suspend the 
interview process. No participants needed to stop or suspend the interview process. 
Members of the Walden University IRB ensure compliance with federal 
regulations and Walden University’s ethical standards. Prior to receipt of IRB approval of 
the submitted research proposal, no data collection took place. Before beginning data 
collection, I successfully completed and passed the National Institutes of Health (NIH) 
web-based training course pertaining to the protection of human subjects. 
Prior to the conduct of interviews, I provided all participants with information 
about the study objectives and intent and provided each participant with an informed 
consent form (Appendix C) to review and sign. Potential participants did not receive 
incentives in exchange for participation. All participants had the opportunity to decide if 
they wished to participate in the study based on information provided in the consent 
form.  
I also ensured the confidentiality and subsequent privacy of all study participants 
and their affiliated institutions through the de-identification of participants during the 
data analysis process (Conway, 2014). Participants were not asked to share any 
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information they perceived may compromise their professional status. Participants did 
not have to respond to specific interview questions if they felt uncomfortable responding. 
All document references were in the text of the research, appended in the appendices, and 
identified in the table of contents. 
I will store all data collected during the data gathering and analysis process in a 
safe, secure location for a period of 5 years to protect the rights of participants. 
Participants will receive direction on the method to withdraw from the study process at 
any time without any negative consequences. All electronic copies of all collected data 
and files are kept on a password-protected computer in a locked container maintained in 
my home office. All hard copies of data, notes, recordings, and analytical materials are 
kept in a secure fashion. Walden University issued IRB number 08-12-16-0327496 for 
this study.  
Data Collection 
Instruments 
Xu and Storr (2012) suggested that in qualitative research the researcher was the 
data collection instrument. Based on the discussion of Camfield and Palmer-Jones 
(2013), in a qualitative research study method, I was the data collection instrument. I 
collected study data from a review of public documents, news releases, website 
information, and the conduct of face-to-face semistructured interviews with individuals in 
hospital pharmaceutical procurement leadership positions in three health care settings in 
the Eastern region of the United States. The participants were responsible for the 
administration, provision, and procurement of drugs and drug supplies. Marshall and 
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Rossman (2016) indicated the use of multiple sources of data support study construct 
credibility through triangulation. Yin (2014) stated case study researchers could use 
triangulation by collecting information from multiple sources of data to corroborate the 
same phenomenon and to ensure overall study quality. Denzin (2012) suggested 
methodological triangulation as the use of several different data sources to support the 
comprehensive examination of identified phenomena. Methodological triangulation 
provides confirmation of similarities found in different data collection sources (Bekhet & 
Zauszniewski, 2012; Drouin, Stewart, & Van Gorder, 2015; Houghton, Casey, Shaw, & 
Murphy, 2013). Data sources are not the methods used to gather information but are the 
observational units used for the collection of information.  
Researchers developing a case study protocol ensure the dependability of the 
study by outlining procedures to follow during the conduct of research (Yin, 2014). Use 
of this protocol ensures data collection, analysis, and reporting efforts remain focused on 
the study line of inquiry (Marshall & Rossman, 2016; Yin, 2014). The case study 
protocol included seven steps to be followed (a) an overview; (b) descriptions of the 
purpose and intended use; (c) descriptions of data collection procedures; (d) an outline of 
the case study report content; (e) a list of interview questions; (f) a summary of the data 
analysis techniques and tools; and (g) a description of the study dependability, credibility, 
and transferability methods (Yin, 2014). Appendix D included the case study protocol. 
Qualitative researchers may also enhance the dependability of case studies by 
creating and utilizing case study databases (Yin, 2014). The development of a case study 
database by the researcher supports the process to study, which strategies health systems 
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pharmaceutical procurement leaders need to address the problem of inconsistent drug 
supplies. The database will include (a) notes from the document reviews and the 
interviews; (b) copies of documents, audio files from interviews, and transcripts; (c) 
tables of codes and patterns; and (d) initial (draft) narratives written during the analysis. 
Data Collection Technique 
Qualitative interviewing reconstructs complex situations and events from multiple 
perspectives, which help the investigator to create mental representations of the problem 
(Rubin & Rubin, 2012). Rubin and Rubin also suggested qualitative interviews help the 
investigator explore matters, which are complex, chaotic, and contradictory. One of the 
drawbacks of qualitative interviewing was the difficulty to use the results to estimate or 
generalize the characteristics of the findings to other groups. 
I collected study data from the review of documents and information obtained 
from qualitative interviews. Yin (2014) proposed researchers conduct case studies using 
letters, memoranda, e-mail communications, written reports, administrative documents, 
and newspaper articles as forms of study documentation. Singh (2014) reviewed archives, 
reports, policies, and other organizational documents to understand non-profit 
organizations. Boblin, Ireland, Kirkpatrick, and Robertson (2013) gathered data by 
reviewing an organization's strategic documents, artifacts, and observations of the 
environment. Boblin et al. gathered project proposals, operational policies, internal 
communications, and data from audits to understand the process of implementing new 
best practice guidelines. 
Information gathered from a review of publicly available documentation 
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supported the exploration of how health systems leaders addressed problems of 
inconsistent drug supplies. Study participants had the opportunity to provide copies of 
administrative documents, public reports, and or memoranda they reason may provide 
beneficial information for the assessment of individual perspectives regarding the 
problem of inconsistent drug supplies. I did not require study participants to provide 
documents to support their opinions and perceptions and stressed the provision of such 
information was voluntary. I did not conduct a pilot study because there was no need to 
validate a new data-gathering instrument with reliability and validity data. Helpful in 
conducting data triangulation were resources referenced by study participants once the 
IRB had approved the study for data collection and independent exploration for 
informational resources relevant to the study research question.  
All participants were able to request face-to-face interviews in private conference 
rooms convenient to their location. When participants selected their interview locations, 
they were less likely to experience inconvenience and were able to effectively participate 
in the interviews. During the conduct of each interview, I monitored and assessed the 
participant’s emotional and physical responses to each question to ensure lines of 
communication did not create any undue discomfort for the participants. 
An investigator conducting semistructured interviews supports the exploration 
and description of how health systems pharmaceutical procurement leaders need to 
address inconsistent drug supplies problems efficaciously. Rubin and Rubin (2012) 
proposed to conduct semistructured interviews allowing investigators to focus the 
discussion on topics specifically related to study research questions. Schatz (2012) 
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employed nesting of semistructured interviews within surveys to explore deeper micro 
perspectives of a gender context study. Lynch, Bruhn, and Henriksen (2013) used 
semistructured interviews in determining how educators should prepare when counseling 
lesbian, gay, bisexual, or transgendered clients. 
Participants were able to request a telephone or Internet-based interview as a 
follow-up discussion from the initial interview for member checking. Irvine, Drew, and 
Sainsbury (2013) noted telephone interviews provide a less effective means of building 
rapport with participants and may result in less information or elaboration in response to 
interview questions. Bryman and Bell (2015) supported researchers in using the 
telephone to conduct interviews as long as they followed a specific qualitative protocol. 
Mikecz (2012) discovered telephone interviews were equally effective as face-to-face 
interviews; however, Mikecz argued the researcher must confirm knowledgeability of the 
participants for a successful interview. During any phone interviews, participants would 
have the opportunity to respond to each interview question and any follow-up questions 
in as much detail as they desired. 
I electronically recorded each interview using standard technology applications. 
Before starting individual interviews, all participants provided expressed written 
permission for recording the interview session. A password-protected laptop was used to 
store electronic copies of all interview audio files for the creation of successive 
transcripts for interview analysis. 
Before commencing data analysis, I sent the transcribed interviews to the 
participants to verify the accuracy of the data through transcript review and a validation 
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process of member checking as suggested by Maxwell (2013). Member checking was a 
rigorous review process of the qualitative participant responses to interview questions, 
which provide the researcher with confirmation of the understanding and meaning of the 
responses to the interview questions (Marshall & Rossman, 2016). Participants examined 
the documents from their recent interviews to determine if the researcher captured their 
responses to the interview questions accurately and completely (Houghton et al. 2013; 
Koelsch, 2013; Morse 2015; Sinkovics & Alfoldi, 2012).  
Data Organization Techniques 
I created and maintained electronic data logs on a password-protected computer. 
Entries in the log for every data element included information on (a) the data type, (b) 
data identifier, (c) date of collection, (d) place of collection, and (e) corresponding 
research notes identifier. I recorded notes during the review of collected documents and 
interviews. Formalized note taking during the conduct of case study research was an 
essential practice for ensuring researchers captures the core messages from the discussion 
during interviews and immediately following the collection of data in the field (Yin, 
2012).  
I have stored all research materials (organizational documents, electronically 
recorded interviews, electronic transcripts, coded data files, and analytical reports) in a 
password-protected laptop computer. Encrypted electronic files, a backup archival system 
for secondary copies of study materials, are subsequently stored in a secured location. 
The data collection and analysis process included the deidentification of study 
participants. Data and analysis files will include references to participant identification 
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numbers only. I also plan to store all collected data and analytical results for 5 years. 
Destruction of all data copies (both electronic and hard copy) will take place after 5 years 
from the publication of the manuscript. 
Data Analysis Technique 
I developed interview questions to facilitate the exploration of the primary 
research question guiding the conduct of the qualitative case study: What strategies do 
health systems pharmaceutical procurement leaders use to address drug supply chain and 
distribution channel disruptions? Structuring of open-ended interview questions will 
encourage study participants to share and describe their perspectives (Irvine, Drew, & 
Sainsbury, 2013; Wilson, 2012) and experiences regarding the problems of drug 
shortages and inconsistent drug supplies. 
I have aligned the collection and analysis of study data with the complex adaptive 
systems conceptual framework on completion of the interviews with the study 
participants. Study participants will share insights and perspectives on operational 
strategies pharmaceutical procurement leaders utilize addressing disruptions in drug 
supply chains and or distribution channels. Augmented data gathered from analyzing 
organizational documents and artifacts using methodological triangulation (Lichtman, 
2014; Maxwell, 2013; Patton, 2015) may support further assessment of how individual, 
institutional, and societal factors affect the strategic response to disruptions in the drug 
supply chain.  
I have assessed the operational strategies of health systems procurement leaders in 
planning or response to drug supply disruptions affecting the health care system. My 
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intent was to utilize feedback loop modeling concepts from complex adaptive systems 
related to general systems theory (GST) to understand paradigms in the pharmaceutical 
supply chains and the distribution channel.  
Boulding (2013), a contemporary of von Bertalanffy, described GST as 
theoretical modeling of levels existing between abstract principles of mathematics and 
distinctly specialized disciplines. Corning (2014) considered the influence of synergies 
among empirical system objects on the overall biological complexity of living systems. 
Researchers using systems theory utilize a methodological approach to understanding the 
functions and behaviors of system objects. Systems consist of dynamic information 
driven feedback loops, which transforms the system to achieve its goal or purpose. I have 
endeavored to capture and identify systems objects related to the operational strategies 
employed by the health systems. 
A researcher can use GST to focus on the behaviors of whole systems. 
Researchers understand the whole system was greater than the sum of all parts (Anaafo, 
2013). Drack (2009) argued the impossibility to know every part and know every 
relationship in a system; however, possibilities exist to research effects of the system 
above the individual parts of the system. Pharmaceutical supply chains and distribution 
channels exhibit many of the same challenges specified by Drack. The supply and 
distribution elements may demonstrate emergent characteristics of highly structured and 
highly functional systems. Shah (2004) suggested pharmaceutical supply chains and 
distribution channels contain many complex processes, formulas, coordination issues, and 
development challenges.  
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Using GST approach, I have conducted document reviews and interviews for 
collecting data to characterize the various factors, which influence and impede leadership 
strategies related to drug supply disruptions. Coding was useful as the primary data 
analysis technique for the exploratory qualitative multiple case study. Qualitative 
researchers use coding methodologies for categorizing and describing collected data. 
Bernard (2013) has suggested coding methodologies should include both deductive 
coding and inductive (open) coding. 
The researcher can use both deductive and open coding to support the 
comprehensive analysis of data collected for a qualitative case study. I have employed 
deductive coding to develop codes for the analysis of document reviews and interview 
data. Deductive coding was useful in the study of management perspectives, which 
identify emerging themes believed important in the service creation process (Russell-
Bennett, Härtel, & Worthington, 2013). In addition, Fourie and Theron’s (2012) data 
analysis technique employed deductive coding to develop coded categories on the coping 
resiliency of young women with a specific health issue. Creating unique deductive codes 
from analyzing the responses to the interview questions enables the identification of key 
words and themes, which relate to the conceptual framework selected for this study. 
Open coding involves the identification of themes and conceptual thoughts, which 
emerge from a review of collected qualitative data (Bernard, 2013; Rubin & Rubin, 
2012). Russell-Bennett, Härtel, and Worthington (2013) employed open coding to isolate 
conceptions and themes, which emerged from managers’ responses to interview 
questions. Open coding was useful to isolate new themes and theoretical concepts during 
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the review of data collected using formal business plans, policies, project plans, and 
internal communications (Fourie & Theron, 2012). I used open coding throughout the 
review of the study documents and interview data to examine concepts and themes, 
which were supplemental to the deductive codes used during the analysis process. Stake 
(1995) suggested the use of open coding supports the application of theoretical 
triangulation: the exploration of alternative explanations for an observed social 
phenomenon.  
Categorization of deductive and open codes by research subquestions and 
conceptual framework facilitates the identification of themes related to the study research 
question and conceptual framework. Creation of additional subcategories of codes 
enables the evaluation of the nature of participant responses and document content. I 
created code subcategories to categorize responses of the participant group and to capture 
miscellaneous comments, which may emerge during the document analysis process. 
Yin (2014) concluded the reasonableness to utilize software technology to analyze 
coded case study transcripts. I used data from document reviews and interviews during 
the study to interface with ATLAS.ti, a software tool for qualitative research. Researchers 
using ATLAS.ti software find support in the management, taxonomy, and analysis of 
data. Researchers using ATLAS.ti find support in the performance of (a) keywords-in-
context (KWIC) analysis, (b) constant comparison analysis, and (c) classical content 
analysis. Application of ATLAS.ti to perform KWIC analysis permitted me to ensure 
analysis of collected study data would appear robust via data analysis triangulation 
(Sanders & Woodward, 2014).  
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Saiki and Kloyes (2014) and Sanders and Woodward (2014) conducted KWIC 
analysis to explore the use of keywords in context and to identify underlying connections 
within document wording or language used by participants. Moreover, the researcher can 
use a KWIC analysis with ATLAS.ti to support the identification of open codes within 
the collected study data. Constant comparison analysis involves the identification of 
underlying themes within collected data by the way of the deductive and inductive coding 
of passages of text (Sanders & Woodward, 2014). I utilized ATLAS.ti to perform 
constant comparison analysis of collected documents and interview transcripts and to 
identify and document emerging themes.  
A researcher can use software applications (e.g., Atlas.ti) to support qualitative 
and mixed methods research designs when utilized to support data coding and thematic 
identification in the creation of a cluster analysis (Ware, 2012). Ware suggested these 
types of applications encourage the discovery of triangulated data. I utilized ATLAS.ti to 
perform classical content analysis of the collected study data to determine the 
accumulated total count for each code isolated during analysis. Information regarding 
code counts support the determination of the relevant importance of deductive and 
inductive codes and identification of prominent underlying themes within the data. The 
use of ATLAS.ti to conduct co-occurrence analysis facilitated exploration of 
relationships or thematic links between codes. 
To assess code saliency, I compiled and developed information about the 
frequency of codes across all study source materials (documents and interview 
transcripts) to determine which codes to preserve during final thematic analysis. Bernard 
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(2013) noted the frequency of a code within a data set indicates the saliency (importance) 
of the code. Collingridge (2013) suggested methods of turning qualitative data into 
quantitative values to the extent mathematical formulas could determine statistical 
significances in code frequencies. Collingridge concluded appropriate use of permutation 
testing may identify p values and analyze code. 
Reliability and Validity 
Reliability 
Richie, Lewis, Nicholls, and Ormston (2014) posited qualitative researchers 
answer the reliability question when other researchers replicate their research findings. 
Making certain the results of the study are consistent with the data collected was one of 
the key tenets of consideration during the study design phase, and qualitative studies 
include mechanisms for ensuring dependability (Lichtman, 2014). Dependability ensures 
the integrity of the data and findings in the study (Marshall & Rossman, 2016). 
Qualitative researchers demonstrate the consistency of their research efforts through the 
focus on dependability instead of reliability (Marshall & Rossman, 2016; Morse, 2015). 
Study databases and study protocols are useful to researchers in demonstrating case study 
dependability (Yin, 2014). 
Yin (2014) advocated documenting the research process to strengthen reliability 
and dependability. To ensure the dependability and reliability of the research findings, I 
recorded and utilized a precise case study protocol. The study protocol (Appendix D) 
included: (a) research study summary, (b) a statement of the protocol purpose and use, (c) 
data collection process flow chart, (d) an outline of the case study report content, (e) 
114 
 
interview questions, (f) a brief description of the data analysis techniques and 
instruments, and (g) a dependability assessment and study credibility. Lynch, Bruhn, and 
Henriksen (2013) utilized a case study protocol to document their research questions, 
research methodologies, and guidelines for data collection and analysis during a study of 
counselor educators. 
I also created and maintained a case study database for the study of how health 
systems pharmaceutical procurement leaders have addressed the problem of inconsistent 
drug supplies. The database will contain: (a) document review and interview notes, (b) 
copies of documents, interview audio files, and transcripts; (c) tables of codes and 
thematic elements, and (d) initial (draft) narratives written during the analysis of 
collected data and summarization of study findings. Use of the case study database 
enhances the study dependability and reliability by providing other investigators with 
insight into the data products and analytical methods used to derive study findings and 
conclusions. 
Validity 
Research quality was dependent on the qualitative researcher’s focus on key 
means of study validity. Contrastingly, quantitative researchers ensure the integrity of 
their research through the execution of procedures, which ensures study credibility (Bell 
& Waters, 2014; Marshall & Rossman, 2016). I utilized the following processes, which 
demonstrated study credibility: (a) methodological triangulation, (b) the assessment of 
contending explanations, (c) bias identification of the researcher, and (d) member 
checking as outlined by Lichtman (2014). 
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To enhance credibility, Boutin (2012) in an open communication piece 
recommended utilizing a clear and comprehensive evaluation process to increase 
credibility and relevancy during the conduct of case studies. To achieve study credibility 
and enhance quality elements of a case study, Yin (2014) discussed the utilization of 
document reviews, interviews, and direct observations in businesses case studies. I 
collected data from the review of available documents, artifacts, observations, and 
information from semistructured interviews. Yin (2013) suggested methodological 
triangulation increases the notion of validity of case study research. 
Marshall and Rossman (2016) recommended establishing the credibility of the 
study by using: (a) the assessment of rival explanations, (b) researcher bias identification, 
(c) member checking, and (d) method triangulation. Strategies to establish validity in case 
study research included the use of multiple sources of evidence, which maintains a link 
between evidence and member checking methodologies (Houghton et al., 2013; Lub, 
2015). Utilization of member checking methods by the researcher enhances the 
credibility of this study. Gathering data from other sources such as company documents 
was useful to triangulate findings and enhance the study quality. Gathering study data 
across multiple sites in the Eastern region of the United States will ensure appropriate 
spatial variability in the study of observational units and will support the comprehensive 
examination of leadership perspectives regarding drug supply disruptions. 
Zitomer and Goodwin (2014) stated internal validity was a parallel of credibility 
in the lens of postpositivist qualitative research. Credibility was a primary concern for 
explanatory case studies only (Yin, 2014). I conducted an exploratory multiple case study 
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of pharmaceutical procurement leadership strategies used to address disruptions in the 
drug supply chain and the distribution channel. Accordingly, methods described by Yin 
(2014) as suitable for establishing credibility for explanatory case studies (e.g., pattern 
matching and explanation building) were not strictly applicable to my study; however, 
one method suggested by Yin (2014) for achieving credibility was the assessment of 
contending explanations. Moreover, Yin advocated the use of researcher bias 
identification methods and member checking during the data collection and data analysis 
phases of the research study enhances study credibility. Contending explanations for 
phenomena do not undermine case study designs or procedures but pose challenges to the 
interpretation of study findings and formulation of study conclusions (Yin, 2012). 
Researchers may face challenges to credibility and transferability of the findings 
conducting online research, because of the potential of inadequate substantive data in 
online communities, which may lead to inaccuracies in data interpretation (Richie, Lewis, 
& Nichols, 2014). Conversely, Synnot, Summers, and Taylor (2014) found in their study 
online interviewing and data collection was generally comparable to in-person interviews 
because of the technological advances in internet communications.  
I explored alternative conceptual frameworks during the data analysis process and 
examined the suitability of systems theory as a framework for study findings. A single 
conceptual framework, the complex adaptive systems network (Akgun et al., 2014) 
supported the collection and analysis of study related data. The premise of systems theory 
was interactions and interrelationships among components of a system governing the 
properties and behaviors of the system (Sturmberg, Martin, & Katerndahl, 2014).  
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As a second strategy, I utilized researcher bias identification to ensure credibility 
and validity of this case study. Yin (2012) cautioned researchers’ theories, personal 
views, or presumptions may influence the methodology and conduct of the intended 
studies. Engaging in self-reflection, having an internal discussion with one’s self, before 
conducting case study interviews, helps identify and articulate attitudes about the 
research topic, which may influence the collection and analysis of data (Peredaryenko & 
Krauss, 2013). Corrupted data collection and analytical processes may be the result of 
researchers who did not recognize or manage the data capture, data translation, or data 
analysis process (Hurst et al., 2015). 
Yin (2012) posited researchers’ personal values, individual theories, or prejudices 
may influence their intended study construct. I conducted a personal assessment of 
biases, prior to the initiation of data collection, for the study of drug supply disruptions. 
An assessment matrix will include each identified bias with an accompanying narrative 
description. Review and assessment of the bias identification matrix throughout the data 
collection, analytical process, and during the preparation of study completion enable 
effective strategies to manage or mitigate personal biases.  
I used a third technique called member checking for establishing the credibility in 
a qualitative case study. Member checking was a process for assuring the validity of the 
researcher’s summaries. Qualitative researchers provide study participants with selected 
data elements, draft findings, and conclusions then ask the study participants to comment 
on the degree of accuracy of the materials provided (Marshall & Rossman, 2016). During 
the 2011 study of the social dynamics of a community associated with college football, 
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faculty colleagues, athletic experts, and participants in focus groups shared study findings 
and participant perceptions (Reilly, 2013). Burda, van den Akker, van der Horst, 
Lemmens, and Knottnerus (2016) involved participants in assessing and providing 
commentary on the credibility of the findings as a method of member checking. 
I also provided study participants with a copy of initial study findings and 
conclusions and offer an opportunity to review and provide commentary. Comments from 
participants will enhance the accuracy and credibility of study data collection and 
analysis efforts. Study participants received a summary of the study’s findings, 
recommendations, and conclusions after receipt and notification of the final study 
approval. The participant’s summary may include findings, recommendations, and 
conclusions detailed in this study and less than three pages in length to ensure study 
participants receive a brief document they can reference efficiently. 
Case study researchers enhance the transferability of case studies by providing a 
deep analysis of the reasons for the selection of case study populations and describing the 
unique details of case study contexts (Alex da, Näslund, & Jasmand, 2012; Reybold, 
Lammert, & Stribling, 2013). Qualitative research emphasizes transferability of the 
methods used in the study instead of the external validity of study findings (Marshall & 
Rossman, 2016; Yilmaz, 2013). Holloway et al. (2015) demonstrated transferability of 
their study findings by providing thorough definitions, demographics, and geographical 
boundaries of the study participants  
I documented in the study a detailed description of the sample population and 
geographic boundaries for the study. The inclusion of rich descriptions of the study 
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population and the context for the collected data and study findings would enable a reader 
to judge the transferability of study findings and supporting conclusions. Specific to this 
study, readers received the information necessary to assess the transferability of findings, 
conclusions, and to the characteristics of drug supply disruptions. 
Confirmability was the extent to which the findings of a study reflect the 
participants’ responses as opposed to the researcher’s imagination or preconceived biases 
(Cuthbert & Moules, 2014; Elo et al., 2014; Polit & Beck, 2013). To create transparency 
and confirmability in this study, I provided documentation of all the steps in the data 
collection and analysis process. Saturation occurs when no new findings or information 
emerges during the interview and research process (Roy et al., 2015). I continued to 
interview members of the sample using member checking until I was satisfied that I had 
fully captured the complexity and variation of the phenomenon under study and had 
reached data saturation. In qualitative research, a small sample size was generally 
appropriate to achieve saturation (Marshall et al., 2013). In this study, the population 
under consideration consisted of 5 pharmaceutical leaders who were knowledgeable 
about drug shortages. I continued the interview process until no new information 
emerged from the participants. 
Transition and Summary 
Section 2 includes an outline of the intent of the research study, the research 
design, the population sample, and the analytical methodologies used for the study of 
drug supply disruptions in the United States. The conduct of a qualitative case study 
enables exploration of how health care procurement leaders in the Eastern region of the 
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United States perceive strategy limitations in the mitigation and detection of drug supply 
disruptions. I gathered data from the review of documents and the conduct of 
semistructured interviews to build a deep understanding and extensive knowledge of 
leadership strategies. New information obtained supported advances in new operational 
protocols, which may detect, control, and potentially eliminate drug supply disruptions. 
Section 3 will include an overview of the study and presentation of findings from the 
analysis of collected data from study participants. Section 3 includes applications of the 
research to professional practice and the presentation of recommendations, reflections, 
and conclusions resulting from the conduct of the study. 
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Section 3: Application to Professional Practice and Implications for Change 
A description of the general and specific business problems appears in Section 1. 
The purpose of this exploratory multiple case study was the exploration of the central 
research question: What strategies do pharmaceutical procurement leaders of health 
systems use to address drug supply chain and distribution channel disruptions. Section 1 
contained a description of the conceptual framework used in this study and the review of 
the professional literature. A description of my role as a researcher, the study’s 
population, participants, and ethical research requirements were in Section 2. Section 2 
contains an explanation of the research approach, data collection tools, and data analysis 
process. 
In Section 3, I discuss an overview of the findings and the relevance of the 
findings to professional practice in contemporary business settings. This section includes 
my discussion of how researchers and senior leaders in health care systems may use the 
findings and my recommendations to effect changes in social structures. Section 3 also 
includes a discussion on topics for further research. Conclusions in Section 3 contain 
final reflections on completing the research study. 
Overview of Study 
The purpose of this qualitative multiple case study was to explore the strategies 
that health care pharmaceutical procurement leaders use to address disruptions in the drug 
supply chain and distribution channel. The qualitative approach allowed me to develop a 
deeper understanding of the participants’ perceptions regarding pharmaceutical supply 
disruptions. The objective of the study was to develop a comprehensive understanding of 
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the strategies used to address pharmaceutical supply disruptions. The participants, senior 
leaders in health systems, in this research study answered the specific research question: 
What strategies do pharmaceutical procurement leaders of health systems use to address 
drug supply chain and distribution channel disruptions? The analysis of the transcripts of 
the interviews resulted in the identification of 59 codes and 557 meaningful quotes that 
supported the identification of emerging themes and confirm the underlying conceptual 
framework. I used the process of text analytics (Gururajan et al., 2016) to weight and 
categorize clusters of text to develop hidden insights and assign weighted values to the 
participant’s responses. I also used the query tool in Atlas ti to identify and or confirm the 
saliency of text clusters and code categorization. 
Three key themes emerged from my analysis of the aggregation of the codes that 
summarized the strategies pharmaceutical procurement leaders used to address 
pharmaceutical supply chain disruptions (Table 1). The three themes were (a) 
pharmaceutical procurement leaders proactively plan for supply chain and distribution 
channel disruptions, (b) pharmaceutical procurement leaders create strategic processes for 
alternative procurement methods, and (c) pharmaceutical procurement leaders rely on 
proven sources of actionable information. The three themes support the conceptual 
framework of Kauffman (1995) and aligned with the research topic of pharmaceutical 
supply chain and distribution channel disruptions. Alignment of the emerging themes was 






Presentation of the Findings 
The overarching research question was as follows: What strategies do 
pharmaceutical procurement leaders of health systems use to address drug supply chain 
and distribution channel disruptions? I developed specific interview questions to explore 
the strategies used to address pharmaceutical supply chain and distribution channel 
disruptions. I used interview transcripts, field notes, and publically available documents 
to triangulate the data (see Fusch & Ness, 2015). The interview questions supported my 
exploration of strategies used by senior leaders to mitigate a critical social problem with 
broad-range effects.  
Emergent Theme 1: Pharmaceutical Procurement Leaders Proactively Plan for 
Disruptions  
The first key theme of the study identifies the complex planning process used by 
pharmaceutical procurement leaders for ensuring adequate pharmaceutical inventory for 
scheduled admissions, outpatient treatment therapies, and commonly used pharmaceutical 
consumables. The strategy of closely monitoring available inventory to compare with the 
usage requirements for acute care, outpatient care, and trauma care was repeatedly 
Table 1
Code Clusters Relating to the Three Emerging Themes of the Research Study 
Participant Proactive planing Creating alternate  processes
Developing reliable sources 
of actionable information
P1 38 84 6
P2 60 123 24
P3 21 56 9
P4 27 37 13
P5 33 55 19
Total 179 355 71
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emphasized by participants and recorded in my field notes. Another highly emphasized 
strategy of the study participants was the ongoing contract negotiations for increased 
access to products through group purchasing organizations (GPO) or wholesale 
distributors. Additionally, codes related to reporting to stakeholders and assessing trends 
of alternative sources showed significant frequencies in the participants’ responses. Table 
2 depicts the response frequencies for highly emphasized strategies in Emerging Theme 
1.  
 
Participants expressed feelings that proactively analyzing on-hand supply and 
comparing it to usage trends helped identify potential risks of disruptions before they 
influenced patient treatment schedules. Specifically, participants expressed a strong 
desire to connect to external data sources containing advanced warning information to 
support potential changes in their procurement practices. Jagsi et al.( 2014) concluded 
relying solely on advanced warning may not be an adequate measure to stop supply 
disruptions, which Participants 2 and 5 supported in their responses. Both Participant 2 
and 5 felt the information in advanced warnings was often incomplete. Missing critical 
Table 2
Strategies Relating to the  Emerging Theme One of Proactive Planning for Disruptions 
Participant
Conduct regular 
analysis of on-hand 
inventory and usage 
trends
Negotiate increased 
access to drugs 





Assess trends with 
alternate source 
providers
P1 30 17 15 6
P2 67 50 29 19
P3 50 38 15 18
P4 99 49 45 6
P5 59 30 32 4
Total 305 184 136 53
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information about the duration of the disruption perplexes health care leaders. Participant 
5 felt that “the earlier the health system receives the notification of a shortage, the more 
likely a comprehensive game plan is implemented.” 
Adomavicius et al. (2013) suggested complex systems drive dynamic information 
through networks of feedback loops in complex systems. IMS Health, Inc. (2012) 
concluded complexities in systems may impair an individual’s ability to analyze 
allocative efficiencies and feedback in the supply chain and distribution channel. 
Participant 2 felt that even though they received advanced notifications from their GPO’s 
and wholesalers, the information cannot be completely relied on to make informed 
decisions. Participants 3 and 4 have received conflicting information from one source of 
notification and entirely different information from the actual manufacturer. Participant 3 
said they spent time validating the disruption with the manufacturer because they did not 
trust the grey market sources on the original notification.  
Participants felt the decrease of supply chain capacity caused by lean inventories 
may increase the risk of supply disruption. Mehralian et al. (2015) support the 
participant’s perceptions because of the demand uncertainty in the supply chain. The 
uncertainty of demand and the uncertainty of supply caused participants to negotiate with 
their GPOs and wholesalers for expanded access to pharmaceutical supplies. Participant 2 
explained some drugs or manufacturers are exclusive with one wholesaler. Participant 2 
added, “there is difficulty in some circumstances trying to procure an exclusive product 
from a non-contracted wholesaler.” Participant 3 indicated when the wholesaler is unable 
to provide a specific drug, because of disruption, and the health system has to go outside 
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of the contract provisions and procure the drug from an alternate supplier, the health 
system receives the difference through reimbursement between the contract price and the 
acquisition price from the alternate supplier. 
All participants reported increased levels of communications to physicians, 
pharmaceutical buyers, and wholesalers related to supply chain disruptions. Participant 1 
felt that keeping the physicians who were prescribing medications aware of the details 
about a disruption would decrease the level of interdepartmental animosity. Participants 1 
and 2 felt their departments were unjustly subject to unprofessional behavior by some 
physicians affected by supply chain disruptions. Participant 1 stated  
I think the strategies can be successful if you are creative and if the people 
involved have a willingness. If you have a doctor who doesn’t care or doesn’t 
want to hear that we can’t get Lasix and he or she just keeps pounding the table, 
then your strategies aren’t going to work. 
Systems that operate on the fringes of chaos disrupt strategic managerial control (Croson 
et al., 2014). Conversely, participant 4 believed much of the anxiety or animosity 
dissipates when all stakeholders are involved in the mitigation of the disruptions.  
Participants 1, 2, 3, and 4 believed assessing the trends of alternate source 
providers added new dimensions and insights into supply chain disruptions. Specifically, 
Participant 3 revealed grey markets are “a sore spot because they do seem to always have 
the products that are on backorder.” Participant 3 stated  
The hard to find companies may find out that something is not going to be 
produced in mass or the end of the year. You always wind up with backorders, so 
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they go ahead and buy all this stuff, and then they try to turn around and sell it to 
us at increased cost. So, they create a lot of the problems. 
Parallel to the response of Participant 3, Participant 1 thought “I think that there are 
certainly people who will take advantage of the system.” Emergent behaviors analyzed in 
the context of a grey market provide alternate sources of feedback to the pharmaceutical 
procurement leaders to use in the planning of their strategic process.  
Emergent Theme 2: Pharmaceutical Procurement Leaders Create Strategic 
Processes for Alternative Methods 
The second emergent theme was the essential process of creating alternative 
methods. Participants discussed the necessity to utilize alternative methods of supply 
delivery. The participants demonstrated a high degree of consensus when relating their 
experiences of alternatives in drug choice, treatment regimen, and wholesaler access. 
Participant 1 felt occasionally increased difficulty explaining the use of an 
alternate drug to a prescribing physician. Participant 1 stated “trying to convince 
physicians that Drug X might be as good as Drug Y because the reason they chose Drug 
X in the beginning because they think that it is the best.” Participant 5 felt more confident 
using the health systems’ electronic health records to identify near-term shortages. 
Participant 5 indicated alternates and substitutes were available but potentially not as 
optimal as the prescribed drug. All participants reported patient safety as the greatest 
concern when switching to an alternate or substitute drug. 
Participants felt switching drug treatment plans had distinct safety concerns, but 
the affected patients were mostly long-term outpatient cases. Participant 3 indicated the 
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physician is counseled to reduce the dose or decrease the use of a specific drug until the 
supply chain has regained capacity. Participant 4 supported Participant 3’s process but 
warned “it can add extra hoops to the process. Generally, though you are limited in the 
number of treatment plans you can put the patient on.” Changing the system design, 
however minute, may create other more amplified problems not directly related to the 
changes (Krishnamurthy, 2015). Janvier-James (2012) supported a dynamic method and 
thought process to change supply chain structures and workflow. 
Participants introduced two novel strategies in their responses. The first strategy 
was trading or borrowing from neighbor hospitals. The second strategy involved the 
limited use of compounding pharmacies to manufacture small amounts of drugs subject 
to supply chain disruptions. Outterson (2012) supported the structured use of 
compounding pharmacies to add redundancy and a safe alternative for health systems to 
acquire drugs in short supply. Trading and bartering are an emergent behavior, which was 
not present in the review of the current professional literature. Table 3 identifies the 
strategy coding disbursement among the participants for Emergent Theme 2.  
 
Table 3




Trade or barter Alternative therapy
Compounding 
pharmacy
P1 105 31 27 30 27
P2 80 46 22 18 33
P3 34 46 19 16 13
P4 127 46 33 32 19
P5 78 27 18 19 11
Totals 424 196 119 115 103
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Emergent Theme 3: Pharmaceutical Procurement Leaders Develop Reliable 
Sources of Actionable Information 
Feedback is a critical component of any complex adaptive system involving 
production (Spencer & Carlan, 2008). Feedback within the pharmaceutical supply chain 
and distribution channel is a vital source of analytics used by pharmaceutical 
procurement leaders to make informed decisions. Emergent Theme 3 is bound to the 
identification and use of reliable sources of actionable information or feedback. 
All participants felt analyzing feedback in the system supported the creation of 
departmental strategies used to eliminate or reduce the risk of supply chain disruptions. 
Participant 5 stated  
we utilize intelligence that we get from our group purchasing organization, 
wholesaler, some news articles, and list services, basically monitoring the buzz of 
pharmacy and what even some sales representatives we get intelligence from. 
Then, once we identify there is a shortage, we bring it to a weekly meeting that 
we have, a drug shortage meeting. For us, the key is first to identify that there is 
going to be an issue. 
Participant 2 supported the strategy of participant 5 by stating 
I have a new buyer at one of our other hospitals, and we’ve told her don’t close 
your screen to the wholesaler. You gotta keep looking and you gotta watch when 




All participants reported feedback comes from internal and external sources across 
multiple systems and through multiple filters. Pharmaceutical procurement leaders assess 
the sources of feedback and make a determination on the degree of legitimacy associated 
with the source. Participants 1, 2, and 5 hold weekly roundtable meetings to discuss 
current and potential supply chain disruptions with internal stakeholders.  
Pharmaceutical procurement leaders have to train their staff on the process of 
discerning information in the system. Participant 4 described “So you have to go a step 
further than just listening to what the wholesaler is telling you. They code things back 
ordered even if they are waiting for shipment to come in to them.” Yamaguchi et al., 
(2012) classifies this circumstance as a false negative or false indicator, which may 
impair strategic decisions. Participant 3 supported the strategy of Participant 4 through 
additional qualification of the feedback source and the on-going training of departmental 
staff.  
Participants felt using actionable information from reliable sources supported the 
deeper development and strengthening of relationships with internal and external 
stakeholders. Strong relationships with stakeholders reinforced the strategic information 
analysis process. Participant 3 reported, “So if we are going to bring in a different 
product, we want to make sure we educate people about it.” Participants reported an 
increased sense of purposeful communication even to the extent of excessive 




When you are stuck like that you might be borrowing it from one of our own 
hospitals, maybe an outside hospital, maybe you could get an emergency delivery 
from a wholesaler, we go through a myriad, or you come up with a substitution 
you know and then communicate the plan to the physician real-time. 
Participant 2 and 3 reported their departments communicate to physicians and other 
clinical staff on a regular basis of all known or potential disruptions affecting the patient 
population of the health system. All participants felt the levels of interdepartmental 
animosity diminished as the relationships between the pharmacy staff and clinical staff 
removed much of the systems chaotic or complex behaviors and replaced them with 
reliable sources of information. 
Participants reported varying degrees of repurposing staff to accommodate the 
increased influence of supply chain disruptions. Although new tools were available to 
health systems from manufacturers and wholesalers, the participants offered no 
consensus on the use of new inventory checking or inventory management tools. 
Participant 5 reported the most significant advances in the repurposing of staff,  
We put in a specific policy and probably the most effective thing we did is we 
utilize the residents. We have 2 pharmacy residents we use to lead this once a 
week drug shortage call where we pull together a myriad of people and basically 
come up with a game plan for each individual drug shortage. 
Participants 1, 2, 3, and 4 felt training the individuals who buy pharmaceutical products 
for the health systems were ideal candidates to use new tools and training on methods of 
analyzing the supply chain. All participants distinguish the need for additional resources 
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to analyze supply chain information; however, cost control is a key factor in the decision 
process to add new roles to the pharmacy department. 
Emergent Theme 3 reflects the principles of emergent behaviors and self-
organization in complex adaptive systems (Reimana, Rollenhagen, Pietikäinen, & 
Heikkiläc J., 2015). New patterns of networks among dissimilar agents suggest changes 
in the normative behaviors in the work groups within the health system. The new patterns 
may lead to increased success rates of reducing or mitigating pharmaceutical supply 
chain disruptions. Table 4 identifies the strategies coded to Emergent Theme 3.  
 
Pharmaceutical procurement leaders have a difficult challenge creating strategies 
that may eliminate or reduce supply chain disruptions. Nonlinear complex adaptive 
systems confound the leader’s ability draw conclusions about the dynamic supply chain 
environment (Croson et al., 2014). Kulkarni (2017) suggests using models to thoroughly 
analyze and explain stochastic behaviors over time in such objects like supply chains. I 
offer a feedback model to explicate the causal relationships between the external drivers 
to the complex adaptive system, implementation of strategies from the pharmaceutical 
procurement leaders, and the relationship to reducing or eliminating supply chain 
Table 4
Codes Relating to the  Emerging Theme of Develop Reliable Sources of Actionable Information
Participant
Development and equiping 
departmental  staff
Strenghten relationships with 
internal and external 
stakeholders
Deploy department resources 
in unconventional roles
P1 27 28 4
P2 56 17 29
P3 16 20 5
P4 44 30 41
P5 25 18 28
Total 168 113 107
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disruptions (see Figure 1). A feedback model identifies a visually simplistic method of 
depicting relationships between elements occurring within a system (Higgins, 2013; 
Kulkarni, 2017). Variables and associations among system elements in the feedback 
model identify the relationship between choices and results (see Figure 1). Interactions 
among system components create causal loops, which demonstrate foundational problems 
exclusive of whole system complexities (Mella, 2015; Strauss & Borenstein, 2015). 
Direct relationships (+) represent changes from X to Y in the same direction. If X 
increases then Y increases; if X decreases then Y decreases. Inverse relationships (-) 
represent changes from X to Y in the opposite direction. If X increases then Y decreases; 
if X decreases then Y increases. The feedback model first presents external variables, 
which may affect any system regardless of complexity or simplicity. As the external 
variables increase so shall the demands for access to the health care continuum. 
Additionally, the increase or decrease of access demands increase or decrease the demand 
for health care products and services because of the positive causal relationship in the 
feedback loop (see Figure 1).  
Increases in demands for health care products and services increase the demands 
on the US pharmaceutical supply chain and distribution channel for related products. The 
increased consumer demands shall also increase the improvement or degradation of the 
supply chain efficiencies; thereby, affecting the degree of risk for frequencies in the 
supply chain or distribution channel disruption. When the demands of the US 
pharmaceutical supply chain and distribution channel flow through the management 
strategies introduced in this study, the feedback loop split into one positive and one 
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negative relationship (see Figure 1). The applications of management strategies from this 
study have a direct relationship to improvements in pharmaceutical supply chain 
efficiencies and an inverse relationship over the degradation of supply chain efficiencies. 
Strategies identified in the three emergent themes affect both sides of the research 
problem (see Figure 1). Strengthening and standardizing the supply chain efficiencies 
through management strategies found in this research study may also support growth 
rates of pharmaceutical products and services at the same rates of demand growth driven 
by increased access by individual consumers to the health care continuum. The findings 
strongly suggest the identification and implementation of best practices within the 
organizational process lens of systems thinking (Medvedeva, 2012; Stephens, 2013; 








Applications to Professional Practice 
The pharmaceutical supply chain and distribution channel have sustained long-
term vulnerability to disruptions causing health care providers to endure the effects of a 
chaotic, complex system while attempting to maintain proven treatment protocols (Chen 
et al., 2016). After conducting an exhaustive search of scholarly literature and other 
academic publications, no direct alignment between the present study and previous 
academic studies was identified. The findings from this study provide an important 
exploration of the strategies used by pharmaceutical procurement leaders who create 
policies associated with pharmaceutical procurement and distribution. The findings 
illustrated the perceptions of pharmaceutical procurement leaders in health systems in the 
eastern region of the United States.  
Creating a series of comprehensive strategies in the health system address 
pharmaceutical supply levels augment the sustainability of the pharmaceutical supply 
chain for long-term viability. Findings from the study indicate strategic decisions from 
the pharmaceutical procurement leaders are focused on (a), proactive methods of 
planning for patient needs, (b) open access to safe alternate procurement methods, and (c) 
acquiring rich sources of actionable information. Strategic planning is required for drug 
supply chain disruptions with the same level of acuity as weather and mass casualty 
related events (Fox et al., 2009). The results also suggest pharmaceutical leaders are 
focusing strategies on ex-ante processes to acquire rich forms of feedback from internal 
and external sources. 
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Pharmaceutical procurement leaders prioritize needs and allocate resources to 
meet those needs. Findings from this study amplify two central characteristics of a 
complex adaptive system. The first amplified characteristic is emergence through self-
organization (Baykasoglu, 2016; Drack, 2009). The second amplified characteristic is 
leaders within a CAS operate in the grey area between predictable and unpredictable or 
on the edge of chaotic behaviors (Gimenez et al., 2012). Strategies from the procurement 
leaders focused intensely on using emergent behaviors to develop new strategic 
methodologies, which may reduce unpredictability or uncertainty in the supply chain and 
distribution channel. 
The practical application of the findings from this study exists in the overall 
strengthening of technical capacities of the supply chain and distribution channel, which 
may increase system awareness and reduce chaotic behaviors. Strengthening supply chain 
and distribution channel technologies build analytical and trending capabilities required 
to predict future states of supply and demand. Specifically, pharmaceutical procurement 
leaders must develop reliable methods to predict supply levels in anticipation of demand 
trends. Utilization of predictive supply chain management strategies, through connecting 
to enhanced new feedback mechanisms in the CAS, may influence the degree and 
duration of the severity of the disruption. Findings from this study are consistent with 
Becker et al. (2013), Blome et al. (2013), Chaudhuri (2015), Cherici et al. (2011), Fox et 
al.(2009), Faucher (2013), and Kaakeh et al. (2011) because of similar characteristics of 
systems and feedback mechanisms identified in the academic literature.  
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Drug shortages of some magnitude may continue in the future. Senior 
pharmaceutical procurement leaders creating or improving strategies aligning with the 
main themes of this study will reduce or eliminate the risk of critical disruptions. 
Pharmaceutical procurement leaders must create more process-oriented strategies to 
enhance knowledge exchange versus supply chain element exchange (Narayana et al., 
2014). Kauffman’s body of work (1986 – 1998) on complexity at the Santé Fe Institute 
conceptualized greater areas of application than previous investigators. Concepts and 
themes found in this study support notions of complex adaptive systems from Arsenault 
et al. (2013), Di Toni and Comello (2013), Drack (2009), Geer-Frazier (2014), Gossett 
(1989), Iosim (2016), Kuziemsky (2016), and Mazzocchi (2012). 
Senior procurement leaders desiring to implement improvements to their 
strategies will appreciate the results of this study. Investigators from previous studies 
concluded the need for similar strategic goals, which may eliminate or reduce 
pharmaceutical supply chain and distribution channel disruptions. Investigators from 
previous studies desired the need for proactive analysis (Chabner, 2011; Fox et al., 2009; 
Griffith, et al., 2012; Jagsi et al., 2014; Johnson, 2011; Krisl et al., 2013; Quilty et al., 
2011; & Ventola, 2011). Investigators from previous studies encouraged developing or 
strengthening strategies for alternate procurement methods (Dorsey et al., 2009; Goldsack 
et al., 2014; Hoffman et al., 2012; ISMP, 2010; Kaakeh et al., 2011; Krisl et al., 2013; Le 
et al., 2011; McBride et al., 2013; McLaughlin & Skoglund, 2015; Metzger et al., 2013; 
Mullins & Cook, 2011; & Ventola, 2011). Finally, investigators from previous studies 
inferred the need to acquire and maintain reliable sources of actionable information, 
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which may be used in strategic planning scenarios (Janvier-James, 2012; Kaakeh et al., 
2011; Marshall & Farahbakhsh, 2013; Mullins & Cook, 2011; Shah, 2004; & Wallis, 
2013).  
Implications for Social Change 
The implications for positive social change include effective leadership strategies 
to mitigate pharmaceutical supply disruptions. Health care systems with low incidents of 
supply chain disruptions recognize competitive advantages above health systems, which 
may struggle to maintain continuity of care for drug therapies (ISMP, 2010). Senior 
procurement leaders may achieve lower costs through the reduction of disruptive or 
chaotic behavior in a complex supply and demand system using strategies identified in 
this study. Elimination of systematic inefficiencies, caused by an absence of actionable 
information, through the development of refined networks of feedback analysis and 
predictive supply chain modeling may strengthen basic foundational procurement 
processes. The development and refinement of the strategies presented in this study may 
stimulate increased information exchange and relationship building among stakeholders 
and health systems employees.  
My desire is to envision the influence of the study findings on senior procurement 
leaders who may formulate new strategies addressing supply chain and distribution 
channel disruptions. My hope is the study findings compel senior procurement leaders 
and stakeholders to participate in dialogs leading to the exploration and revalidation of 
system configurations, strategies, and pharmaceutical procurement processes. Ultimately, 
my aspiration for this study it to change the trajectory of the health care cost curve. The 
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measure of success to the degree of positive social change brought about through the 
findings of this research study correlates to the quality of new informed decisions and 
strategies in the health system. 
Recommendations for Action 
The findings from this study prompted the development of recommendations for 
senior pharmaceutical procurement leaders to create supply chain and distribution 
channel strategies, which eliminate or mitigate disruptions. A programmatic process to 
analyze internal and external trends in pharmaceutical supply and demand utilizing 
distributor, supplier, and industry feedback models is a necessary recommendation to 
plan proactively for potential disruptions. Strategic processes allowing additional 
methods of procurement through alternate (a) distributors, (b) drug substitutes, (c) trade 
and barter relationships, and (d) compounding pharmacies, is a crucial recommendation 
for health systems to sustain disruptions. Additionally, feedback consistency must 
improve to support repeatable informed and actionable decisions; therefore, a needed 
recommendation is to build skill sets and tools to extract reliable feedback from sources 
utilizing staff and stakeholders. 
The findings from this study are relevant to senior pharmaceutical procurement 
leaders. Utilizing the recommendations, senior procurement leaders responsible for 
creating supply chain strategies could introduce modifications to their procurement 
process. As an agent for positive social change, I am dedicated to ensuring the 
dissemination of the study findings at local, regional, national, and international 
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conferences and academic or trade publications. I will be available to senior leaders and 
managers seeking clarification or deeper understanding of the findings. 
Recommendations for Further Study 
My study may provide the first  academic opportunity to analyze disruptions in 
pharmaceutical supply chains and distribution channels in United States health systems 
through the lens of complex adaptive systems. Avoidable costs to health care spending 
exceed $400 million resulting from supply and distribution disruptions (Fox, Sweet, & 
Jensen, 2014; Hoffman et al., 2012; Kaakeh et al., 2011). Recommendations for further 
research include a mixed methods approach to quantifying post implementation outcome 
of new strategies. Metrics from further studies may include measurements of duration 
and severity of disruptions. Additional metrics may focus on cost per disruption event 
and lost revenue from disruptions. A limitation of this study was the geographic area. 
Increasing geographic areas of the participant pool may identify additional qualitative 
viewpoints or opinions relating to supply and distribution disruptions. 
Another opportunity for further research exists in the exploration of strategies at 
pharmaceutical manufacturers. Limited information exists on the strategies of 
pharmaceutical manufacturers to procure raw materials, which is another critical supply 
chain in health care, without disruption. A comparison of strategies between 
manufacturers and health systems may highlight conflicting processes that confound the 




My objective for conducting this study was to build my academic and 
professional competencies as a researcher exploring the qualitative nature of 
pharmaceutical supply chain and distribution channel disruptions. Engaging study 
participants in an open and probing manner enabled me to explore senior procurement 
leaders’ strategies for mitigating or eliminating pharmaceutical supply disruptions. I 
remained mindful of personal biases throughout my conduct of the study. I retained a 
focus on capturing and representing the opinions and perspectives of participants in an 
unbiased manner. Sun Tzu wrote, “The line between disorder and order lies logistics.” 
Peter Drucker said, “What gets measured gets improved.” Both quotes contain deep 
concepts applicable to this study, and both authors share a strong presence in modern 
business management.  
Prior to commencing data collection, I identified areas of potential personal bias. 
Specifically, how my professional experience in pharmaceutical distribution may 
influence the data analysis process of participants’ responses towards leadership 
strategies. All participants of this study acknowledged that supply chain and distribution 
channel disruptions exist in health care with varying degrees. Participants were quick to 
add that the system is too complex and too chaotic to suggest eradication of disruptions is 
plausible in the current state. Conduct of the data gathering and data analysis created a 
new awareness in me. Participants stated a willingness to adopt strategies to reduce and 
or eliminate disruptions if the strategies were cost effective. One profound note I 
uncovered in this study, the participant response contained a great number of words and 
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phrases related to uncertainty or unpredictability. This statistic caught me off guard but 
challenged by this discovery; I will continue to research complex and chaotic systems. 
Summary and Study Conclusions 
This study concluded an exhaustive journey to provide a comprehensive 
exploration of how senior pharmaceutical procurement leaders set strategies to mitigate 
supply chain and distribution channel disruptions. Senior leaders and stakeholders in the 
health care delivery system must consider including themes from this study, which are (a) 
proactive planning, (b) alternate procurement methods, and (c) reliable and actionable 
information. The completion of this research came at an important time for this nation. 
Access to affordable universal health care is a primary concern to congressional leaders 
and American citizens alike. I offered comprehensive recommendations and a call for 
action based on the findings of this study.  
Pharmaceutical products are a critical element in today’s health care continuum. 
The more drugs you take, the longer you may live. The longer that you live, the more 
drugs you may take. The costs of pharmaceutical products have the ability to bend the 
health care cost curve, only when sufficient profit margins are sustainable across all drug 
classes. A sustainable pharmaceutical supply chain and distribution channel is a key 
element to the entire health care system and should be subject to additional research 
studies and findings from academic scholars pursuing an understanding of the complex 
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Appendix A: Invitation to Participate 
Date 
Dear ____________: 
My name was Adrian G. Scioli, and I am a Doctor of Business Administration (DBA) 
candidate at Walden University. I am conducting a doctoral study project to explore the 
research question of what strategies do health systems pharmaceutical procurement 
leaders need to address inconsistent drug supplies Based on your experiences as a health 
systems pharmaceutical procurement leader; I would like to interview you to gather 
information about your perceptions and beliefs about drug supply disruptions. The 
interview may require 45-90 minutes of your time and will be scheduled at your 
convenience within [INSERT TIME PERIOD FOR INTERVIEW PROCESS 
FOLLOWING COMPLETION OF IRB PROCESS]. I will conduct this in person 
interview at a location most convenient for you. I am also inviting you to share with me 
any e-mail messages, administrative documents, reports, and/or memoranda, which you 
think may provide additional information regarding your participation in mitigating drug 
supply disruptions. However, I note the provision of any documents on your part was 
voluntary. If you do not wish to provide documents, I am still asking you participate in 
the study as a participant. 
Your participation in my study will be instrumental in ensuring I gather data from health 
systems pharmaceutical procurement leaders in the Easter region of the United States. If 
you decide to participate in my study, I will send you an informed consent form via e-
mail for your review and signature. This informed consent form provides background 
information on the study and outlines your rights during the interview process. Please 
contact me if you have any questions or require additional information. My telephone 
number was 215-234-0466 or 215-285-0861. I kindly request an email response to this 
letter indicating your agreement to participate or your declination by ______________. 
My e-mail address was adrian.scioli@waldenu.edu. I thank you in advance for your 
consideration and your support of my doctoral study. 
 
Sincerely, 




Appendix B: Case Study Participants’ Eligibility Requirements 
 Greater than 3 years in leadership position 
 Employed within Eastern US health system 
 Responsible for the administration and development of pharmaceutical supply 
chain and distribution strategies 
 Responsible for administration, provision, delivery, and regulation of 
pharmaceutical supplies 
 Successful implementation of operational strategies relating to pharmaceutical 
supply chain and distribution channel disruptions 
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Appendix C: Informed Consent 
CONSENT FORM 
You are invited to take part in a research study of how health systems pharmaceutical 
procurement leaders in the Eastern region of the United States describe limitations for the 
detection and mitigation of drug supply disruptions. The researcher was inviting health 
care leaders with experience administering, providing, and procuring pharmaceutical 
products in the Eastern region of the United States to participate in the study. This form 
was part of a process called “informed consent” to allow you to understand this study 
before deciding whether to take part. 
 
This study was being conducted by Adrian G. Scioli, a Doctor of Business 
Administration (DBA) candidate at Walden University. The researcher was conducting 
this study in his capacity as a doctoral candidate at Walden University. The study has no 
relationship to the researcher’s professional activities and affiliations. 
 
Background Information: 
The purpose of this study was to examine and explore how health care procurement 
leaders in the Eastern region of the United States describe the necessary strategies for 
managing  the effects of drug supply chain and distribution channel disruptions.  
Procedures: 
If you agree to be in this study, you will be asked to:  
 Participate in a single interview requiring no more than 45-60 minutes of your 
time 
 Agree to have the interview audiotaped for later transcription and analysis by the 
researcher 
 Provide copies of documents, (e-mail messages, administrative documents, 
policies, procedures, reports, and/or memoranda) which provide additional 
information and perspectives on strategies utilized to eliminate or reduce the 
effects of drug supply disruptions. 
 Review a copy of initial study findings and conclusions provided to you by the 
researcher and to provide the researcher with feedback on the accuracy of the 
findings and conclusions 
 
The provision of documents to the researcher was encouraged and voluntary. You are not 
obligated to do so. If you are not comfortable providing documents to the researcher, you 
are still requested to participate in a single interview described above. 
 
Questions for the interview are as follows: 
 Interview Questions 
o What types of strategies do you use to manage the pharmaceutical supply 
chain and distribution channel? 
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o What are the most important factors you use when implementing strategies 
to reduce or eliminate supply chain disruptions?  
o What strategies have been the least effective in reducing or eliminating 
supply chain and or distribution channel disruptions?  
o What specific supply chain management strategies do you use to address 
disruptions in the supply chain or distribution channel? 
o How have your organization’s supply chain management strategies 
changed or evolved? 
o In your experience, what barriers prohibit supply chain management 
strategies from becoming successful?  
o What other information would you like to discuss, which we have not 
already addressed? 
The researcher will provide you with a copy of the transcript of your interview. You will 
have the opportunity to review and concur with the transcript contents prior to the 
researcher proceeding with the analysis of the transcript contents. At the completion of 
the study, the researcher will provide you with a brief document, (no more than two 
pages in length) which summarizes findings, recommendations, and conclusions from the 
study.  
 
Voluntary Nature of the Study: 
This study was voluntary. You will not be provided with any thank you gifts, 
compensation or reimbursement (for travel costs, etc.) in exchange for your participation 
in this study. Your decision regarding whether or not to participate in the interview and 
provide documents will be respected, and you will not be treated differently by the 
researcher should you elect not to participate. If you decide to participate in the study 
now, you can still change your mind during or after the study. You may end your 
participation in the study at any time.  
 
Risks and Benefits of Being in the Study: 
Being in this type of study involves some risk of minor discomforts, which can be 
encountered in daily life, such as fatigue, stress, or becoming upset should sensitive 
topics arise for discussion. The risk of such discomforts occurring is, however, 
considered to be low. Additionally, the researcher will endeavor to ensure the potential 
for personal discomfort was kept to a minimum during the conduct of the interview. 
Being in this study would not pose a risk to your safety or well-being. 
 
Participation in the study will provide you with the opportunity to share your knowledge, 
thoughts, and experiences with the pharmaceutical supply chain and limitations in the 
detection and mitigation of drug supply disruptions. This study could contribute to 
greater understanding of how administrative and leadership responses are formulated in 
response to the problem (drug supply disruptions) of national significance. Conduct of 
this study may support the development of leadership models supportive of effective drug 




Privacy and Limits to Confidentiality: 
The information you provide will be kept confidential. However, should you reveal 
evidence of criminal activity or abuse during the conduct of the interview, the researcher 
was obligated to report such evidence to relevant law enforcement authorities. The 
researcher will not use your personal information for any purposes outside of this 
research project. In addition, the researcher will not include your name, organizational 
affiliation, or any other information, which could identify you in study reports. Electronic 
data will be kept secure by participant deidentification and archival on a password-
protected laptop computer and a private cloud data storage account accessible only to the 
researcher. The researcher will store any hard copies of data (e.g., printed interview 
transcripts used for notation and analysis) in a lockable container. The researcher will 
keep data for a period of at least 5 years as required by Walden University. 
 
Contacts and Questions: 
You may ask the researcher any questions you have at this time. Should you have 
questions following the conduct of the interview, you may contact the researcher via 
phone or e-mail. If you want to talk privately about your rights as a participant, you can 
contact the Walden University Research Participant Advocate via phone at 1-800-925-
3368, extension 1210 within the USA or 001-612-312-1210 from outside the USA. You 
may also contact the Walden University Research Participant Advocate via e-mail at 
irb@waldenu.edu. Walden University’s approval number for this study was 
_____________ and it expires on ________________.  
 




Statement of Consent: 
 
I have read the above information, and I feel I understand the study well enough to make 
a decision about my involvement. By signing below, I understand, and I agree to the 
terms described above. 
 






Participant’s Written or Electronic* Signature
 ________________________________ 
 
Researcher’s Written or Electronic* Signature
 ________________________________ 
 
* Electronic signatures are regulated by the Uniform Electronic Transactions Act. 
Legally, an "electronic signature" can be a person’s typed name, their email address, or 
any other identifying marker. An electronic signature was just as valid as a written 




Appendix D: Case Study Protocol 
A. Case Study Introduction 
1. Research Question 
a. What strategies do health systems pharmaceutical procurement 
leaders need to address inconsistent drug supplies? 
2. Conceptual Framework 
a. Complexity Theory 
B. Protocol Purpose and Intended Use 
1. The protocol serves as the primary guidance in the conduct of study 
data collection, data analysis, and interpretation research efforts 
2. The protocol used ensures reliability of case study methodology, 
research findings, and research conclusions 
C. Data Collection Procedures 
1. Data to be collected from the review of documents voluntarily provided 
by participants and the conduct of semistructured interviews with health 
system procurement leaders from a purposeful sample.  
2. The researcher will recruit participants from the development of a 
purposeful sample of potential participants. 
3. Identification and finalization of specific study sites and site-specific 
contact persons occur after the invitation to participate letters are sent, and 
responses are received from participants 
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4. Expected preparation activities to take place prior to site visits to 
conduct 
interviews 
a. Preparation of informed consent forms for each participant 
b. Prepare interview question guide for each participant 
5. Data collection tools 
a. Digital audio recordings 
b. Researcher field notes 
c. Case study database 
D. Outline of Case Study Report Contents 
1. Overview of study 
2. Presentation of the findings 
3. Applications to professional practice 
4. Implications for social change 
5. Recommendations for action 
6. Recommendations for further study 
7. Reflections 
8. Summary 
9. Study conclusions 
E. Case Study Interview Questions 
Interview Questions 
1. What types of strategies do you use to manage supply disruptions in the 
pharmaceutical supply chain and distribution channel? 
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2. What are the most important factors you consider when implementing 
strategies to reduce or eliminate supply chain disruptions?  
3. What strategies have been the least effective in reducing or eliminating supply 
chain and or distribution channel disruptions?  
4. What specific supply chain management strategies do you use to address 
disruptions in the supply chain or distribution channel? 
5. How have your organization’s supply chain management strategies changed 
or evolved since you assumed the leadership role? 
6. What barriers prohibit supply chain management strategies from becoming 
successful?  
7. What other information would you like to discuss, which we have not already 
addressed? 
F. Data Analysis Techniques and Tools 
1. Coding 
2. Analysis tools 
a. ATLAS.ti.7 
b. Microsoft Excel 
G. Study Reliability and Validity Methods 
1. Reliability methods 
a. Use of case study protocol 
b. Creation of case study database 
2. Validity methods 
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a. Construct validity 
i. Multiple data sources 
b. Internal validity 
ii. Research bias identification 
b. External validity 




Appendix E: National Institutes of Health (NIH) Office of Extramural Research 
Protecting Human Research Participants Certification 
   
 
Certificate of Completion 
The National Institutes of Health (NIH) Office of Extramural Research 
certifies that Adrian Scioli successfully completed the NIH Web-based 
training course “Protecting Human Research Participants”. 
Date of completion: 03/06/2012  
Certification Number: 883410  
 
 




Appendix F: Case Study Interview Protocol Checklist 
 
Pre-Interview  
Interview date: Interview time: 
Interview location: Interview duration estimate: 
Participant pseudonym: Participant code:  
 
Interview documentation and materials 
Receipt of Informed Consent (Yes or No):  Eligibility criteria met (Yes or No):  
Receipt of Permission to Record and 
Transcribe (Yes or No): 
Test Primary and back-up recording device 
(Yes or No):  
 
Conduct of interview 
Introductions (Yes or No):  Overview of research topic (Yes or No): 
Discuss purpose  Questions from participant (Yes or No): 
Discuss risk Questions from participant (Yes or No): 
Discuss confidentiality Questions from participant (Yes or No): 
Discuss right to withdraw Questions from participant (Yes or No): 
Discuss benefits Questions from participant (Yes or No): 
Discuss data security Questions from participant (Yes or No): 
 
Interview 
My observations and actions:  
a. Body language 
b. Non-verbal cues 
c. Paraphrasing 
d. Probing questions 
e. Follow-on questions 
a) What types of strategies do you use 
to manage supply disruptions in the 
pharmaceutical supply chain and 
distribution channel? 
b) What are the most important 
factors you consider when implementing 
strategies to reduce or eliminate supply 
chain disruptions? 
c) What strategies have been the least 
effective in reducing or eliminating supply 
chain and or distribution channel 
disruptions? 
d) What specific supply chain 
management strategies do you use to 
address disruptions in the supply chain or 
distribution channel? 
e) How have your organization’s 
supply chain management strategies 




f) What barriers prohibit supply chain 
management strategies from becoming 
successful? 
g) What other information would you 
like to discuss, which we have not already 
addressed? 
 
Post-interview follow-up  
Thank participant for contribution Actual interview duration:  
Discuss next steps: Questions from participant (Yes or No): 
a. Completion of transcript 
b. Concept of member checking 
c. Set up a date for member checking 
follow-up 
d. Notification of findings 






Questions from participant (Yes or No): 
 
Member checking follow-up 
Follow-up date:  Provide copy of synthesis for each question 
Introduce member checking process Questions from participant (Yes or No): 
My observations and actions: 
 Additional probing questions 
 Affirm synthesis for each question 
 Ask for further interpretation or 
additional information 
 Ask what was missed in the initial 
interview 
 
a) Synthesis of 1st question 
b) Synthesis of 2nd question 
c) Synthesis of 3rd question 
d) Synthesis of 4th question 
e) Synthesis of 5th question 
f) Synthesis of 6th question 





Appendix G: Organizational Letter of Cooperation 
 




Date: <Date of Correspondence> 
 
Dear Adrian G. Scioli,  
 
Based on my review of your research proposal, I give permission for you to conduct 
the study entitled Leadership Strategies for Addressing U.S. Pharmaceutical Drug 
Shortages and Supply Chain Disruptions. As part of this study, I authorize you to solicit 
eligible participants for participation, conduct data collection through interviews and 
member checking activities. Individuals’ participation will be voluntary and at their 
discretion. We understand that our organization’s responsibilities include: The time for 
eligible participants to participate in the study. We reserve the right to withdraw from the 
study at any time for any reason if our circumstances change.  
I confirm that I am authorized to approve said research activities in this setting and 
the plan complies with the organization’s policies. 
I understand data collected from the above activities will remain entirely confidential 
and may not be provided to anyone outside of the student’s supervising faculty/staff 







(Printed name and title) 
 
 
Walden University policy on electronic signatures: An electronic signature was just as 
valid as a written signature as long as both parties have agreed to conduct the transaction 
electronically. Electronic signatures are regulated by the Uniform Electronic Transactions 
Act. Electronic signatures are only valid when the signer was either (a) the sender of the 
email or (b) copied on the email containing the signed document. Legally an "electronic 
signature" can be the person’s typed name, their email address, or any other identifying 
marker. Walden University’s staff verify any electronic signatures not originating from a 
password-protected source (i.e., an email address officially on file with Walden 
University) 
 
 
